{"PMC7354780": [["IntroductionThe mean-variance model (MVM) originally formulated by Markowitz [1] plays a critical and vital role in modern finance theory.", [["The mean-variance model (MVM)", "TREATMENT", 12, 41]]], ["Inspired by the Markowitz\u2019s idea, numerous extensions have been proposed, e.g., multi-period mean-variance formulation [2], behavioral mean-variance portfolio selection [3].", [["behavioral mean", "TEST", 124, 139]]], ["Nevertheless, one of the assumptions of MVM is that the returns of assets are symmetrically distributed.", [["MVM", "ORGANISM", 40, 43], ["MVM", "PROBLEM", 40, 43], ["symmetrically", "OBSERVATION_MODIFIER", 78, 91], ["distributed", "OBSERVATION_MODIFIER", 92, 103]]], ["Actually, in reality, there are shreds of empirical evidence [4, 5] suggesting that many security returns follow the asymmetrical distribution.", [["many", "OBSERVATION_MODIFIER", 84, 88], ["security", "OBSERVATION", 89, 97], ["asymmetrical", "OBSERVATION_MODIFIER", 117, 129], ["distribution", "OBSERVATION_MODIFIER", 130, 142]]], ["People start to considerate asymmetry of return distributions to overcome the inadequacy of the MVM.", [["MVM", "ORGANISM", 96, 99], ["People", "SPECIES", 0, 6]]], ["As a result, some scholars such as Prakash et al. [7] extend MVM to mean\u2013variance\u2013skewness model (MVSM).", [["MVM", "ORGANISM", 61, 64]]], ["The other directly use downside risk measure to avoid sacrificing a large amount of expected return in removing both high and low return extremes.", [["large", "OBSERVATION_MODIFIER", 68, 73], ["amount", "OBSERVATION_MODIFIER", 74, 80], ["high", "OBSERVATION_MODIFIER", 117, 121]]], ["Semivariance [8] which is clear, comparatively simple and direct in mirroring investors\u2019 intuition about risk is one of the well-known downside risk measures.IntroductionMoreover, another basic assumption of MVM is that the asset markets in the future can accurately reflect the asset data in the past.", [["MVM", "ORGANISM", 208, 211], ["MVM", "PROBLEM", 208, 211], ["clear", "OBSERVATION", 26, 31]]], ["However, it is impossible to produce correct expectations for future risks and returns based on historical data exclusively in the uncertain economic environment.", [["historical data", "TEST", 96, 111]]], ["Thus, the fuzzy set theory [9] is well suited to deal with vagueness and uncertainty of any stock market attributes in portfolio optimization (PO).IntroductionAs a fresh comer of swarm intelligence (SI), bacterial foraging optimization (BFO) [10] has gotten much attention from different areas, and widely used in many real-world problems including supply chain optimization problem [11], flexible job-shop scheduling problem [12], and vehicle routing problem [13].", [["vagueness", "PROBLEM", 59, 68], ["bacterial foraging optimization", "TREATMENT", 204, 235]]], ["And a modified BFO with linear decreasing chemotaxis step (BFO-LDC) has been already successfully applied to solve the PO [14].IntroductionSine function, one of the trigonometric functions, has been applied in the generation of n-scroll attractors [15], the design of ship course-keeping autopilot [16], sound encryption scheme [17], etc.IntroductionBased on the analysis of the recent literature, the problems about how to modify MVM to become more suitable for the real stock market and promote the ability of BFO to achieve better solutions in the PO attracts our attention.", [["BFO", "CHEMICAL", 15, 18], ["BFO", "CHEMICAL", 512, 515], ["PO [14]", "CHEMICAL", 119, 126], ["BFO", "SIMPLE_CHEMICAL", 15, 18], ["MVM", "ORGANISM", 431, 434], ["BFO", "SIMPLE_CHEMICAL", 512, 515], ["a modified BFO", "TREATMENT", 4, 18], ["linear decreasing chemotaxis step (BFO-LDC", "TREATMENT", 24, 66], ["sound encryption scheme", "TREATMENT", 304, 327], ["the analysis", "TEST", 359, 371], ["linear", "OBSERVATION_MODIFIER", 24, 30], ["decreasing", "OBSERVATION_MODIFIER", 31, 41]]], ["In this paper, we propose a novel BFO with decreasing chemotaxis step combined with sine function (BFO-SDC) and build a more complex PO model.", [["BFO", "CHEMICAL", 34, 37], ["BFO", "SIMPLE_CHEMICAL", 34, 37], ["a novel BFO", "TREATMENT", 26, 37], ["decreasing chemotaxis step", "TREATMENT", 43, 69], ["a more complex PO model", "TREATMENT", 118, 141]]], ["The main contributions of this paper are listed as follows.", [["main", "OBSERVATION_MODIFIER", 4, 8]]], ["First of all, a decreasing strategy based on sine function replaces the constant chemotaxis step size to investigate the optimization ability of BFO through combing decreasing strategy with sine function to create a nonlinear decreasing strategy.", [["BFO", "CHEMICAL", 145, 148], ["BFO", "SIMPLE_CHEMICAL", 145, 148], ["a decreasing strategy", "TREATMENT", 14, 35], ["the constant chemotaxis step size", "TREATMENT", 68, 101], ["a nonlinear decreasing strategy", "TREATMENT", 214, 245]]], ["Next, use semivariance to replace variance and take skewness into account to generate asymmetry of asset distributions.", [["semivariance", "TREATMENT", 10, 22], ["asymmetry", "OBSERVATION", 86, 95]]], ["Finally, fuzzy logic [18] is used to express uncertainty to make it suitable for representing the intrinsic vagueness nature of the PO problem.IntroductionThe remainder of the paper is organized as follows.", [["the PO problem", "PROBLEM", 128, 142]]], ["Section 3 reviews BFO and describes BFO-SDC.", [["BFO", "CANCER", 18, 21], ["BFO-SDC", "CANCER", 36, 43]]], ["A trapezoidal fuzzy number A with tolerance interval [a, b], left-width \u03b1 > 0 and right-width \u03b2 > 0 is fully determined by the quadruplet (a, b, \u03b1, \u03b2).", [["quadruplet", "PROTEIN", 127, 137], ["\u03b1", "PROTEIN", 145, 146], ["\u03b2", "PROTEIN", 148, 149], ["trapezoidal fuzzy", "OBSERVATION", 2, 19], ["left", "ANATOMY_MODIFIER", 61, 65], ["right", "ANATOMY_MODIFIER", 82, 87]]]], "b281ffd13e1ca8492cc60ae608b6b24a7be46a1f": [["BackgroundMatrix visualization [4] , for example the Cluster and TreeView package [5] , is an important exploratory data analysis tool in the study of microarray gene expression profiles.", [["BackgroundMatrix visualization", "TEST", 0, 30], ["the study", "TEST", 138, 147]]], ["The visual patterns of genes (rows) and arrays (columns) in the permuted gene-by-array expression pro-file matrix are useful for clustering purposes.", [["rows", "DNA", 30, 34]]], ["The hierarchical clustering tree and the singular value decomposition are the two methods for identifying suitable gene/array permutations.", [["the singular value decomposition", "PROBLEM", 37, 69], ["suitable gene/array permutations", "TREATMENT", 106, 138], ["hierarchical", "OBSERVATION_MODIFIER", 4, 16], ["clustering tree", "OBSERVATION", 17, 32]]], ["This section briefly reviews the advantages and disadvantages of the two techniques using the fibroblast to serum gene expression data [1, 6] .BackgroundThe branching structure of a dendrogram plays an important role in identifying permutations of genes and arrays by its arrangement of intermediate nodes.", [["fibroblast", "ANATOMY", 94, 104], ["serum", "ANATOMY", 108, 113], ["nodes", "ANATOMY", 300, 305], ["fibroblast", "CELL", 94, 104], ["serum", "ORGANISM_SUBSTANCE", 108, 113], ["intermediate nodes", "MULTI-TISSUE_STRUCTURE", 287, 305], ["the two techniques", "TREATMENT", 65, 83], ["intermediate nodes", "PROBLEM", 287, 305], ["branching", "OBSERVATION_MODIFIER", 157, 166], ["intermediate nodes", "OBSERVATION", 287, 305]]], ["For a given HCT with n terminal nodes (genes or arrays), there are n-1 intermediate nodes.", [["HCT", "CANCER", 12, 15], ["n terminal nodes", "DNA", 21, 37], ["HCT", "TEST", 12, 15], ["n terminal nodes (genes or arrays)", "PROBLEM", 21, 55], ["nodes", "OBSERVATION", 32, 37], ["intermediate", "OBSERVATION_MODIFIER", 71, 83], ["nodes", "OBSERVATION", 84, 89]]], ["Each of these intermediate nodes can be flipped independently resulting in 2 n-1 possible orderings of the terminal nodes from the same dendrogram built on the identical proximity matrix.", [["terminal nodes", "MULTI-TISSUE_STRUCTURE", 107, 121], ["matrix", "CELLULAR_COMPONENT", 180, 186], ["the terminal nodes", "PROBLEM", 103, 121], ["intermediate", "OBSERVATION_MODIFIER", 14, 26], ["nodes", "OBSERVATION", 27, 32], ["terminal", "ANATOMY_MODIFIER", 107, 115], ["nodes", "OBSERVATION", 116, 121], ["proximity matrix", "OBSERVATION", 170, 186]]], ["Bar-Joseph et al. [7] had detailed discussion on the HCT intermediate nodes flipping phenomena.", [["HCT intermediate nodes", "ANATOMY", 53, 75], ["the HCT intermediate nodes flipping phenomena", "TREATMENT", 49, 94], ["nodes", "OBSERVATION", 70, 75], ["flipping phenomena", "OBSERVATION", 76, 94]]], ["To order the leaves of a binary HCT when two ordered branches are merged, the new branch is formed by placing the similar endpoints of the joining branches adjacent to each other.", [["HCT", "CANCER", 32, 35], ["branches", "MULTI-TISSUE_STRUCTURE", 53, 61], ["a binary HCT", "TEST", 23, 35], ["branches", "ANATOMY_MODIFIER", 53, 61], ["new", "OBSERVATION_MODIFIER", 78, 81], ["branch", "OBSERVATION_MODIFIER", 82, 88], ["similar", "OBSERVATION_MODIFIER", 114, 121], ["endpoints", "OBSERVATION_MODIFIER", 122, 131], ["joining", "ANATOMY_MODIFIER", 139, 146], ["branches", "ANATOMY_MODIFIER", 147, 155]]], ["Bar-Joseph et al. [7] presented a fast optimal leaf ordering for the hierarchical clustering algorithm that maximizes the sum of the similarities of adjacent leaves in the Travelling Salesman sense [11] , and we refer to this approach as the optimal tree method.", [["leaf", "ANATOMY", 47, 51], ["leaves", "ANATOMY", 158, 164], ["leaf", "ORGAN", 47, 51], ["leaves", "ORGAN", 158, 164], ["the hierarchical clustering algorithm", "PROBLEM", 65, 102]]], ["Bar-Joseph et al. [12] proposed a heuristic algorithm for constructing k-ary trees by extending and improving the optimal leaf ordering algorithm in [7] .Singular value decomposition (SVD) and Rank-two ellipse seriation (R2E)For identifying smooth transitional expression patterns and more global-grouping structures, people turn to dimension reduction techniques, such as singular value decomposition, for help [2, 13, 14] .", [["leaf", "ANATOMY", 122, 126], ["leaf", "ORGAN", 122, 126], ["people", "SPECIES", 318, 324], ["a heuristic algorithm", "TREATMENT", 32, 53], ["constructing k-ary trees", "TREATMENT", 58, 82], ["Singular value decomposition", "PROBLEM", 154, 182], ["smooth transitional expression patterns", "PROBLEM", 241, 280], ["dimension reduction techniques", "TREATMENT", 333, 363], ["smooth", "OBSERVATION_MODIFIER", 241, 247], ["transitional expression", "OBSERVATION", 248, 271]]], ["Alter et al. [2] laid down the mathematics of SVD for analyzing gene expres-sion profiles and proposed the concept of eigenarrays and eigengenes as representative linear combinations of original arrays and genes.", [["SVD", "DNA", 46, 49], ["eigenarrays", "DNA", 118, 129], ["eigengenes", "DNA", 134, 144], ["analyzing gene expres-sion profiles", "PROBLEM", 54, 89]]], ["They further suggested that one sort the arrays and genes according to the relative positions on the subspaces spanned by the two leading eigenarrays and eigengenes.Singular value decomposition (SVD) and Rank-two ellipse seriation (R2E)Chen [3] introduced a sorting algorithm called rank-two ellipse (R2E) seriation which improves the SVD method by extracting the elliptical structure of the converging sequence of iteratively formed correlation matrices using the eigenvalue decomposition.", [["eigenarrays", "DNA", 138, 149], ["eigengenes", "DNA", 154, 164], ["Singular value decomposition", "PROBLEM", 165, 193], ["a sorting algorithm", "TEST", 256, 275], ["two ellipse (R2E) seriation", "TREATMENT", 288, 315], ["the SVD method", "PROBLEM", 331, 345], ["the eigenvalue decomposition", "TREATMENT", 461, 489]]], ["Figure 1b displays the resulting matrix visualization of the human fibroblasts expression profile sorted by the R2E algorithm.", [["matrix", "ANATOMY", 33, 39], ["fibroblasts", "ANATOMY", 67, 78], ["matrix", "CELLULAR_COMPONENT", 33, 39], ["human", "ORGANISM", 61, 66], ["fibroblasts", "CELL", 67, 78], ["human fibroblasts", "CELL_TYPE", 61, 78], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 61, 66], ["the R2E algorithm", "TEST", 108, 125], ["human fibroblasts", "OBSERVATION", 61, 78]]], ["We see that the R2E sorted correlation matrix identifies a very smooth transitional pattern.", [["matrix", "CELLULAR_COMPONENT", 39, 45], ["R2E", "DNA", 16, 19], ["a very smooth transitional pattern", "PROBLEM", 57, 91], ["very", "OBSERVATION_MODIFIER", 59, 63], ["smooth", "OBSERVATION_MODIFIER", 64, 70], ["transitional pattern", "OBSERVATION", 71, 91]]], ["More advantages of the R2E method over the SVD method will be discussed in the Methods section.The proposed rank-two ellipse seriation-guided hierarchical clustering tree (HCT_R2E)We propose to guide the flipping mechanism of a conventional agglomerative HCT using the rank-two ellipse (R2E) seriation of Chen [3] as an external reference.", [["R2E", "DNA", 23, 26], ["HCT_R2E", "CELL_LINE", 172, 179], ["the R2E method", "TREATMENT", 19, 33], ["the SVD method", "TREATMENT", 39, 53], ["two ellipse seriation", "TREATMENT", 113, 134], ["a conventional agglomerative HCT", "TREATMENT", 226, 258]]], ["The resulting algorithm automatically integrates the desirable properties of HCT and R2E so that users have access to a clustering and visualization environment for gene expression profiles that preserves coherent local clusters and identifies global grouping trends.The proposed rank-two ellipse seriation-guided hierarchical clustering tree (HCT_R2E)The R2E-guided HCT with the corresponding permuted matrices can be seen in Figure 1c .", [["HCT", "CANCER", 77, 80], ["HCT", "CANCER", 367, 370], ["HCT_R2E", "CELL_LINE", 344, 351], ["R2E-guided HCT", "CELL_LINE", 356, 370], ["HCT and R2E", "TREATMENT", 77, 88], ["gene expression profiles", "PROBLEM", 165, 189], ["The R2E-guided HCT", "TEST", 352, 370], ["the corresponding permuted matrices", "TREATMENT", 376, 411]]], ["The permuted correlation and gene expression matrices in Figure 1c resemble the corresponding matrices in Figure 1b extremely well, meaning that the coherent local structure (clusters) identified by the HCT architecture and the smooth global transitional pattern explored by the R2E algorithm do not necessarily conflict with each other.", [["HCT", "CANCER", 203, 206], ["gene expression matrices", "TREATMENT", 29, 53], ["the HCT architecture", "TEST", 199, 219], ["the smooth global transitional pattern", "PROBLEM", 224, 262], ["HCT architecture", "OBSERVATION", 203, 219], ["smooth", "OBSERVATION_MODIFIER", 228, 234], ["global", "OBSERVATION_MODIFIER", 235, 241], ["transitional pattern", "OBSERVATION", 242, 262]]], ["The only thing different is the flipping mechanism of intermediate nodes.Global trend and the Robinson matrixIt is not common to permute the orders of arrays with time series nature for preserving the time-to-time local structure and the overall global time-trend.", [["nodes", "ANATOMY", 67, 72], ["intermediate nodes", "MULTI-TISSUE_STRUCTURE", 54, 72], ["Robinson matrixIt", "DNA", 94, 111], ["intermediate nodes", "PROBLEM", 54, 72], ["Global trend", "PROBLEM", 73, 85], ["intermediate nodes", "OBSERVATION", 54, 72], ["trend", "OBSERVATION_MODIFIER", 80, 85]]], ["The local pattern and the global trend usually do not co-exist well in a given matrix unless a Robinson form [15] can be permuted from the matrix.", [["matrix", "CELLULAR_COMPONENT", 79, 85], ["matrix", "CELLULAR_COMPONENT", 139, 145], ["local", "OBSERVATION_MODIFIER", 4, 9], ["pattern", "OBSERVATION_MODIFIER", 10, 17]]], ["A Robinson Matrix, R = [r ij ], is a symmetric matrix such that r ij \u2264 r ik if j <k <i and r ij \u2265 r ik if i <j <k.", [["matrix", "CELLULAR_COMPONENT", 47, 53], ["a symmetric matrix", "PROBLEM", 35, 53], ["r ij", "TREATMENT", 64, 68], ["ij", "ANATOMY", 26, 28], ["symmetric", "OBSERVATION_MODIFIER", 37, 46], ["matrix", "OBSERVATION", 47, 53], ["ij", "ANATOMY", 66, 68], ["ij", "ANATOMY", 93, 95]]], ["The basic property of a Robinson matrix is monotonicity as one proceeds from the main-diagonal elements to all four margins of the given matrix.", [["matrix", "CELLULAR_COMPONENT", 137, 143], ["main-diagonal elements", "DNA", 81, 103], ["Robinson matrix", "OBSERVATION", 24, 39], ["main", "OBSERVATION_MODIFIER", 81, 85], ["diagonal", "ANATOMY_MODIFIER", 86, 94], ["four", "OBSERVATION_MODIFIER", 111, 115], ["margins", "OBSERVATION_MODIFIER", 116, 123]]], ["For a permuted Matrix visualization for expression profiles map with corresponding pair-wise correlation map for Fibroblast to serum data [1]ResultsThree additional real data sets, together with the fibroblast to serum gene expression data, are analyzed to demonstrate the performance of the proposed method.", [["Fibroblast", "ANATOMY", 113, 123], ["serum", "ANATOMY", 127, 132], ["fibroblast", "ANATOMY", 199, 209], ["serum", "ANATOMY", 213, 218], ["Fibroblast", "CELL", 113, 123], ["serum", "ORGANISM_SUBSTANCE", 127, 132], ["fibroblast", "CELL", 199, 209], ["serum", "ORGANISM_SUBSTANCE", 213, 218], ["a permuted Matrix visualization", "TEST", 4, 35], ["expression profiles map", "TEST", 40, 63], ["Fibroblast to serum data", "TEST", 113, 137], ["the fibroblast to serum gene expression data", "TEST", 195, 239]]], ["The first one is the annotated subset cell cycle data from [16] ; the second is the severe acute respiratory syndrome coronavirus (SARS-CoV) studied in [17] ; the transition metal study in [18] is the final example.", [["cell", "ANATOMY", 38, 42], ["acute respiratory syndrome coronavirus", "DISEASE", 91, 129], ["SARS", "DISEASE", 131, 135], ["cell", "CELL", 38, 42], ["[18]", "SIMPLE_CHEMICAL", 189, 193], ["severe acute respiratory syndrome coronavirus", "SPECIES", 84, 129], ["SARS-CoV", "SPECIES", 131, 139], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 80, 129], ["the transition metal study", "TEST", 159, 185], ["subset cell", "OBSERVATION", 31, 42], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["acute", "OBSERVATION_MODIFIER", 91, 96], ["respiratory syndrome coronavirus", "OBSERVATION", 97, 129]]], ["The same eight sorting algorithms (SVD with one eigenvector (SVD1), SVD with two eigenvectors (SVD2), self-organizing maps (SOM) [19] , rank-two ellipse (R2E), HCT with random flips (HCT_RAM), optimal tree (HCT_OPT), SOM-guided tree (HCT_SOM), and R2E-guided tree (HCT_R2E)) are tested for all data sets.", [["R2E", "PROTEIN", 248, 251], ["HCT_R2E", "CELL_LINE", 265, 272], ["one eigenvector (SVD1)", "TREATMENT", 44, 66], ["SVD", "PROBLEM", 68, 71], ["rank", "TEST", 136, 140], ["HCT", "TEST", 160, 163], ["random flips (HCT_RAM", "PROBLEM", 169, 190], ["R2E-guided tree (HCT_R2E)", "TREATMENT", 248, 273]]], ["We only summarize the results of two HCT and two non-HCT algorithms: SVD2, R2E, HCT_OPT, and HCT_R2E.", [["HCT", "CANCER", 37, 40], ["two HCT", "TEST", 33, 40], ["two non-HCT algorithms", "TEST", 45, 67], ["SVD2", "TEST", 69, 73], ["HCT_OPT", "TEST", 80, 87], ["HCT", "TEST", 93, 96]]], ["(Please see Additional file 1 for detailed comparison of all eight sorting algorithms.)Fibroblast to serum dataFor the gene expression data matrix of 517 genes observed in 12 arrays from the time series of fibroblasts to serum in [1] , we plot the GAR loss scores and the RGAR loss scores in Figures 3ab without redrawing the permuted matrix visualizations.ResultsThe GAR curves (window-size ranges from 1 to 516) for the four sorting algorithms plotted in Figure 3a produce the following observations:Results\u2022 the R2E (smooth green line) clearly outperforms (lowest GAR scores) the other three methods ;Results\u2022 the HCT_OPT algorithm has poor global (large windowsize) performance;Results\u2022 the proposed HCT_R2E method outperforms HCT_OPT, and is nearly as good as the SVD2 algorithm in the global sense.ResultsWe plot in Figure 3b the relative generalized anti-Robinson (RGAR) loss scores for better comparison of local behaviours among the four methods, to observe the following:Results\u2022 both HCT algorithms (curves with dots) outperform two non-HCT (smooth curves) in small window-size area (1 \u03f9 w \u03f9 50);Results\u2022 the optimal hierarchical clustering tree, HCT_OPT, has the best performance among the four HCTs for the smallest window-size area (1 \u03f9 w \u03f9 35);Results\u2022 the proposed HCT_R2E method actually scores best for a small period in the middle range (35 \u03f9 w \u03f9 75);Results\u2022 the R2E algorithm dominates the competition from w = 100 on.ResultsWithout the visualization of two smooth transitional patterns for up-and down-regulated genes in Figure 1b , HCT in Figure 1a suggests many gene-clusters with very coherent expression profiles, but with no knowledge of the possible embedded smooth transitional patterns.", [["Fibroblast", "ANATOMY", 87, 97], ["serum", "ANATOMY", 101, 106], ["fibroblasts", "ANATOMY", 206, 217], ["serum", "ANATOMY", 221, 226], ["Fibroblast", "CELL", 87, 97], ["serum", "ORGANISM_SUBSTANCE", 101, 106], ["fibroblasts", "CELL", 206, 217], ["serum", "ORGANISM_SUBSTANCE", 221, 226], ["GAR", "GENE_OR_GENE_PRODUCT", 248, 251], ["matrix", "CELLULAR_COMPONENT", 335, 341], ["HCT", "CANCER", 1555, 1558], ["517 genes", "DNA", 150, 159], ["fibroblasts", "CELL_TYPE", 206, 217], ["GAR", "PROTEIN", 248, 251], ["RGAR", "PROTEIN", 272, 276], ["GAR", "PROTEIN", 368, 371], ["R2E (smooth green line", "CELL_LINE", 515, 537], ["GAR", "PROTEIN", 567, 570], ["HCT_R2E", "DNA", 704, 711], ["HCT_OPT", "CELL_LINE", 731, 738], ["HCT_OPT", "CELL_LINE", 1158, 1165], ["regulated genes", "DNA", 1524, 1539], ["Fibroblast to serum data", "TEST", 87, 111], ["the GAR loss scores", "PROBLEM", 244, 263], ["the RGAR loss scores", "PROBLEM", 268, 288], ["the permuted matrix visualizations", "TEST", 322, 356], ["The GAR curves", "TEST", 364, 378], ["the four sorting algorithms", "TEST", 418, 445], ["the HCT_OPT algorithm", "TEST", 613, 634], ["poor global (large windowsize) performance", "PROBLEM", 639, 681], ["ResultsWe plot", "TEST", 804, 818], ["the relative generalized anti-Robinson (RGAR) loss scores", "PROBLEM", 832, 889], ["both HCT algorithms", "TEST", 990, 1009], ["two non-HCT (smooth curves", "TEST", 1040, 1066], ["the four HCTs", "TEST", 1198, 1211], ["the R2E algorithm", "TEST", 1379, 1396], ["the visualization", "TEST", 1454, 1471], ["HCT", "TEST", 1555, 1558], ["embedded smooth transitional patterns", "PROBLEM", 1678, 1715], ["GAR loss", "OBSERVATION", 248, 256], ["large", "OBSERVATION_MODIFIER", 652, 657], ["small", "OBSERVATION_MODIFIER", 1071, 1076], ["window", "OBSERVATION_MODIFIER", 1077, 1083], ["size", "OBSERVATION_MODIFIER", 1084, 1088], ["clustering tree", "OBSERVATION", 1141, 1156], ["size", "OBSERVATION_MODIFIER", 1236, 1240], ["small", "OBSERVATION_MODIFIER", 1323, 1328], ["middle", "ANATOMY_MODIFIER", 1343, 1349], ["smooth", "OBSERVATION_MODIFIER", 1479, 1485], ["transitional", "OBSERVATION", 1486, 1498], ["smooth", "OBSERVATION_MODIFIER", 1687, 1693], ["transitional patterns", "OBSERVATION", 1694, 1715]]], ["The proposed HCT_R2E method automatically integrates the coherent local property of HCT and the smooth global trend of R2E to provide users the improved Figure 1c .", [["HCT", "CANCER", 84, 87], ["HCT_R2E", "DNA", 13, 20], ["R2E", "CELL_LINE", 119, 122], ["HCT", "TEST", 84, 87], ["smooth", "OBSERVATION_MODIFIER", 96, 102]]], ["The visualization of the expression profile and the correlation matrices in Figure 1c provide users exploration for local behaviour of genes function closely together in small time scale and for more complicate global relationship with larger time interval simultaneously in such a time series expression experiment.ResultsGeneralized anti-Robinson (GAR) loss scores for Fibroblast to serum data [1]Yeast cell cycle dataThese data are a subset of the original 6240 genes expressed at 17 time points used in Cho et al. [16] .", [["Fibroblast", "ANATOMY", 371, 381], ["serum", "ANATOMY", 385, 390], ["cell", "ANATOMY", 405, 409], ["Fibroblast", "CELL", 371, 381], ["serum", "ORGANISM_SUBSTANCE", 385, 390], ["Yeast cell", "CELL", 399, 409], ["GAR", "PROTEIN", 350, 353], ["6240 genes", "DNA", 460, 470], ["Yeast", "SPECIES", 399, 404], ["exploration", "TEST", 100, 111], ["Generalized anti-Robinson (GAR) loss scores", "PROBLEM", 323, 366], ["Fibroblast to serum data", "TEST", 371, 395], ["cell cycle", "OBSERVATION", 405, 415]]], ["We selected the 145 genes that have been biologically characterized and assigned to five different cell cycle phases (early G1, late G1, S, G2, and M).", [["cell", "ANATOMY", 99, 103], ["cell", "CELL", 99, 103], ["145 genes", "DNA", 16, 25]]], ["Expression at one abnormal time point was removed from the data set (as suggested by [20] ) resulting in our gene expression profile of 145 genes at 16 time points.ResultsIn addition to lower intermediate to global GAR and RGAR loss scores (see Additional file 1 for details), the permutation identified by the proposed HCT_R2E method also possesses more meaningful biological implications than the other algorithms.", [["GAR", "GENE_OR_GENE_PRODUCT", 215, 218], ["145 genes", "DNA", 136, 145], ["GAR", "PROTEIN", 215, 218], ["RGAR", "PROTEIN", 223, 227], ["HCT_R2E", "DNA", 320, 327], ["global GAR and RGAR loss scores", "PROBLEM", 208, 239]]], ["The cell cycle phase diagrams for the three seriation algorithms (SVD2, HCT_OPT, and HCT_R2E) are shown in Figure 4 , where the identical inner circle represents the 145 genes sorted with the known cell cycle phase information.", [["cell", "ANATOMY", 4, 8], ["inner circle", "ANATOMY", 138, 150], ["cell", "ANATOMY", 198, 202], ["cell", "CELL", 4, 8], ["inner circle", "MULTI-TISSUE_STRUCTURE", 138, 150], ["cell", "CELL", 198, 202], ["SVD2", "PROTEIN", 66, 70], ["HCT_OPT", "PROTEIN", 72, 79], ["145 genes", "DNA", 166, 175], ["The cell cycle phase diagrams", "TEST", 0, 29], ["the three seriation algorithms", "TEST", 34, 64], ["SVD2", "TEST", 66, 70], ["HCT_OPT", "TEST", 72, 79], ["HCT", "TEST", 85, 88], ["cell cycle phase", "OBSERVATION", 4, 20], ["cell cycle phase", "OBSERVATION", 198, 214]]], ["The outer circle for each algorithm is rotated to its best position among all 145 possible rotations according to the following criteria: the simple match score computes the proportion of correct (against known phase information) matches for all 145 gene positions, ranging from 0 (worst) to 1 (best); the weighted match score assigns weights of (2, 1, 0) to genes that deviate from the known phase by (0, 1, 2) phase groups, and is also scaled to 0 (worst) to 1 (best); the total deviation score sums the deviations (by number of genes) of all 145 genes to the boundaries of their known phases.", [["weights", "TEST", 335, 342], ["the total deviation score", "PROBLEM", 471, 496], ["outer", "ANATOMY_MODIFIER", 4, 9]]], ["Both the simple match and weighted match are gain scores (the higher the better) while the total deviation is a loss score (the lower the better).ResultsFrom Table 1 we see that the proposed HCT_R2E algorithm outperforms the other seven algorithms in all three matching scores.", [["HCT_R2E", "DNA", 191, 198], ["a loss score", "PROBLEM", 110, 122], ["simple", "OBSERVATION_MODIFIER", 9, 15]]], ["Through visualization, the cell cycle diagrams sorted by the three algorithms can be roughly separated into three classes:Results\u2022 SVD2 performed rather poorly;Results\u2022 HCT_OPT permutation showed better correlation to the known phases than SVD2;Results\u2022 HCT_R2E arranged the 145 genes at positions very close to their annotated phase positions.ResultsAlthough the HCT_R2E algorithm aligned the 145 genes close to their known phases, several genes deviated far away from their annotated cell cycle phases, as can be seen from the cell cycle diagram in Figure 4c .", [["cell", "ANATOMY", 27, 31], ["cell", "ANATOMY", 486, 490], ["cell", "ANATOMY", 529, 533], ["cell", "CELL", 27, 31], ["cell", "CELL", 486, 490], ["cell", "CELL", 529, 533], ["SVD2", "PROTEIN", 131, 135], ["SVD2", "DNA", 240, 244], ["HCT_R2E", "DNA", 254, 261], ["145 genes", "DNA", 275, 284], ["HCT_R2E algorithm", "DNA", 364, 381], ["145 genes", "DNA", 394, 403], ["the cell cycle diagrams", "TEST", 23, 46], ["HCT_OPT permutation", "TEST", 169, 188], ["the HCT_R2E algorithm", "TEST", 360, 381]]], ["We further examined the phase annotations provided by another yeast cell cycle study of Spellman et al. [21] ; the cross-annotated phase labels for both studies are listed in Additional file 2.ResultsCell cycle phase diagrams for Yeast cell cycle data [16] The 15 genes with largest deviations from their annotated phase groups sorted by the proposed HCT_R2E algorithm are bold-faced.", [["cell", "ANATOMY", 68, 72], ["Cell", "ANATOMY", 200, 204], ["Yeast cell", "ANATOMY", 230, 240], ["yeast cell", "CELL", 62, 72], ["Cell", "CELL", 200, 204], ["Yeast cell", "CELL", 230, 240], ["HCT_R2E algorithm", "DNA", 351, 368], ["yeast", "SPECIES", 62, 67], ["yeast", "SPECIES", 62, 67], ["another yeast cell cycle study", "TEST", 54, 84], ["the cross-annotated phase labels", "TEST", 111, 143], ["Cell cycle phase diagrams", "TEST", 200, 225], ["Yeast cell cycle data", "TEST", 230, 251], ["largest deviations", "PROBLEM", 275, 293], ["largest", "OBSERVATION_MODIFIER", 275, 282]]], ["From the corresponding annotated phases of [21] , in the last column, we see that the Spellman et al. [21] annotated phases for these 15 genes either fit better into the overall cell cycle pattern (e.g., YKL067W from S to G1, and YEL017W from early G1 to S/G2), or their phase conditions are not annotated (7 out of 15).", [["cell", "ANATOMY", 178, 182], ["cell", "CELL", 178, 182], ["overall cell cycle", "OBSERVATION", 170, 188]]], ["This result further implies the proposed algorithm can be applied to either verify known biological conditions or to explore unknown phenomena.Severe acute respiratory syndrome coronavirus (SARS-CoV) dataIn the severe acute respiratory syndrome (SARS) study of Lee et al. [17] , the expression profiles of 52 signature genes are used to explore the between-sample severity pattern from normal controls to acute SARS patients.", [["acute respiratory syndrome coronavirus", "DISEASE", 150, 188], ["SARS", "DISEASE", 190, 194], ["acute respiratory syndrome", "DISEASE", 218, 244], ["SARS", "DISEASE", 246, 250], ["SARS", "DISEASE", 411, 415], ["patients", "ORGANISM", 416, 424], ["52 signature genes", "DNA", 306, 324], ["patients", "SPECIES", 416, 424], ["Severe acute respiratory syndrome coronavirus", "SPECIES", 143, 188], ["SARS-CoV", "SPECIES", 190, 198], ["known biological conditions", "PROBLEM", 83, 110], ["unknown phenomena", "PROBLEM", 125, 142], ["Severe acute respiratory syndrome coronavirus", "PROBLEM", 143, 188], ["the severe acute respiratory syndrome", "PROBLEM", 207, 244], ["the expression profiles", "TEST", 279, 302], ["acute SARS patients", "PROBLEM", 405, 424], ["acute", "OBSERVATION_MODIFIER", 150, 155], ["respiratory syndrome coronavirus", "OBSERVATION", 156, 188], ["severe", "OBSERVATION_MODIFIER", 211, 217], ["acute", "OBSERVATION_MODIFIER", 218, 223], ["respiratory syndrome", "OBSERVATION", 224, 244], ["normal", "OBSERVATION", 386, 392]]], ["A Euclidean distance matrix among 55 samples (11 acute SARS (AS) patients, 33 recovering SARS (RS) patients, and 11 normal control (NC) subjects) using these 52 genes is computed to identify a potential order that could reflect the severity structure of the disease.", [["samples", "ANATOMY", 37, 44], ["SARS", "DISEASE", 55, 59], ["SARS", "DISEASE", 89, 93], ["RS", "DISEASE", 95, 97], ["patients", "ORGANISM", 65, 73], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 65, 73], ["patients", "SPECIES", 99, 107], ["A Euclidean distance matrix", "TEST", 0, 27], ["acute SARS", "PROBLEM", 49, 59], ["the disease", "PROBLEM", 254, 265], ["disease", "OBSERVATION", 258, 265]]], ["There are three major differences between this SARS example and the yeast cell cycle data analysis.", [["cell", "ANATOMY", 74, 78], ["SARS", "DISEASE", 47, 51], ["yeast cell", "CELL", 68, 78], ["yeast", "SPECIES", 68, 73], ["yeast", "SPECIES", 68, 73], ["this SARS example", "TEST", 42, 59], ["the yeast cell cycle data analysis", "TEST", 64, 98], ["three", "OBSERVATION_MODIFIER", 10, 15], ["major", "OBSERVATION_MODIFIER", 16, 21], ["yeast cell", "OBSERVATION", 68, 78]]], ["These are not time series gene expression data; the focus is on the between-sample structure instead of the gene set; and the proximity measure adopted is the between-sample Euclidean distance instead of the correlation coefficient.ResultsThe same eight algorithms are used to sort the Euclidean distance matrices for the 55 samples but only results of the three methods, HCT_OPT, R2E, and HCT_R2E are displayed.", [["HCT_R2E", "GENE_OR_GENE_PRODUCT", 390, 397], ["HCT_OPT", "DNA", 372, 379], ["R2E", "DNA", 381, 384], ["HCT_R2E", "DNA", 390, 397], ["HCT_OPT", "TEST", 372, 379]]], ["The corresponding expression profile matrices with related HCT dendrograms and the sorted colour bands for sample identities are displayed in Figure 5 .", [["sample", "ANATOMY", 107, 113], ["HCT", "CANCER", 59, 62], ["HCT dendrograms", "DNA", 59, 74], ["related HCT dendrograms", "PROBLEM", 51, 74], ["the sorted colour bands", "PROBLEM", 79, 102], ["sample identities", "TEST", 107, 124]]], ["We observe the following:Results\u2022 there is a clear uni-dimensional Robinson pattern for this SARS Euclidean matrix;Results\u2022 the HCT_OPT (Figure 5a ) algorithm presented rather coherent local structure;Results\u2022 R2E ( Figure 5b ) sorted samples identify colour bands that exhibit a clear blue (NC) to yellow (RS) to red (AS) severity structure of the disease;Results\u2022 the Euclidean matrix sorted by the proposed HCT_R2E (Figure 5c ) method displays very coherent local relationships, as well as extremely good global structure.", [["samples", "ANATOMY", 235, 242], ["R2E", "PROTEIN", 210, 213], ["this SARS Euclidean matrix", "PROBLEM", 88, 114], ["the HCT_OPT", "TEST", 124, 135], ["sorted samples", "TEST", 228, 242], ["colour bands", "TEST", 252, 264], ["a clear blue", "PROBLEM", 278, 290], ["red (AS) severity structure of the disease", "PROBLEM", 314, 356], ["clear", "OBSERVATION_MODIFIER", 280, 285], ["blue", "OBSERVATION", 286, 290], ["disease", "OBSERVATION", 349, 356]]], ["Its identity colour band has a coherent within sample-subtype patternResultsWe have summarized the numerical comparisons (GAR, RGAR) for the eight sorting algorithms in Additional file 1.ResultsIn [17] , the R2E permuted sample rank of SARS severity was identified to be significantly correlated with the clinical pulmonary infection score (CPIS) and other clinical factors.", [["pulmonary", "ANATOMY", 314, 323], ["SARS", "DISEASE", 236, 240], ["pulmonary infection", "DISEASE", 314, 333], ["pulmonary", "ORGAN", 314, 323], ["GAR", "PROTEIN", 122, 125], ["SARS severity", "PROBLEM", 236, 249], ["the clinical pulmonary infection score", "PROBLEM", 301, 339], ["CPIS", "TEST", 341, 345], ["other clinical factors", "PROBLEM", 351, 373], ["colour", "OBSERVATION_MODIFIER", 13, 19], ["band", "OBSERVATION_MODIFIER", 20, 24], ["coherent", "OBSERVATION_MODIFIER", 31, 39], ["subtype pattern", "OBSERVATION", 54, 69], ["pulmonary", "ANATOMY", 314, 323], ["infection", "OBSERVATION", 324, 333]]], ["The severity rank of samples was also found to be highly correlated with the suppression of the human Table 2 and we note the following:Results\u2022 the proposed HCT_R2E algorithm has the highest correlation with number of days after the onset of disease while the R2E method comes next;Results\u2022 the proposed HCT_R2E algorithm has the highest correlation with CPIS among all eight sorting methods, while the SVD1 and HCT_OPT algorithms share second place From these comparisons we observe a significant advantage of the proposed R2E-guided hierarchical clustering tree in searching for meaningful biomedical information and correlation such that researchers can further propose more precise hypotheses and conducting more accurate experiments.Transition metal stress dataKaur et al. [18] ).", [["samples", "ANATOMY", 21, 28], ["human", "ORGANISM", 96, 101], ["HCT_R2E", "DNA", 158, 165], ["HCT_R2E", "DNA", 305, 312], ["SVD1 and HCT_OPT algorithms", "DNA", 404, 431], ["R2E", "DNA", 525, 528], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 96, 101], ["disease", "PROBLEM", 243, 250], ["CPIS", "TEST", 356, 360], ["the SVD1 and HCT_OPT algorithms", "TEST", 400, 431], ["disease", "OBSERVATION", 243, 250]]], ["Halobacterium NRC-1 was exposed for five hours to at least three concentrations of each of the six transition metals.", [["Halobacterium NRC-1", "CELL", 0, 19], ["Halobacterium NRC-1", "SPECIES", 0, 19], ["Halobacterium NRC", "PROBLEM", 0, 17], ["the six transition metals", "TREATMENT", 91, 116]]], ["In Figure 5 of [18] , using 468 genes that changed significantly in at least two conditions out of a total of 19 (3 concentrations for , an HCT and a correspondence analysis (CA, [22] ) are carried out (we only obtained 444 genes using identical selection criteria).", [["an HCT", "TEST", 137, 143], ["a correspondence analysis", "TEST", 148, 173], ["CA", "TEST", 175, 177]]], ["Their HCT permutation for the 19 metal conditions does not correlate well with the pattern displayed in their CA plot for the conditions.", [["Their HCT permutation", "TREATMENT", 0, 21]]], ["Our task here is to guide the flips of HCT intermediate nodes by the R2E algorithm with the hope that the resulting permutation does not contradict that of the CA analysis.ResultsThe CA plot is reconstructed in Figure 6a .", [["HCT intermediate nodes", "ANATOMY", 39, 61], ["HCT intermediate nodes", "MULTI-TISSUE_STRUCTURE", 39, 61], ["CA", "GENE_OR_GENE_PRODUCT", 160, 162], ["HCT intermediate nodes", "PROBLEM", 39, 61], ["the CA analysis", "TEST", 156, 171], ["The CA plot", "TEST", 179, 190], ["intermediate nodes", "OBSERVATION", 43, 61]]], ["The optimal HCT and the proposed elliptical seriation-guided HCT with their permuted Euclidean matrices are displayed in Figure 6bc .", [["HCT", "CANCER", 12, 15], ["The optimal HCT", "TEST", 0, 15], ["HCT", "TEST", 61, 64], ["their permuted Euclidean matrices", "TREATMENT", 70, 103]]], ["Although HCT_OPT does identify good local clusters for the metal groups, the overall permutation does not correlate well with the linear trend from the CA analysis.", [["HCT_OPT", "PROTEIN", 9, 16], ["the CA analysis", "TEST", 148, 163]]], ["The HCT_R2E permutation not only correlates with the linear trend of transition metal groups very well, it also sorts the within-metal group concentration levels precisely following those orders in the CA analysis in Figure 6a .ResultsThis study illustrates well that the proposed HCT_R2E method is capable of providing permutations with both good global and local properties, although the optimal HCT still outputs better local orders numerically.", [["transition metal", "CHEMICAL", 69, 85], ["HCT_R2E", "DNA", 4, 11], ["CA", "PROTEIN", 202, 204], ["HCT_R2E", "DNA", 281, 288], ["The HCT_R2E permutation", "PROBLEM", 0, 23], ["the CA analysis", "TEST", 198, 213], ["This study", "TEST", 235, 245], ["the optimal HCT", "TEST", 386, 401]]], ["The accompanying distance matrix map clearly indicates the Zn(0.005) and Cu(0.7) conditions, in addition to the Ni [II] conditions, deviate from the main linear trend of these transition metals and the Robinson pattern.Discussion and ConclusionWhen analyzing gene expression profile data sets, researchers usually apply a hierarchical clustering tree (HCT) to search for coherent local clusters and the singular value decomposition (SVD) to identify smooth global trends.", [["Zn", "CHEMICAL", 59, 61], ["Cu", "CHEMICAL", 73, 75], ["Ni", "CHEMICAL", 112, 114], ["Zn", "CHEMICAL", 59, 61], ["Cu", "CHEMICAL", 73, 75], ["Ni [II]", "CHEMICAL", 112, 119], ["coherent local clusters", "PROBLEM", 371, 394], ["main", "OBSERVATION_MODIFIER", 149, 153], ["linear", "OBSERVATION_MODIFIER", 154, 160], ["trend", "OBSERVATION_MODIFIER", 161, 166], ["transition metals", "OBSERVATION", 176, 193], ["Robinson pattern", "OBSERVATION", 202, 218]]], ["Users of HCT dendrograms would identify only local clusters without knowing the existence of global structure that might accompany cell cycle-regulated experiments, dosage level studies, or subtypes of tumours.", [["cell", "ANATOMY", 131, 135], ["tumours", "ANATOMY", 202, 209], ["tumours", "DISEASE", 202, 209], ["cell", "CELL", 131, 135], ["tumours", "CANCER", 202, 209], ["HCT dendrograms", "TREATMENT", 9, 24], ["cell cycle-regulated experiments", "PROBLEM", 131, 163], ["dosage level studies", "TEST", 165, 185], ["tumours", "PROBLEM", 202, 209], ["cell cycle-regulated", "OBSERVATION", 131, 151], ["tumours", "OBSERVATION", 202, 209]]], ["Applications of SVD on the other hand may overlook the importance of local behaviour.Discussion and ConclusionWhile the optimal HCT [7] always produces permutations with best local behaviour, the rank-two ellipse seriation [3] gives the best global grouping patterns and smooth transitional trends.", [["SVD", "PROBLEM", 16, 19], ["the optimal HCT", "TEST", 116, 131], ["SVD", "OBSERVATION", 16, 19], ["smooth", "OBSERVATION_MODIFIER", 271, 277], ["transitional trends", "OBSERVATION", 278, 297]]], ["The proposed hierarchical clustering tree guided by rank-two ellipse seriation (HCT_R2E) nicely integrates these two extremes and provides users both coherent local clusters and smooth global patterns for gene expression profile studies.Discussion and ConclusionIn four data analyses, the proposed HCT_R2E algorithm not only exhibits outstanding numerical (statistical) performance, it also provides us better insights into the biomedical information embedded in these high dimensional data structures.", [["HCT_R2E algorithm", "DNA", 298, 315], ["two ellipse seriation (HCT_R2E", "TREATMENT", 57, 87], ["gene expression profile studies", "TEST", 205, 236], ["four data analyses", "TEST", 265, 283], ["hierarchical", "OBSERVATION_MODIFIER", 13, 25], ["clustering tree", "OBSERVATION", 26, 41]]], ["Visualization of sorted proximity matrices in addition to the visualization of the expression profile matrices also greatly enhances the overall comprehension of the association structures of arrays and genes.Applicability and limitationAs was illustrated in the two time series data sets, the proposed rank-two ellipse-guided hierarchical clustering (HCT_R2E) is very powerful in identifying smooth time series patterns.", [["overall", "OBSERVATION_MODIFIER", 137, 144], ["comprehension", "OBSERVATION", 145, 158]]], ["The SARS data and the transitional metal data, on the other hand, showed the proposed method can also be used to search for potential global grouping structure for genes, and for arrays embedded in the given gene expression profiles.", [["The SARS data", "TEST", 0, 13], ["the transitional metal data", "TEST", 18, 45]]], ["Transition metal stress data [18] Figure 6 Transition metal stress data [18] .", [["metal stress data", "TEST", 11, 28], ["metal stress data", "TEST", 54, 71]]], ["Visualization of differential gene expression profiles of Halobacterium NRC-1 exposed for five hours to at least three concentrations of each of the six transition metals ( When the underlying clustering pattern is a clear disjoint one, the rank-two ellipse seriation method is only capable of identifying the global between-cluster pattern, not the within-cluster relationship.", [["Halobacterium NRC-1", "CELL", 58, 77], ["Halobacterium NRC-1", "SPECIES", 58, 77], ["Halobacterium NRC", "TREATMENT", 58, 75], ["the six transition metals", "TREATMENT", 145, 170]]], ["The optimal tree method gives better permutations than the proposed method for such circumstances.Applicability and limitationThe R2E algorithm (and the HCT_R2E method) is computationally more time consuming than other methods.", [["The R2E algorithm", "TEST", 126, 143]]], ["It takes a personal computer (Celeron (R) 3.2 GHz CPU with 512 MB RAM) running C++ on Windows XP about (0.09 sec, 9.09 sec, and 2.71 hr) to obtain the R2E permutations for proximity matrices with (50, 500, 5000) rows/ columns.", [["MB RAM", "TEST", 63, 69], ["proximity matrices", "TEST", 172, 190]]], ["The computation complexity for R2E is of order n 3 .", [["R2E", "DNA", 31, 34]]], ["The computing speed is much slower in the current Java version GAP package although we are implementing a much faster algorithm now.", [["GAP", "GENE_OR_GENE_PRODUCT", 63, 66], ["GAP", "PROTEIN", 63, 66]]], ["We have also developed a prototype PC cluster system for performing the proposed methods for very large proximity matrices that will be released after it has been fully tested.MethodsVarious concepts have been proposed for rearranging objects in statistical graphs in order to display information structure more effectively.", [["a prototype PC cluster system", "TREATMENT", 23, 52], ["the proposed methods", "TREATMENT", 68, 88], ["very large proximity matrices", "PROBLEM", 93, 122], ["statistical graphs", "TEST", 246, 264]]], ["Chen [3] proposed the concept of \"relativity of a statistical graph\" for placing similar (different) objects at closer (distant) positions in a statistical graph.", [["a statistical graph", "TEST", 142, 161]]], ["The local property optimized by the aforementioned HCT techniques realizes only half of the relativity concept when it places similar objects in closer proximity without the necessity of distancing distinct objects.Rank-two ellipse seriationChen [3] introduced a sorting algorithm called rank-two ellipse (R2E) seriation that extracts the elliptical structure at iteration with rank two of the converging sequence of iteratively formed correlation matrices.", [["the aforementioned HCT techniques", "TREATMENT", 32, 65], ["a sorting algorithm", "TEST", 261, 280], ["two ellipse (R2E) seriation", "TREATMENT", 293, 320], ["elliptical", "OBSERVATION_MODIFIER", 339, 349]]], ["R2E improves SVD in identifying even smoother global permutations.", [["R2E", "DNA", 0, 3], ["SVD", "PROBLEM", 13, 16], ["SVD", "OBSERVATION", 13, 16], ["smoother", "OBSERVATION_MODIFIER", 37, 45], ["global permutations", "OBSERVATION", 46, 65]]], ["There are two advantages of the R2E method over the SVD method in the sorting of arrays and genes in expression profile matrices.", [["the R2E method", "TREATMENT", 28, 42], ["the SVD method", "TREATMENT", 48, 62]]], ["The first is that users do not need to choose the number of leading components; the R2E method always summarizes the embedding variation structure into the final two eigenvectors of the rank-two correlation matrix.", [["matrix", "CELLULAR_COMPONENT", 207, 213], ["the R2E method", "TREATMENT", 80, 94]]], ["With a uni-dimensional underlying structure, the two eigenvectors form a half-ellipse pattern for sorting purposes.", [["a uni-dimensional underlying structure", "PROBLEM", 5, 43], ["structure", "OBSERVATION", 34, 43]]], ["The second advantage is that it can be applied to any given proximity matrix, be it correlation, covariance, Euclidean distance, or other proximity matrix for genes and arrays.Proximity matrix visualizationAlthough both the dendrogram of an HCT and representative genes (arrays) of an SVD are generated from given proximity matrices, researchers usually do not pay much attention to the sorted proximity matrices.Proximity matrix visualizationComparing the permuted gene-by-gene correlation matrices in Figures 1a and 1c we see that the HCT forms many blocks along the main diagonal of the correlation matrix while rank-two method identifies two smooth transitional patterns for up-and down-regulated genes.", [["matrix", "CELLULAR_COMPONENT", 70, 76], ["matrix", "CELLULAR_COMPONENT", 148, 154], ["matrix", "CELLULAR_COMPONENT", 186, 192], ["HCT", "CANCER", 241, 244], ["matrix", "CELLULAR_COMPONENT", 423, 429], ["HCT", "CANCER", 537, 540], ["matrix", "CELLULAR_COMPONENT", 602, 608], ["SVD", "DNA", 285, 288], ["HCT", "DNA", 537, 540], ["regulated genes", "DNA", 691, 706], ["Proximity matrix visualization", "TEST", 176, 206], ["an HCT", "TEST", 238, 244], ["an SVD", "PROBLEM", 282, 288], ["Proximity matrix visualization", "TEST", 413, 443], ["the HCT", "TEST", 533, 540], ["many blocks", "PROBLEM", 547, 558], ["main", "OBSERVATION_MODIFIER", 569, 573], ["diagonal", "ANATOMY_MODIFIER", 574, 582], ["smooth", "OBSERVATION_MODIFIER", 646, 652], ["transitional patterns", "OBSERVATION", 653, 674]]], ["Without the visualization of correlation matrix in Figure 1a , HCT suggests many gene-clusters with very coherent expression profiles, but with no knowledge of the possible embedded smooth transitional patterns.", [["HCT", "CANCER", 63, 66], ["HCT", "TEST", 63, 66], ["embedded smooth transitional patterns", "PROBLEM", 173, 210], ["smooth", "OBSERVATION_MODIFIER", 182, 188], ["transitional patterns", "OBSERVATION", 189, 210]]], ["In light of both correlation matrices in Figures 1a and 1c one can see that the gene-clusters actually are formed only because of the constraints imposed by the HCT dendrogram branching structure; the within-cluster coherent expression profiles are correctly identified, but the between-clusters contrasting patterns may not be applicable.Proximity matrix visualizationIn addition to the visualization of permuted expression profile matrices, we want to emphasize the importance of visualization of sorted proximity matrices for comparing the differences in permutations that result from various sorting algorithms.Integration of local clustering patterns and global grouping structuresLocal coherent gene clusters with very similar expression profiles may represent groups of genes that are co-regulated by certain transcription factors or activated by identical binding sites.", [["matrix", "CELLULAR_COMPONENT", 349, 355], ["transcription factors", "PROTEIN", 816, 837], ["binding sites", "DNA", 864, 877], ["the HCT dendrogram branching structure", "PROBLEM", 157, 195], ["Proximity matrix visualization", "TEST", 339, 369], ["various sorting algorithms", "TEST", 588, 614], ["global grouping structures", "PROBLEM", 660, 686], ["branching", "OBSERVATION_MODIFIER", 176, 185], ["local clustering", "OBSERVATION", 630, 646], ["global", "OBSERVATION_MODIFIER", 660, 666], ["gene clusters", "OBSERVATION", 701, 714]]], ["Global clustering patterns and smooth transitional trends on the other hand, could signal some biological processes at a higher-level control, such as metabolite pathways or the cell-cycle operation.", [["cell", "ANATOMY", 178, 182], ["cell", "CELL", 178, 182], ["Global clustering patterns", "PROBLEM", 0, 26], ["smooth transitional trends on the other hand", "PROBLEM", 31, 75], ["some biological processes", "PROBLEM", 90, 115], ["a higher-level control", "TREATMENT", 119, 141], ["the cell-cycle operation", "TREATMENT", 174, 198], ["clustering", "OBSERVATION", 7, 17], ["smooth", "OBSERVATION_MODIFIER", 31, 37], ["transitional trends", "OBSERVATION", 38, 57]]], ["It is necessary to develop clustering and visualization methods that can simultaneously explore local behaviours as well as global grouping effects of gene expression profiles.Integration of local clustering patterns and global grouping structuresThis study proposes to guide the flipping mechanism of a conventional agglomerative HCT with the rank-two ellipse (R2E) seriation as an external reference.", [["HCT", "CANCER", 331, 334], ["visualization methods", "TEST", 42, 63], ["gene expression profiles", "PROBLEM", 151, 175], ["global grouping structures", "PROBLEM", 221, 247], ["This study", "TEST", 247, 257], ["a conventional agglomerative HCT", "TEST", 302, 334], ["two ellipse (R2E) seriation", "TREATMENT", 349, 376], ["local clustering", "OBSERVATION", 191, 207], ["global", "OBSERVATION_MODIFIER", 221, 227]]], ["The standard working procedure of the proposed algorithm for gene clustering is illustrated as steps 0~5 in Figure 7 ,Generalized anti-Robinson criteriaIn order to compare the performances of different sorting algorithms, some standard criteria have to be established.", [["the proposed algorithm", "TREATMENT", 34, 56], ["Generalized anti-Robinson criteriaIn", "TREATMENT", 118, 154]]], ["As is illustrated in Figure 8a , the minimum travelling distance in a travelling salesman problem can be used to evaluate local behaviour, while the anti-Robinson eventcount (AR in equation 1 and Figure 8b ) works well for global performance.", [["AR", "PROTEIN", 175, 177], ["the anti-Robinson eventcount", "TREATMENT", 145, 173]]], ["Given a distance-type proximity matrix, Proposed R2E guided HCT procedure for gene clustering Figure 7 Proposed R2E guided HCT procedure for gene clustering.", [["matrix", "CELLULAR_COMPONENT", 32, 38], ["HCT", "CANCER", 123, 126], ["R2E", "DNA", 49, 52], ["R2E", "DNA", 112, 115], ["a distance-type proximity matrix", "TREATMENT", 6, 38], ["Proposed R2E guided HCT procedure", "TREATMENT", 40, 73], ["gene clustering Figure", "TREATMENT", 78, 100], ["Proposed R2E guided HCT procedure", "TREATMENT", 103, 136], ["gene clustering", "PROBLEM", 141, 156]]], ["The proposed algorithm for constructing the R2E-guided HCT for gene permutation using the between array correlation matrix in Figure 2 .Generalized anti-Robinson criteria0.", [["HCT", "CANCER", 55, 58], ["R2E", "DNA", 44, 47], ["gene permutation", "TREATMENT", 63, 79], ["Generalized anti-Robinson criteria0", "PROBLEM", 136, 171]]], ["Given a gene-by-array expression profile matrix, M gg , (Figure 3a ).Generalized anti-Robinson criteria2.", [["matrix", "CELLULAR_COMPONENT", 41, 47], ["Generalized anti-Robinson criteria2", "PROBLEM", 69, 104]]], ["Select an HCT linkage type (e.g., single, complete, average, centroid, etc.) and construct the hierarchical clustering tree, HCT, for R gg and obtain the rank-two ellipse seriation, R2E, for R g*g .", [["R gg", "GENE_OR_GENE_PRODUCT", 134, 138], ["R g*g", "GENE_OR_GENE_PRODUCT", 191, 196], ["R gg", "DNA", 134, 138], ["R2E", "DNA", 182, 185], ["an HCT linkage type", "TEST", 7, 26], ["HCT", "TEST", 125, 128], ["R gg", "TEST", 134, 138], ["the rank", "TEST", 150, 158]]], ["Define relative positions (1, \u2026, g) of the g terminal nodes, the travelling salesman algorithm optimizes the permutation by minimizing the total consecutive distances along the entire permutation.", [["g terminal nodes", "ANATOMY", 43, 59], ["g terminal nodes", "DNA", 43, 59], ["the g terminal nodes", "PROBLEM", 39, 59], ["the permutation", "TREATMENT", 105, 120], ["positions", "OBSERVATION_MODIFIER", 16, 25], ["terminal", "ANATOMY_MODIFIER", 45, 53], ["nodes", "OBSERVATION", 54, 59], ["total", "OBSERVATION_MODIFIER", 139, 144]]], ["That is, one minimizes the summation along the off-diagonal containing the ith to (i+1)st components of the matrix (Figure 8a ).Generalized anti-Robinson criteriaFor a permuted proximity matrix, D n \u00d7 n = [d ij ], the generalized anti-Robinson loss function is defined as the number of deviation from the Robinson form,Generalized anti-Robinson criteriawhere w is the window-size defining the range of summation, and I is an indicator function that outputs 1 if the condition is satisfied.", [["anti-Robinson loss", "DISEASE", 230, 248], ["matrix", "CELLULAR_COMPONENT", 108, 114], ["matrix", "CELLULAR_COMPONENT", 187, 193], ["off-diagonal", "DNA", 47, 59], ["Generalized anti-Robinson criteria", "PROBLEM", 128, 162], ["a permuted proximity matrix", "TREATMENT", 166, 193], ["D n \u00d7 n", "TREATMENT", 195, 202], ["the generalized anti-Robinson loss function", "PROBLEM", 214, 257], ["Generalized anti-Robinson criteriawhere", "PROBLEM", 319, 358], ["summation", "OBSERVATION_MODIFIER", 27, 36], ["diagonal", "ANATOMY_MODIFIER", 51, 59], ["matrix", "ANATOMY_MODIFIER", 108, 114], ["ij", "ANATOMY", 208, 210], ["generalized", "OBSERVATION_MODIFIER", 218, 229], ["anti-Robinson loss", "OBSERVATION", 230, 248], ["size", "OBSERVATION_MODIFIER", 375, 379]]], ["Window-size is the number of col-Generalized anti-Robinson criteriaGeneralized anti-Robinson criteria (c) umns (rows) from the diagonal of D that we consider in calculating the anti-Robinson events.", [["Generalized anti-Robinson criteria (c) umns (rows", "PROBLEM", 67, 116], ["size", "OBSERVATION_MODIFIER", 7, 11]]], ["Small window-sizes refer to criteria for considering only local behaviours, and larger window-sizes refer to criteria for more global relationship between subjects.Generalized anti-Robinson criteriaThe minimum travelling distance can be treated as one special Robinson form with a smallest window-size (w = 1) in counting the anti-Robinson events, while the original AR (equation 1) criterion has the largest window-size (w = n -1).", [["AR", "PROTEIN", 367, 369], ["Small window-sizes", "PROBLEM", 0, 18], ["Generalized anti-Robinson criteria", "PROBLEM", 164, 198], ["the anti-Robinson events", "PROBLEM", 322, 346], ["window", "OBSERVATION", 6, 12], ["sizes", "OBSERVATION_MODIFIER", 13, 18], ["larger", "OBSERVATION_MODIFIER", 80, 86], ["sizes", "OBSERVATION_MODIFIER", 94, 99], ["minimum", "OBSERVATION_MODIFIER", 202, 209], ["size", "OBSERVATION_MODIFIER", 297, 301], ["largest", "OBSERVATION_MODIFIER", 401, 408], ["size", "OBSERVATION_MODIFIER", 416, 420]]], ["A window-size between 1 and n-1 opens up a banding area from the main-diagonal for counting the number of anti-Robinson events.", [["A window-size", "TREATMENT", 0, 13], ["a banding area", "TREATMENT", 41, 55], ["anti-Robinson events", "PROBLEM", 106, 126], ["size", "OBSERVATION_MODIFIER", 9, 13], ["banding", "OBSERVATION", 43, 50], ["main", "OBSERVATION_MODIFIER", 65, 69], ["diagonal", "ANATOMY_MODIFIER", 70, 78]]], ["When we plot the GAR scores against w (window-size) we usually see a monotonic smooth increasing curve since the number of anti-Robinson events grows larger with window-size.", [["GAR", "GENE_OR_GENE_PRODUCT", 17, 20], ["GAR", "PROTEIN", 17, 20], ["the GAR scores", "TEST", 13, 27], ["a monotonic smooth increasing curve", "PROBLEM", 67, 102], ["anti-Robinson events", "PROBLEM", 123, 143], ["smooth", "OBSERVATION_MODIFIER", 79, 85], ["increasing", "OBSERVATION_MODIFIER", 86, 96], ["larger", "OBSERVATION_MODIFIER", 150, 156], ["size", "OBSERVATION_MODIFIER", 169, 173]]], ["In order to have better comparison among different sorting algorithms for small window-sizes we also define the relative generalized anti-Robinson loss function, which ranges between 0 (no anti-Robinson events) to 1 (all anti-Robinson events).", [["anti-Robinson loss", "DISEASE", 133, 151], ["small window-sizes", "TREATMENT", 74, 92], ["the relative generalized anti-Robinson loss function", "PROBLEM", 108, 160], ["anti-Robinson events", "PROBLEM", 189, 209], ["generalized", "OBSERVATION_MODIFIER", 121, 132], ["anti-Robinson loss", "OBSERVATION", 133, 151]]], ["The RGAR curves have better resolution for small window-size region than the GAR curves for comparing performance of algorithms.Availability and requirementsThe rank-two ellipse (R2E) seriation and the R2E-guided hierarchical clustering tree methods are implemented in the GAP (generalized association plots) system.", [["GAP", "GENE_OR_GENE_PRODUCT", 273, 276], ["RGAR", "PROTEIN", 4, 8], ["GAR", "PROTEIN", 77, 80], ["R2E", "DNA", 202, 205], ["GAP", "PROTEIN", 273, 276], ["The RGAR curves", "TEST", 0, 15], ["small window-size region", "PROBLEM", 43, 67], ["the GAR curves", "TEST", 73, 87], ["algorithms", "TEST", 117, 127], ["The rank", "TEST", 157, 165], ["seriation", "TEST", 184, 193], ["the R2E", "TEST", 198, 205], ["small", "OBSERVATION_MODIFIER", 43, 48], ["window", "OBSERVATION", 49, 55], ["size", "OBSERVATION_MODIFIER", 56, 60], ["clustering tree", "OBSERVATION", 226, 241]]], ["Genes are arranged by the proposed HCT_R2E algorithm; phase conditions for [16] are colour coded according to the phase legend provided in Figure 4 .Availability and requirementsClick here for file [http://www.biomedcentral.com/content/supplementary/1471-2105-9-155-S2.zip]", [["HCT_R2E", "DNA", 35, 42]]]], "PMC7223883": [["IntroductionThere are several studies indicating that presence of pediatric intensivist improves the quality of care in pediatric intensive care units (PICUs) [1, 2].", [["several studies", "TEST", 22, 37]]], ["In those countries, favorable impact of 24 h in-hospital presence of a PICU attending physician had been demonstrated [3, 4].", [["favorable", "OBSERVATION_MODIFIER", 20, 29]]], ["In Turkey, before the graduation of pioneer PICU fellows, only 30% of the PICUs were attended by pediatric intensivists [5].", [["PICUs", "CANCER", 74, 79]]], ["In high-income countries, organization of PICUs were completed 30 y ago and many studies about the quality of care were conducted since then.", [["high", "OBSERVATION_MODIFIER", 3, 7]]], ["There had been no PICU specialists in that hospital previously and this situation allowed authors to measure how the presence of an intensivist affected the quality of care in a PICU.IntroductionIn this study authors evaluated the effect of pediatric intensivist on the process of care and PICU outcomes.Material and MethodsThis study is an observational study with a retrospective cohort conducted in the 16-bed PICU of the Dr. Sami Ulus Children\u2019s Hospital in Ankara-Turkey, which is a tertiary referral center with 400 pediatric beds.", [["Children", "SPECIES", 439, 447], ["this study", "TEST", 198, 208], ["pediatric intensivist", "TREATMENT", 241, 262], ["This study", "TEST", 324, 334], ["an observational study", "TEST", 338, 360], ["no", "UNCERTAINTY", 15, 17]]], ["Pediatrics residency program has 80 residents and lasts 4 y as in all residency programs in Turkey.Material and MethodsPICU admissions from January 2013 through January 2017 were included in the study.", [["the study", "TEST", 191, 200]]], ["At nighttime, PGY-2 resident on duty was responsible for the patient care in PICU and was supervised by a PGY-3 or PGY-4 resident, who was in-charge of the other pediatric wards also.", [["patient", "ORGANISM", 61, 68], ["patient", "SPECIES", 61, 68]]], ["PICU admission decisions were given by the senior residents (PGY-3 or PGY-4) on duty and they were responsible for stabilizing the critically ill patients during their initial admission to PICU.Material and MethodsBefore the arrival of pediatric intensivist post-operative cardiac patients were managed in the cardiac-PICU which was directed by the cardiac surgeons.Material and MethodsDuring the entire study period there were a total number of 32 nurses for 16 beds in the PICU and patient per nurse ratio was 2 during shifts.", [["cardiac", "ANATOMY", 273, 280], ["cardiac", "ANATOMY", 310, 317], ["cardiac", "ANATOMY", 349, 356], ["critically ill", "DISEASE", 131, 145], ["patients", "ORGANISM", 146, 154], ["patients", "ORGANISM", 281, 289], ["patient", "ORGANISM", 484, 491], ["patients", "SPECIES", 146, 154], ["patients", "SPECIES", 281, 289], ["patient", "SPECIES", 484, 491], ["cardiac", "ANATOMY", 310, 317], ["cardiac", "ANATOMY", 349, 356]]], ["Although, 30% of the nurses have stopped working in the PICU during the study period, the number of nurses was kept constant at 32 with new appointments.", [["the study", "TEST", 68, 77]]], ["Personnel staffing and structure of the PICU remained stable throughout the study period.Material and MethodsOn January 1st, 2015 the first ever graduate of the PICU fellowship program started practice and was appointed as the intensivist in-charge of the PICU.", [["stable", "OBSERVATION", 54, 60]]], ["He directly participated in acute interventions.", [["acute interventions", "TREATMENT", 28, 47], ["acute", "OBSERVATION_MODIFIER", 28, 33]]], ["Senior residents covering all wards of the hospital participated in the evening PICU rounds in order to be kept updated for patients in the PICU.", [["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132]]], ["Pediatric intensivist was on call for 24 h/day, and remained available for any acute changes in patients, new admissions or need for revised plans in ongoing treatments.", [["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["ongoing treatments", "TREATMENT", 150, 168]]], ["Pediatric intensivist was consulted for all new unstable admissions and acute worsening of PICU patients.", [["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["acute", "OBSERVATION_MODIFIER", 72, 77], ["worsening", "OBSERVATION_MODIFIER", 78, 87]]], ["All central venous catheter implementations were carried out and all laboratory results were reviewed by the pediatric intensivist with the accompanying PGY-2 resident on duty.Material and MethodsUpon starting working, cardiac-PICU was also consulted by the pediatric intensivist and patients who were not extubated in the early post-operative period and patients requiring prolonged medical follow-up were transferred to the PICU.Material and MethodsNumber of admissions, center where the patients were transferred from, mean age of the patients, gender, PRISM-III scores, length of stay, number of mechanically ventilated patients, mean mechanical ventilator duration, number of patients that underwent tracheotomy, mean mechanical ventilator duration before tracheotomy, number of implemented central venous catheters, and number of patients on dialysis, plasma exchange and ECMO applications, nosocomial infections, crude and standard mortality rate (SMR) were recorded and compared between the pre and post pediatric intensivist periods [6].Material and MethodsMortality rate, SMR, number of admissions, length of stay, mechanical ventilator duration and number of nosocomial infections were compared between the two periods as primary outcome measures.Material and MethodsData were analyzed using the SPSS version 21.0 software program (Statistical Package for Social Sciences v.21, IBM, Chicago, IL).", [["venous", "ANATOMY", 12, 18], ["cardiac", "ANATOMY", 219, 226], ["venous", "ANATOMY", 804, 810], ["plasma", "ANATOMY", 858, 864], ["nosocomial infections", "DISEASE", 897, 918], ["nosocomial infections", "DISEASE", 1170, 1191], ["central venous", "MULTI-TISSUE_STRUCTURE", 4, 18], ["patients", "ORGANISM", 284, 292], ["patients", "ORGANISM", 355, 363], ["patients", "ORGANISM", 490, 498], ["patients", "ORGANISM", 538, 546], ["patients", "ORGANISM", 624, 632], ["patients", "ORGANISM", 681, 689], ["central venous", "MULTI-TISSUE_STRUCTURE", 796, 810], ["patients", "ORGANISM", 836, 844], ["plasma", "ORGANISM_SUBSTANCE", 858, 864], ["patients", "SPECIES", 284, 292], ["patients", "SPECIES", 355, 363], ["patients", "SPECIES", 490, 498], ["patients", "SPECIES", 538, 546], ["patients", "SPECIES", 624, 632], ["patients", "SPECIES", 681, 689], ["patients", "SPECIES", 836, 844], ["All central venous catheter implementations", "TREATMENT", 0, 43], ["mechanically ventilated", "TREATMENT", 600, 623], ["mean mechanical ventilator duration", "TREATMENT", 634, 669], ["tracheotomy", "TREATMENT", 705, 716], ["mean mechanical ventilator duration", "TREATMENT", 718, 753], ["tracheotomy", "TREATMENT", 761, 772], ["implemented central venous catheters", "TREATMENT", 784, 820], ["dialysis", "TREATMENT", 848, 856], ["plasma exchange", "TREATMENT", 858, 873], ["ECMO applications", "TREATMENT", 878, 895], ["nosocomial infections", "PROBLEM", 897, 918], ["MethodsMortality rate", "TEST", 1059, 1080], ["mechanical ventilator duration", "TREATMENT", 1125, 1155], ["nosocomial infections", "PROBLEM", 1170, 1191], ["primary outcome measures", "TREATMENT", 1233, 1257], ["MethodsData", "TEST", 1271, 1282], ["the SPSS version", "TEST", 1303, 1319], ["central", "ANATOMY_MODIFIER", 4, 11], ["venous", "ANATOMY", 12, 18], ["catheter", "OBSERVATION", 19, 27], ["mechanically ventilated", "OBSERVATION", 600, 623], ["mechanical ventilator", "OBSERVATION", 639, 660], ["tracheotomy", "OBSERVATION", 705, 716], ["tracheotomy", "OBSERVATION", 761, 772], ["central", "ANATOMY_MODIFIER", 796, 803], ["venous", "ANATOMY", 804, 810], ["catheters", "OBSERVATION", 811, 820], ["mechanical ventilator", "OBSERVATION", 1125, 1146], ["nosocomial", "OBSERVATION_MODIFIER", 1170, 1180], ["infections", "OBSERVATION", 1181, 1191]]], ["Pearson Chi-Square test was used to investigate the association between categorical variables.", [["Pearson Chi-Square test", "TEST", 0, 23]]], ["The Student t test was used to compare continuous numerical variables between groups.", [["The Student t test", "TEST", 0, 18]]], ["General linear model was performed to predict the effect of intensivist on the length of stay in PICU, mechanical ventilator duration and mechanical ventilator duration prior to tracheotomy.", [["mechanical ventilator duration", "TREATMENT", 103, 133], ["mechanical ventilator duration", "TREATMENT", 138, 168], ["tracheotomy", "TREATMENT", 178, 189], ["tracheotomy", "OBSERVATION", 178, 189]]], ["To predict the effect of intensivist on the mortality rate, binary logistic regression was used.", [["binary logistic regression", "TREATMENT", 60, 86]]], ["Institutional Ethics Committee approved the study.ResultsA total of 1787 patients were admitted to the PICU during the study period.", [["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["the study", "TEST", 40, 49], ["the study", "TEST", 115, 124]]], ["Characteristics of patients, treatment options, number of infections and PICU outcome of the two periods are shown in Table 1.ResultsAdmission to PICU was directed from national emergency call service (112), inpatient units and among post-surgical patients.", [["infections", "DISEASE", 58, 68], ["patients", "ORGANISM", 19, 27], ["patients", "ORGANISM", 248, 256], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 248, 256], ["treatment options", "TREATMENT", 29, 46], ["infections", "PROBLEM", 58, 68], ["among post-surgical patients", "TREATMENT", 228, 256], ["infections", "OBSERVATION", 58, 68]]], ["In the pre-pediatric intensivist period, 227 patients (44.2%) were transferred to PICU via emergency ambulance service; 275 (53.6%) patients were transferred from inpatient units and 11 (2.1%) post-surgical patients were admitted to the PICU.", [["patients", "ORGANISM", 45, 53], ["patients", "ORGANISM", 132, 140], ["patients", "ORGANISM", 207, 215], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 132, 140], ["patients", "SPECIES", 207, 215]]], ["In post- pediatric intensivist period, 736 patients (57.7%) were transferred to the PICU via emergency ambulance service, 366 (28.7%) patients were transferred from inpatient units and 172 (13.5%) post-surgical patients were admitted to the PICU (Table 1).ResultsA logistic regression analysis was performed to ascertain the effects of presence of intensivist on the likelihood of mortality.", [["patients", "ORGANISM", 43, 51], ["patients", "ORGANISM", 134, 142], ["patients", "ORGANISM", 211, 219], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 134, 142], ["patients", "SPECIES", 211, 219], ["logistic regression analysis", "TEST", 265, 293]]], ["The logistic regression model was statistically significant, (p < 0.001).", [["The logistic regression model", "TEST", 0, 29], ["significant", "OBSERVATION_MODIFIER", 48, 59]]], ["Presence of intensivist reduced mortality rate 2.18 times (95% CI 1.573\u20133.028, p < 0.001).ResultsGeneral linear model was performed to predict the effect of intensivist on the length of stay in PICU, mechanical ventilator duration and mechanical ventilator duration prior to tracheotomy.", [["mortality rate", "TEST", 32, 46], ["CI", "TEST", 63, 65], ["p", "TEST", 79, 80], ["mechanical ventilator duration", "TREATMENT", 200, 230], ["mechanical ventilator duration", "TREATMENT", 235, 265], ["tracheotomy", "TREATMENT", 275, 286], ["tracheotomy", "OBSERVATION", 275, 286]]], ["Presence of intensivist reduced mechanical ventilator duration by 59%, mechanical ventilator duration prior to tracheotomy by 90% and length of stay in PICU by 41.2% (Table 2).DiscussionIn the current study, the positive effect of the management of the PICU by a pediatric intensivist is demonstrated from many aspects.", [["intensivist reduced mechanical ventilator duration", "TREATMENT", 12, 62], ["mechanical ventilator duration", "TREATMENT", 71, 101], ["tracheotomy", "TREATMENT", 111, 122], ["the current study", "TEST", 189, 206], ["reduced", "OBSERVATION_MODIFIER", 24, 31], ["mechanical ventilator", "OBSERVATION", 32, 53]]], ["Number of patients followed in the PICU increased more than 2-fold (513 vs. 1274).", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18]]], ["Admission source of patients changed significantly and most of the patients in the post pediatric intensivist period were accepted from other centers via emergency ambulance transport system.", [["patients", "ORGANISM", 20, 28], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 67, 75]]], ["Number of post-surgical patients increased more than 15-times (11 vs. 172) and more than 6-times in terms of percentage (2.1% vs. 13.5%) (Table 1).", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["percentage", "TEST", 109, 119], ["post-surgical", "OBSERVATION", 10, 23], ["increased", "OBSERVATION_MODIFIER", 33, 42]]], ["Among post-surgical patients, most of them were postoperative congenital heart disease patients who had been managed by cardiac surgeons before the pediatric intensivist\u2019s arrival.", [["heart", "ANATOMY", 73, 78], ["cardiac", "ANATOMY", 120, 127], ["congenital heart disease", "DISEASE", 62, 86], ["patients", "ORGANISM", 20, 28], ["heart", "ORGAN", 73, 78], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 87, 95], ["postoperative congenital heart disease", "PROBLEM", 48, 86], ["heart", "ANATOMY", 73, 78], ["disease", "OBSERVATION", 79, 86]]], ["It has already been reported that management of pediatric postoperative cardiac patients by an intensivist-directed team is associated with improved outcome [7].DiscussionGender, age and PRISM scores of patients followed in the two periods were similar.", [["cardiac", "ANATOMY", 72, 79], ["patients", "ORGANISM", 80, 88], ["patients", "ORGANISM", 203, 211], ["patients", "SPECIES", 80, 88], ["patients", "SPECIES", 203, 211], ["PRISM scores", "TEST", 187, 199]]], ["Percentage of patients mechanically ventilated were 48% and 42% in the two periods respectively.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["mechanically ventilated", "OBSERVATION", 23, 46]]], ["Number of mechanically ventilated patients increased more than 2-fold in the post-intensivist period in accordance with the increased number of admissions (229 vs. 530).", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["mechanically ventilated", "TREATMENT", 10, 33], ["mechanically", "OBSERVATION_MODIFIER", 10, 22], ["ventilated", "OBSERVATION", 23, 33], ["increased", "OBSERVATION_MODIFIER", 43, 52], ["increased", "OBSERVATION_MODIFIER", 124, 133]]], ["Duration of mechanical ventilation shortened from 23.8 d to 7 d with the arrival of the intensivist.", [["mechanical ventilation", "TREATMENT", 12, 34], ["mechanical ventilation", "OBSERVATION", 12, 34]]], ["Presence of the intensivist reduced the mechanical ventilation duration by 59% (Table 2).", [["the mechanical ventilation duration", "TREATMENT", 36, 71], ["mechanical ventilation", "OBSERVATION", 40, 62]]], ["Reduction of the mechanical ventilation duration is important as it is associated with complications such as ventilator associated pneumonia (VAP), subglottic stenosis and tolerance to sedative agents [4, 8\u201310].", [["subglottic", "ANATOMY", 148, 158], ["pneumonia", "DISEASE", 131, 140], ["VAP", "DISEASE", 142, 145], ["subglottic stenosis", "DISEASE", 148, 167], ["subglottic", "PATHOLOGICAL_FORMATION", 148, 158], ["the mechanical ventilation duration", "TREATMENT", 13, 48], ["complications", "PROBLEM", 87, 100], ["ventilator associated pneumonia", "PROBLEM", 109, 140], ["VAP", "PROBLEM", 142, 145], ["subglottic stenosis", "PROBLEM", 148, 167], ["sedative agents", "TREATMENT", 185, 200], ["mechanical ventilation duration", "OBSERVATION", 17, 48], ["pneumonia", "OBSERVATION", 131, 140], ["subglottic", "ANATOMY", 148, 158], ["stenosis", "OBSERVATION", 159, 167]]], ["Patients could be extubated more quickly as a result of more efficient use of mechanical ventilator by the pediatric intensivist.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["mechanical ventilator", "TREATMENT", 78, 99]]], ["This situation resulted in a decrease in the number and rate of VAP in the PICU (5.1 vs. 2.4).DiscussionExtubation failure necessitated tracheotomy for some patients.", [["VAP", "DISEASE", 64, 67], ["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 157, 165], ["a decrease", "PROBLEM", 27, 37], ["VAP", "PROBLEM", 64, 67], ["DiscussionExtubation failure", "PROBLEM", 94, 122], ["tracheotomy", "TREATMENT", 136, 147], ["decrease", "OBSERVATION_MODIFIER", 29, 37], ["tracheotomy", "OBSERVATION", 136, 147]]], ["Percentage of patients who underwent tracheotomy was 17% and 6.4% in the pre- and post-pediatric intensivist periods respectively, reflecting an increased extubation success.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["tracheotomy", "TREATMENT", 37, 48], ["an increased extubation success", "TREATMENT", 142, 173], ["tracheotomy", "OBSERVATION", 37, 48], ["increased", "OBSERVATION_MODIFIER", 145, 154], ["extubation success", "OBSERVATION", 155, 173]]], ["Mean mechanical ventilator duration prior to tracheotomy was 29.2 d in the pre-intensivist period.", [["Mean mechanical ventilator duration", "TREATMENT", 0, 35], ["tracheotomy", "TREATMENT", 45, 56], ["mechanical ventilator", "OBSERVATION", 5, 26]]], ["Presence of intensivist reduced the mechanical ventilation duration prior to tracheotomy by 90% (Table 2).", [["the mechanical ventilation duration", "TREATMENT", 32, 67], ["tracheotomy", "TREATMENT", 77, 88], ["mechanical ventilation", "OBSERVATION", 36, 58]]], ["Timing of tracheotomy is important in prolonged mechanically ventilated patients because tracheotomy facilitates separation from the mechanical ventilation and discharge from the PICU [11].DiscussionPediatric Risk of Mortality (PRISM) scores which represent the illness severity of the patients in two groups were similar, indicating that the severity of the patients in both groups were comparable (7.6 vs. 8.2) (Table 1).", [["illness", "DISEASE", 262, 269], ["patients", "ORGANISM", 72, 80], ["patients", "ORGANISM", 286, 294], ["patients", "ORGANISM", 359, 367], ["patients", "SPECIES", 72, 80], ["patients", "SPECIES", 286, 294], ["patients", "SPECIES", 359, 367], ["tracheotomy", "TREATMENT", 10, 21], ["prolonged mechanically ventilated patients", "TREATMENT", 38, 80], ["tracheotomy", "TREATMENT", 89, 100], ["the mechanical ventilation", "TREATMENT", 129, 155], ["Mortality (PRISM) scores", "PROBLEM", 217, 241], ["the illness severity", "PROBLEM", 258, 278], ["tracheotomy", "OBSERVATION", 10, 21], ["mechanical ventilation", "OBSERVATION", 133, 155]]], ["Central venous catheter implementation, Continuous venovenous hemodiafiltration (CVVHDF), therapeutic plasma exchange (TPE), extracorporeal membrane oxygenation (ECMO) were more frequently used in the treatment of patients after the pediatric intensivist\u2019s arrival.", [["venous", "ANATOMY", 8, 14], ["plasma", "ANATOMY", 102, 108], ["extracorporeal membrane", "ANATOMY", 125, 148], ["venous", "MULTI-TISSUE_STRUCTURE", 8, 14], ["plasma", "ORGANISM_SUBSTANCE", 102, 108], ["patients", "ORGANISM", 214, 222], ["patients", "SPECIES", 214, 222], ["Central venous catheter implementation", "TREATMENT", 0, 38], ["Continuous venovenous hemodiafiltration", "TREATMENT", 40, 79], ["CVVHDF", "TREATMENT", 81, 87], ["therapeutic plasma exchange (TPE", "TREATMENT", 90, 122], ["extracorporeal membrane oxygenation", "TREATMENT", 125, 160], ["ECMO", "TREATMENT", 162, 166], ["venous", "ANATOMY", 8, 14], ["catheter", "OBSERVATION", 15, 23], ["venovenous hemodiafiltration", "OBSERVATION", 51, 79], ["extracorporeal", "OBSERVATION_MODIFIER", 125, 139], ["membrane oxygenation", "OBSERVATION", 140, 160]]], ["Despite of increase in the invasive procedures, the rate of nosocomial infections significantly decreased in the post-pediatric intensivist period (143 vs. 50).", [["infections", "DISEASE", 71, 81], ["the invasive procedures", "TREATMENT", 23, 46], ["nosocomial infections", "PROBLEM", 60, 81], ["increase", "OBSERVATION_MODIFIER", 11, 19], ["invasive", "OBSERVATION_MODIFIER", 27, 35], ["nosocomial", "OBSERVATION_MODIFIER", 60, 70], ["infections", "OBSERVATION", 71, 81], ["significantly", "OBSERVATION_MODIFIER", 82, 95], ["decreased", "OBSERVATION_MODIFIER", 96, 105]]], ["Before the arrival of the pediatric intensivist only one venovenous ECMO was performed which was managed by cardiac surgeons; the patient, unfortunately didn\u2019t survive.", [["cardiac", "ANATOMY", 108, 115], ["patient", "ORGANISM", 130, 137], ["patient", "SPECIES", 130, 137], ["one venovenous ECMO", "TREATMENT", 53, 72]]], ["In the post-pediatric intensivist period, 13 (8 venoarterial, 5 venovenous) ECMO\u2019s were performed under the supervision of the intensivist and decannulation rate reached 61.5% (8/13).", [["ECMO\u2019s", "TEST", 76, 82], ["decannulation rate", "TEST", 143, 161]]], ["ECMO program, including the education of nurses and physicians was started by the pediatric intensivist.", [["ECMO program", "TREATMENT", 0, 12]]], ["In the pre-pediatric intensivist period, CVVHDF and TPE applications could only be performed with support of the technical staff of the supplier company.", [["CVVHDF", "TREATMENT", 41, 47], ["TPE applications", "TREATMENT", 52, 68]]], ["With the arrival of the pediatric intensivist, the nurse team was trained for the procedures of CVVHDF and TPE.", [["CVVHDF", "TREATMENT", 96, 102], ["TPE", "TREATMENT", 107, 110]]], ["Two senior nurses were appointed to be responsible for the CVHDF and TPE program.DiscussionNumber (143 vs. 50), rate (27.9 vs. 3.8) and incidence (19.7 vs. 6.2) of nosocomial infections significantly decreased in the post-intensivist period, despite the increasing number of critically ill patients, mechanical ventilator days, invasive procedures and extracorporeal treatment sessions (Table 1).", [["nosocomial infections", "DISEASE", 164, 185], ["critically ill", "DISEASE", 275, 289], ["patients", "ORGANISM", 290, 298], ["patients", "SPECIES", 290, 298], ["TPE program", "TREATMENT", 69, 80], ["DiscussionNumber", "TEST", 81, 97], ["rate", "TEST", 112, 116], ["nosocomial infections", "PROBLEM", 164, 185], ["mechanical ventilator days", "TREATMENT", 300, 326], ["invasive procedures", "TREATMENT", 328, 347], ["extracorporeal treatment sessions", "TREATMENT", 352, 385], ["nosocomial", "OBSERVATION_MODIFIER", 164, 174], ["infections", "OBSERVATION", 175, 185], ["significantly", "OBSERVATION_MODIFIER", 186, 199], ["decreased", "OBSERVATION_MODIFIER", 200, 209]]], ["This was achieved by staff education, implementation of protocols, strict adherence to infection control methods and rational antibiotic use.DiscussionLength of PICU stay was shortened in the post-pediatric intensivist period which is similar to the previous reports [12].", [["infection", "DISEASE", 87, 96], ["implementation of protocols", "TREATMENT", 38, 65], ["infection control methods", "TREATMENT", 87, 112], ["rational antibiotic use", "TREATMENT", 117, 140]]], ["Presence of intensivist reduced the length of stay in the PICU by 41.2% (Table 2).", [["length", "OBSERVATION_MODIFIER", 36, 42]]], ["Before the pediatric intensivist, indication of PICU admission was not clear and patients with terminal diseases were admitted to the PICU.", [["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["terminal diseases", "PROBLEM", 95, 112]]], ["This was the main underlying reason for the prolonged PICU stay and higher rate of nosocomial infections and misusage of the valuable PICU beds.", [["infections", "DISEASE", 94, 104], ["nosocomial infections", "PROBLEM", 83, 104], ["nosocomial infections", "OBSERVATION", 83, 104]]], ["Prolonged mechanical ventilator duration, higher percentage of extubation failure, prolonged mechanical ventilator duration prior to tracheotomy are also consistent with all factors mentioned above.DiscussionMortality rate decreased from 14.2% to 7% between the pre- and post-pediatric intensivist periods.", [["extubation failure", "DISEASE", 63, 81], ["Prolonged mechanical ventilator duration", "TREATMENT", 0, 40], ["extubation failure", "PROBLEM", 63, 81], ["prolonged mechanical ventilator duration", "TREATMENT", 83, 123], ["tracheotomy", "TREATMENT", 133, 144], ["DiscussionMortality rate", "TEST", 198, 222], ["mechanical ventilator", "OBSERVATION", 10, 31], ["extubation failure", "OBSERVATION", 63, 81], ["mechanical ventilator", "OBSERVATION", 93, 114], ["tracheotomy", "OBSERVATION", 133, 144], ["consistent with", "UNCERTAINTY", 154, 169]]], ["Similarly, SMR decreased from 0.9 to 0.45.", [["SMR", "TEST", 11, 14], ["SMR", "OBSERVATION_MODIFIER", 11, 14], ["decreased", "OBSERVATION_MODIFIER", 15, 24]]], ["Presence of the intensivist reduced the mortality 2.18 times (95% CI 1.573\u20133.028, p < 0.001) (Table 1).DiscussionThere are many studies showing that the presence of a pediatric intensivist reduces mortality in the PICU [1, 13, 14].", [["CI", "TEST", 66, 68], ["p", "TEST", 82, 83], ["many studies", "TEST", 123, 135]]], ["SMR calculation is more reliable than crude mortality rate as an indicator for assessment of quality of medical care in PICUs and presence of a pediatric intensivist is definitely associated with decreased SMR [12].", [["SMR calculation", "TEST", 0, 15], ["medical care", "TREATMENT", 104, 116], ["decreased SMR", "PROBLEM", 196, 209]]], ["SMR reduction in the post-pediatric intensivist period confirms that the presence of an intensivist improves outcome (Table 1).", [["SMR reduction", "TREATMENT", 0, 13], ["reduction", "OBSERVATION_MODIFIER", 4, 13]]], ["This well-known fact is confirmed by the current study conducted in a middle-income country.DiscussionIt is important to emphasize that personnel staffing, structure and technological infrastructure of PICU were same over the course of the study.", [["the current study", "TEST", 37, 54], ["the study", "TEST", 236, 245]]], ["The only variable that changed in the intensive care unit was the management of the team by the pediatric intensivist.", [["variable", "OBSERVATION_MODIFIER", 9, 17]]], ["When the pediatric intensivist attended the PICU, the mortality rate decreased to 7%, which is an acceptable mortality rate for a middle-income country.", [["the mortality rate", "TEST", 50, 68]]], ["PICU mortality rate has been reported as 2.9% and 5.6% in United States and Europe respectively [15, 16].DiscussionAlthough the hospital where the pediatric intensivist started to work is already a tertiary reference hospital, the change in the working system in the PICU caused some systematical/organizational problems.", [["PICU mortality rate", "TEST", 0, 19], ["some systematical/organizational problems", "PROBLEM", 279, 320], ["organizational problems", "OBSERVATION", 297, 320]]], ["At the beginning, decision of not admitting the terminal patients from inpatient services to PICU was questioned by the heads of other departments and the hospital administration.", [["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65]]], ["All the patients who were not at terminal stage and have deteriorated in other departments were transferred to PICU and treated at PICU under the responsibility of the pediatric intensivist.", [["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16]]], ["Administrative officials were convinced by informing them regularly about the changes in the system and updating them about the prognosis of patients in the PICU.DiscussionThis study investigated the effect of only one certified intensivist on the outcomes of PICU.", [["patients", "ORGANISM", 141, 149], ["patients", "SPECIES", 141, 149], ["This study", "TEST", 172, 182]]], ["This is not the ideal working system for the PICU and it has been suggested previously in the literature that intensivist in-house coverage 24 h each day is the best way to care for critically-ill children [14].", [["critically-ill", "DISEASE", 182, 196], ["children", "ORGANISM", 197, 205], ["children", "SPECIES", 197, 205]]], ["It is not possible to provide 100% coverage of PICU beds by intensivists in our country today due to the lack of educated pediatric intensivists.", [["not possible", "UNCERTAINTY", 6, 18]]], ["This study evidently showed that the management of PICU beds by an intensivist constitutes a remarkable positive effect on PICU outcomes in many aspects.", [["This study", "TEST", 0, 10], ["PICU beds", "TREATMENT", 51, 60], ["positive effect", "OBSERVATION", 104, 119]]], ["Although it is not one of the targets of this study, it is obvious that all these mentioned aspects above also influence the high costs of the intensive care.ConclusionsIn summary, this study showed that management of the PICU beds by a pediatric intensivist increased the number of PICU hospitalizations, ensured care for the true critical care patients with more intensive therapies, decreased the length of stay, decreased the number and the rate of nosocomial infections and decreased the mortality rate.ConclusionsAs a conclusion, what transforms a unit full of critically ill patients to an intensive care unit is a dedicated intensivist.", [["infections", "DISEASE", 464, 474], ["critically ill", "DISEASE", 567, 581], ["patients", "ORGANISM", 346, 354], ["patients", "ORGANISM", 582, 590], ["patients", "SPECIES", 346, 354], ["patients", "SPECIES", 582, 590], ["this study", "TEST", 41, 51], ["the intensive care", "TREATMENT", 139, 157], ["this study", "TEST", 181, 191], ["intensive therapies", "TREATMENT", 365, 384], ["nosocomial infections", "PROBLEM", 453, 474], ["high", "OBSERVATION_MODIFIER", 125, 129], ["nosocomial", "OBSERVATION_MODIFIER", 453, 463], ["infections", "OBSERVATION", 464, 474]]], ["The current study demonstrates that the intensivist is the crucial component of PICUs.", [["The current study", "TEST", 0, 17], ["crucial", "OBSERVATION_MODIFIER", 59, 66], ["component", "OBSERVATION_MODIFIER", 67, 76], ["PICUs", "OBSERVATION", 80, 85]]]], "ae7bc51221f77afeb4fa6e9e1b958b5ca71563e4": [["The worst outbreak of desert locusts in decades is currently underway in East Africa.", [["worst", "OBSERVATION_MODIFIER", 4, 9]]], ["It will cause further deprivation for 14m people in the region already considered \"severely food insecure,\" United Nations (UN) specialists warned on February 10th.", [["people", "ORGANISM", 42, 48], ["people", "SPECIES", 42, 48]]], ["UN Food and Agricultural Organisation (FAO) official Keith Cressman describing locusts as \"the most dangerous migratory pest in the world,\" adding that they had recently entered Tanzania and Uganda and were expected to arrive soon in South Sudan, where another several million people face hunger as the country struggles to emerge from civil war.", [["people", "ORGANISM", 277, 283], ["people", "SPECIES", 277, 283]]], ["Al-Shabaab's control of some locust breeding grounds in Somalia is said to have made aerial spraying there virtually impossible.", [["Al-Shabaab", "CHEMICAL", 0, 10], ["aerial spraying", "TREATMENT", 85, 100]]], ["Somalia declared a state of emergency as unusually large swarms of the hungry insects gorged on crops.", [["large", "OBSERVATION_MODIFIER", 51, 56], ["swarms", "OBSERVATION", 57, 63]]]], "PMC7114128": [["IntroductionSevere acute respiratory syndrome (SARS) is an atypical type of contagious pneumonia with a high mortality rate, and is caused by SARS coronavirus (SARS-CoV) (Drosten et al., 2003, Ksiazek et al., 2003), which infected over 8000 patients of whom more than 700 died by July 2003 (Lingappa et al., 2004).", [["acute respiratory syndrome", "DISEASE", 19, 45], ["SARS", "DISEASE", 47, 51], ["pneumonia", "DISEASE", 87, 96], ["SARS coronavirus", "DISEASE", 142, 158], ["SARS-CoV", "DISEASE", 160, 168], ["SARS coronavirus", "ORGANISM", 142, 158], ["SARS-CoV", "ORGANISM", 160, 168], ["patients", "ORGANISM", 241, 249], ["patients", "SPECIES", 241, 249], ["SARS coronavirus", "SPECIES", 142, 158], ["SARS-CoV", "SPECIES", 160, 168], ["acute respiratory syndrome", "PROBLEM", 19, 45], ["SARS", "PROBLEM", 47, 51], ["contagious pneumonia", "PROBLEM", 76, 96], ["a high mortality rate", "PROBLEM", 102, 123], ["SARS coronavirus", "PROBLEM", 142, 158], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45], ["atypical type", "OBSERVATION_MODIFIER", 59, 72], ["contagious", "OBSERVATION_MODIFIER", 76, 86], ["pneumonia", "OBSERVATION", 87, 96], ["high", "OBSERVATION_MODIFIER", 104, 108]]], ["Interferons (Haagmans et al., 2004, Paragas et al., 2005, Tan et al., 2004, Barnard et al., 2006), glycyrrhizin (Cinatl et al., 2003), 1,2,3,6-tetra-O-galloyl-\u03b2-d-glucose (TGG), luteolin (Yi et al., 2004), Lycoris radiate (S.Y. Li et al., 2005), emodin (Ho et al., 2006), N4-hydroxycytidine (Barnard et al., 2004) and protease inhibitor (Chen et al., 2005) have been reported to have anti SARS-CoV activities in vitro.", [["glycyrrhizin", "CHEMICAL", 99, 111], ["1,2,3,6-tetra-O-galloyl-\u03b2-d-glucose", "CHEMICAL", 135, 170], ["luteolin", "CHEMICAL", 178, 186], ["emodin", "CHEMICAL", 246, 252], ["N4-hydroxycytidine", "CHEMICAL", 272, 290], ["glycyrrhizin", "CHEMICAL", 99, 111], ["1,2,3,6-tetra-O-galloyl-\u03b2-d-glucose", "CHEMICAL", 135, 170], ["TGG", "CHEMICAL", 172, 175], ["luteolin", "CHEMICAL", 178, 186], ["emodin", "CHEMICAL", 246, 252], ["N4-hydroxycytidine", "CHEMICAL", 272, 290], ["glycyrrhizin", "SIMPLE_CHEMICAL", 99, 111], ["1,2,3,6-tetra-O-galloyl-\u03b2-d-glucose", "SIMPLE_CHEMICAL", 135, 170], ["TGG", "SIMPLE_CHEMICAL", 172, 175], ["luteolin", "SIMPLE_CHEMICAL", 178, 186], ["emodin", "SIMPLE_CHEMICAL", 246, 252], ["N4-hydroxycytidine", "SIMPLE_CHEMICAL", 272, 290], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 389, 397], ["Interferons (Haagmans et al.", "TREATMENT", 0, 28], ["glycyrrhizin", "TREATMENT", 99, 111], ["tetra", "TEST", 143, 148], ["galloyl", "TEST", 151, 158], ["emodin", "TREATMENT", 246, 252], ["hydroxycytidine", "TREATMENT", 275, 290], ["protease inhibitor", "TREATMENT", 318, 336]]], ["However, the selectivity indices of these materials are as high as 100 and the mechanisms of their actions are not clear (De Clercq, 2004, De Clercq, 2006).", [["selectivity", "OBSERVATION_MODIFIER", 13, 24], ["high", "OBSERVATION_MODIFIER", 59, 63]]], ["Therefore, more research is necessary to discover drugs and to study their mechanisms for the practical interference of SARS-CoV infection.", [["SARS-CoV infection", "DISEASE", 120, 138], ["SARS-CoV", "ORGANISM", 120, 128], ["SARS-CoV", "SPECIES", 120, 128], ["drugs", "TREATMENT", 50, 55], ["SARS", "PROBLEM", 120, 124], ["CoV infection", "PROBLEM", 125, 138], ["CoV", "OBSERVATION_MODIFIER", 125, 128], ["infection", "OBSERVATION", 129, 138]]], ["It was reported that medicinal herbs combined with western medicines improved the symptoms and decreased the required dosage of corticosteroids for SARS patients (Liu et al., 2006).", [["SARS", "DISEASE", 148, 152], ["corticosteroids", "CHEMICAL", 128, 143], ["corticosteroids", "SIMPLE_CHEMICAL", 128, 143], ["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 153, 161], ["medicinal herbs", "TREATMENT", 21, 36], ["western medicines", "TREATMENT", 51, 68], ["the symptoms", "PROBLEM", 78, 90], ["corticosteroids", "TREATMENT", 128, 143], ["SARS", "PROBLEM", 148, 152]]], ["To identify potential inhibitor(s) of SARS-CoV, we screened seven different medicinal herbs that were reported to be used for SARS patients (Zhang et al., 2004).", [["SARS", "DISEASE", 126, 130], ["SARS-CoV", "ORGANISM", 38, 46], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["SARS-CoV", "SPECIES", 38, 46], ["SARS", "PROBLEM", 38, 42], ["CoV", "PROBLEM", 43, 46], ["different medicinal herbs", "TREATMENT", 66, 91]]], ["We also fractionated the extracts to characterize the inhibitory molecule(s).IntroductionThe spike proteins (S) on the surface of the SARS-CoV particle mediate the binding of the virus to its cell surface receptor, angiotensin converting enzyme 2 (ACE2) (Simmons et al., 2004, Li et al., 2003).", [["extracts", "ANATOMY", 25, 33], ["surface", "ANATOMY", 119, 126], ["cell surface", "ANATOMY", 192, 204], ["angiotensin", "CHEMICAL", 215, 226], ["extracts", "ORGANISM_SUBSTANCE", 25, 33], ["surface", "CELLULAR_COMPONENT", 119, 126], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 134, 142], ["cell", "CELL", 192, 196], ["angiotensin converting enzyme 2", "GENE_OR_GENE_PRODUCT", 215, 246], ["ACE2", "GENE_OR_GENE_PRODUCT", 248, 252], ["inhibitory molecule", "PROTEIN", 54, 73], ["spike proteins", "PROTEIN", 93, 107], ["S", "PROTEIN", 109, 110], ["cell surface receptor", "PROTEIN", 192, 213], ["angiotensin converting enzyme 2", "PROTEIN", 215, 246], ["ACE2", "PROTEIN", 248, 252], ["SARS-CoV", "SPECIES", 134, 142], ["The spike proteins", "TEST", 89, 107], ["the SARS", "PROBLEM", 130, 138], ["CoV particle", "PROBLEM", 139, 151], ["the virus", "PROBLEM", 175, 184], ["angiotensin converting enzyme", "TEST", 215, 244], ["SARS", "OBSERVATION", 134, 138], ["CoV particle", "OBSERVATION_MODIFIER", 139, 151]]], ["We used a pseudovirus that consisted of luciferase encoded human immunodeficiency virus (HIV) (Yang et al., 2004) and SARS-CoV S protein for screening inhibitors.", [["human immunodeficiency virus (HIV)", "DISEASE", 59, 93], ["pseudovirus", "ORGANISM", 10, 21], ["luciferase", "GENE_OR_GENE_PRODUCT", 40, 50], ["human immunodeficiency virus", "ORGANISM", 59, 87], ["HIV", "ORGANISM", 89, 92], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 118, 128], ["luciferase", "PROTEIN", 40, 50], ["SARS-CoV S protein", "PROTEIN", 118, 136], ["human", "SPECIES", 59, 64], ["immunodeficiency virus", "SPECIES", 65, 87], ["human immunodeficiency virus", "SPECIES", 59, 87], ["HIV", "SPECIES", 89, 92], ["SARS-CoV", "SPECIES", 118, 126], ["a pseudovirus", "TREATMENT", 8, 21], ["luciferase encoded human immunodeficiency virus", "PROBLEM", 40, 87], ["SARS", "PROBLEM", 118, 122], ["screening inhibitors", "TREATMENT", 141, 161]]], ["Because a pseudotyped virus does not replicate, the luciferase activities specifically reflect single-round infection.", [["infection", "DISEASE", 108, 117], ["pseudotyped", "ORGANISM", 10, 21], ["luciferase", "GENE_OR_GENE_PRODUCT", 52, 62], ["luciferase", "PROTEIN", 52, 62], ["a pseudotyped virus", "PROBLEM", 8, 27], ["the luciferase activities", "TEST", 48, 73], ["single-round infection", "PROBLEM", 95, 117], ["pseudotyped virus", "OBSERVATION", 10, 27], ["round", "OBSERVATION_MODIFIER", 102, 107], ["infection", "OBSERVATION", 108, 117]]], ["The inhibitory activities shown in the pseudotyped virus assay were also confirmed by the wild-type SARS-CoV (wtSARS-CoV) infection assay using SARS-CoV PUMC01 F5 (GenBank accession no. AY350750B.J. Li et al., 2005).IntroductionWhether enveloped or nonenveloped, many viruses depend on the host cell endocytic pathways for entry.", [["cell", "ANATOMY", 295, 299], ["infection", "DISEASE", 122, 131], ["AY350750B", "CHEMICAL", 186, 195], ["AY350750B", "CHEMICAL", 186, 195], ["pseudotyped", "ORGANISM", 39, 50], ["SARS-CoV", "ORGANISM", 100, 108], ["wtSARS-CoV", "ORGANISM", 110, 120], ["AY350750B", "SIMPLE_CHEMICAL", 186, 195], ["cell", "CELL", 295, 299], ["SARS-CoV PUMC01 F5", "DNA", 144, 162], ["pseudotyped virus", "SPECIES", 39, 56], ["SARS-CoV", "SPECIES", 100, 108], ["wtSARS-CoV", "SPECIES", 110, 120], ["SARS-CoV", "SPECIES", 144, 152], ["the pseudotyped virus assay", "PROBLEM", 35, 62], ["type SARS", "PROBLEM", 95, 104], ["wtSARS", "TEST", 110, 116], ["infection assay", "PROBLEM", 122, 137], ["many viruses", "PROBLEM", 263, 275], ["viruses", "OBSERVATION", 268, 275], ["host cell", "OBSERVATION", 290, 299]]], ["SARS-CoV S glycoprotein mediates viral entry through pH-dependent endocytosis, like vesicular stomatitis virus (VSV) (Sun et al., 2005).", [["SARS", "DISEASE", 0, 4], ["vesicular stomatitis", "DISEASE", 84, 104], ["SARS-CoV S glycoprotein", "GENE_OR_GENE_PRODUCT", 0, 23], ["vesicular stomatitis virus", "ORGANISM", 84, 110], ["VSV", "ORGANISM", 112, 115], ["SARS-CoV S glycoprotein", "PROTEIN", 0, 23], ["stomatitis virus", "SPECIES", 94, 110], ["SARS-CoV", "SPECIES", 0, 8], ["stomatitis virus", "SPECIES", 94, 110], ["VSV", "SPECIES", 112, 115], ["SARS", "PROBLEM", 0, 4], ["CoV S glycoprotein mediates", "TEST", 5, 32], ["dependent endocytosis", "PROBLEM", 56, 77], ["vesicular stomatitis virus", "PROBLEM", 84, 110], ["dependent endocytosis", "OBSERVATION", 56, 77], ["vesicular stomatitis virus", "OBSERVATION", 84, 110]]], ["The endocytic pathways taken by viruses can be divided into clathrin-mediated and clathrin-independent pathways (Marsh and Helenius, 2006).", [["clathrin", "GENE_OR_GENE_PRODUCT", 60, 68], ["clathrin", "GENE_OR_GENE_PRODUCT", 82, 90], ["clathrin", "PROTEIN", 60, 68], ["clathrin", "PROTEIN", 82, 90]]], ["Recently, we demonstrated that SARS-CoV mainly utilizes the clathrin-mediated endocytosis pathway for its entry to target cells (Inoue et al., 2007).", [["cells", "ANATOMY", 122, 127], ["SARS", "DISEASE", 31, 35], ["SARS-CoV", "ORGANISM", 31, 39], ["clathrin", "GENE_OR_GENE_PRODUCT", 60, 68], ["cells", "CELL", 122, 127], ["clathrin", "PROTEIN", 60, 68], ["target cells", "CELL_TYPE", 115, 127], ["SARS-CoV", "SPECIES", 31, 39], ["SARS-CoV", "PROBLEM", 31, 39], ["the clathrin", "TREATMENT", 56, 68]]], ["Therefore, we examined whether effective herbs and their purified compounds may affect the endocytotic pathways.Cell lines ::: Materials and methodsThe following cell lines were obtained from Cell Resource Center for Biomedical Research, Institute of Development, Aging and Cancer, Tohoku University; HEK293T, HepG2, VeroE6 and Jurkat cells.", [["Cell lines", "ANATOMY", 112, 122], ["cell lines", "ANATOMY", 162, 172], ["Cell", "ANATOMY", 192, 196], ["Cancer", "ANATOMY", 274, 280], ["HEK293T", "ANATOMY", 301, 308], ["HepG2", "ANATOMY", 310, 315], ["VeroE6", "ANATOMY", 317, 323], ["Jurkat cells", "ANATOMY", 328, 340], ["Cancer", "DISEASE", 274, 280], ["Cell lines", "CELL", 112, 122], ["cell lines", "CELL", 162, 172], ["Cell", "CELL", 192, 196], ["HEK293T", "CELL", 301, 308], ["HepG2", "CELL", 310, 315], ["VeroE6", "CELL", 317, 323], ["Jurkat cells", "CELL", 328, 340], ["cell lines", "CELL_LINE", 162, 172], ["HEK293T", "CELL_LINE", 301, 308], ["HepG2", "CELL_LINE", 310, 315], ["VeroE6", "CELL_LINE", 317, 323], ["Jurkat cells", "CELL_LINE", 328, 340], ["effective herbs", "TREATMENT", 31, 46], ["HEK293T", "TEST", 301, 308], ["HepG2", "TEST", 310, 315], ["VeroE6 and Jurkat cells", "TREATMENT", 317, 340], ["cell lines", "OBSERVATION", 162, 172], ["Cancer", "OBSERVATION", 274, 280], ["Jurkat cells", "OBSERVATION", 328, 340]]], ["The cells were cultured in either Dulbecco's modified Eagle's medium (DMEM) or RPMI-1640 medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 \u03bcg/ml streptomycin antibiotics.Extracts of medicinal herbs and fractionated samples ::: Materials and methodsThe water extracts prepared from 7 kinds of dried medicinal herbs and four fractionated samples of Cinnamomi Cortex (CC) and Caryophylli Flos (CF) were provided by Tsumura & Co. (Tokyo, Japan).", [["cells", "ANATOMY", 4, 9], ["fetal bovine serum", "ANATOMY", 118, 136], ["Extracts", "ANATOMY", 197, 205], ["samples", "ANATOMY", 242, 249], ["extracts", "ANATOMY", 285, 293], ["samples", "ANATOMY", 363, 370], ["RPMI-1640", "CHEMICAL", 79, 88], ["penicillin", "CHEMICAL", 147, 157], ["streptomycin", "CHEMICAL", 172, 184], ["CC", "CHEMICAL", 392, 394], ["penicillin", "CHEMICAL", 147, 157], ["streptomycin", "CHEMICAL", 172, 184], ["cells", "CELL", 4, 9], ["bovine", "ORGANISM", 124, 130], ["serum", "ORGANISM_SUBSTANCE", 131, 136], ["penicillin", "SIMPLE_CHEMICAL", 147, 157], ["streptomycin antibiotics", "SIMPLE_CHEMICAL", 172, 196], ["water extracts", "ORGANISM_SUBSTANCE", 279, 293], ["bovine", "SPECIES", 124, 130], ["bovine", "SPECIES", 124, 130], ["RPMI", "TEST", 79, 83], ["10% fetal bovine serum", "TREATMENT", 114, 136], ["penicillin", "TREATMENT", 147, 157], ["streptomycin antibiotics", "TREATMENT", 172, 196], ["The water extracts", "TREATMENT", 275, 293], ["dried medicinal herbs", "TREATMENT", 319, 340], ["Caryophylli Flos", "TEST", 400, 416], ["medicinal", "ANATOMY", 209, 218], ["Cinnamomi Cortex", "ANATOMY", 374, 390]]], ["The dried medicinal herbs included Forsythiae Fructus, Scutellariae Radix, Astragali Radix, Bupleuri Radix, Glycyrrhizae Radix, CC and CF.", [["Forsythiae Fructus, Scutellariae Radix, Astragali Radix, Bupleuri Radix, Glycyrrhizae Radix", "CHEMICAL", 35, 126], ["CC", "CHEMICAL", 128, 130], ["Forsythiae Fructus", "ORGANISM", 35, 53], ["Scutellariae Radix", "ORGANISM", 55, 73], ["Astragali Radix", "ORGANISM", 75, 90], ["Bupleuri Radix", "ORGANISM", 92, 106], ["Glycyrrhizae Radix", "ORGANISM", 108, 126], ["Bupleuri", "SPECIES", 92, 100], ["The dried medicinal herbs", "TREATMENT", 0, 25], ["Forsythiae Fructus", "TREATMENT", 35, 53], ["Scutellariae Radix", "TREATMENT", 55, 73], ["Astragali Radix", "TREATMENT", 75, 90], ["Bupleuri Radix", "TREATMENT", 92, 106], ["Glycyrrhizae Radix", "TREATMENT", 108, 126], ["Scutellariae Radix", "ANATOMY", 55, 73], ["Astragali Radix", "ANATOMY", 75, 90], ["Radix", "ANATOMY", 101, 106]]], ["Each dried medicinal herb (30 kg) was boiled under reflux in 360 l of distilled water for 1 h.", [["reflux", "DISEASE", 51, 57], ["Each dried medicinal herb", "TREATMENT", 0, 25], ["reflux", "OBSERVATION", 51, 57]]], ["The aqueous extract was separated from the residue by centrifugation followed by concentration under reduced pressure.", [["aqueous extract", "ANATOMY", 4, 19], ["aqueous extract", "ORGANISM_SUBSTANCE", 4, 19], ["The aqueous extract", "TREATMENT", 0, 19], ["aqueous", "OBSERVATION_MODIFIER", 4, 11], ["extract", "OBSERVATION_MODIFIER", 12, 19], ["reduced", "OBSERVATION_MODIFIER", 101, 108], ["pressure", "OBSERVATION_MODIFIER", 109, 117]]], ["The concentrated extracts were lyophilized.", [["extracts", "ANATOMY", 17, 25], ["extracts", "ORGANISM_SUBSTANCE", 17, 25], ["lyophilized", "OBSERVATION_MODIFIER", 31, 42]]], ["Four fractions of CC were obtained by the method shown in Fig. 1.", [["CC", "CHEMICAL", 18, 20], ["CC", "SIMPLE_CHEMICAL", 18, 20]]], ["CC (114.9 g) was extracted with 700 ml of 50% aqueous ethanol (aq.", [["CC", "CHEMICAL", 0, 2], ["ethanol", "CHEMICAL", 54, 61], ["ethanol", "CHEMICAL", 54, 61], ["ethanol", "SIMPLE_CHEMICAL", 54, 61], ["CC", "TEST", 0, 2]]], ["EtOH/H2O under reflux for 2 h.", [["EtOH", "CHEMICAL", 0, 4], ["H2O", "CHEMICAL", 5, 8], ["reflux", "DISEASE", 15, 21], ["EtOH", "CHEMICAL", 0, 4], ["H2O", "CHEMICAL", 5, 8], ["EtOH", "SIMPLE_CHEMICAL", 0, 4], ["H2O", "SIMPLE_CHEMICAL", 5, 8], ["reflux", "OBSERVATION", 15, 21]]], ["The obtained extract was concentrated under reduced pressure to yield a 50% aq.", [["extract", "ANATOMY", 13, 20], ["pressure", "OBSERVATION_MODIFIER", 52, 60]]], ["EtOH/H2O extract (13.5 g, fraction 1).", [["EtOH", "CHEMICAL", 0, 4], ["H2O extract", "CHEMICAL", 5, 16], ["EtOH", "CHEMICAL", 0, 4], ["H2O", "CHEMICAL", 5, 8], ["EtOH", "SIMPLE_CHEMICAL", 0, 4], ["EtOH/H2O extract", "TREATMENT", 0, 16]]], ["Most of this (11.2 g) could be dissolved in distilled water, and it was then extracted with ethylacetate (AcOEt, 200 ml \u00d7 2) and n-butanol (n-BuOH, 200 ml \u00d7 2).", [["ethylacetate", "CHEMICAL", 92, 104], ["AcOEt", "CHEMICAL", 106, 111], ["n-butanol", "CHEMICAL", 129, 138], ["n-BuOH", "CHEMICAL", 140, 146], ["ethylacetate", "CHEMICAL", 92, 104], ["AcOEt", "CHEMICAL", 106, 111], ["n-butanol", "CHEMICAL", 129, 138], ["BuOH", "CHEMICAL", 142, 146], ["ethylacetate", "SIMPLE_CHEMICAL", 92, 104], ["AcOEt", "SIMPLE_CHEMICAL", 106, 111], ["n-butanol", "SIMPLE_CHEMICAL", 129, 138], ["n-BuOH", "SIMPLE_CHEMICAL", 140, 146], ["ethylacetate (AcOEt", "TREATMENT", 92, 111], ["n-butanol (n-BuOH", "TREATMENT", 129, 146]]], ["The n-BuOH layer, aq. layer and AcOEt layer were concentrated under reduced pressure to successively yield fractions 2 (CC/Fr.2, 3.5 g), 3 (CC/Fr.3, 3.7 g) and 4 (CC/Fr.4, 2.8 g), respectively.", [["aq. layer", "ANATOMY", 18, 27], ["AcOEt layer", "ANATOMY", 32, 43], ["CC", "CHEMICAL", 120, 122], ["BuOH", "CHEMICAL", 6, 10], ["aq. layer", "SIMPLE_CHEMICAL", 18, 27], ["The n-BuOH layer", "PROBLEM", 0, 16], ["AcOEt layer", "TREATMENT", 32, 43], ["CC", "TEST", 120, 122], ["CC", "TEST", 140, 142], ["CC", "TEST", 163, 165], ["layer", "OBSERVATION_MODIFIER", 11, 16], ["layer", "OBSERVATION_MODIFIER", 22, 27], ["layer", "OBSERVATION_MODIFIER", 38, 43]]], ["The four fractions of CF were also obtained by an essentially similar method as described above.", [["similar", "OBSERVATION_MODIFIER", 62, 69], ["method", "OBSERVATION", 70, 76]]], ["These fractions were suspended in dimethyl sulfoxide (DMSO) at a concentration of 100 mg/ml and then serially diluted with DMEM.Chemicals ::: Materials and methods2-Phenylethanol (phenethy alcohol), 2\u2032-hydroxyacetophenone (o-hydroxyacetophenone), isoeugenol 2-hydroxycinnamic acid, 3,4-dimethoxycinnamic acid, 4-hydroxy-3-methoxycinnamic acid (ferulic acid), 4-hydroxycoumarin, 7-hydroxycoumarin, p-cymene, 4-allylanisole, ethylcinnamate and cinnamylacetate were purchased from Wako (Osaka, Japan).", [["dimethyl sulfoxide", "CHEMICAL", 34, 52], ["DMSO", "CHEMICAL", 54, 58], ["methods2-Phenylethanol", "CHEMICAL", 156, 178], ["phenethy alcohol", "CHEMICAL", 180, 196], ["2\u2032-hydroxyacetophenone", "CHEMICAL", 199, 221], ["o-hydroxyacetophenone", "CHEMICAL", 223, 244], ["isoeugenol 2-hydroxycinnamic acid", "CHEMICAL", 247, 280], ["3,4-dimethoxycinnamic acid", "CHEMICAL", 282, 308], ["4-hydroxy-3-methoxycinnamic acid", "CHEMICAL", 310, 342], ["ferulic acid", "CHEMICAL", 344, 356], ["4-hydroxycoumarin", "CHEMICAL", 359, 376], ["7-hydroxycoumarin", "CHEMICAL", 378, 395], ["p-cymene", "CHEMICAL", 397, 405], ["4-allylanisole", "CHEMICAL", 407, 421], ["ethylcinnamate", "CHEMICAL", 423, 437], ["cinnamylacetate", "CHEMICAL", 442, 457], ["dimethyl sulfoxide", "CHEMICAL", 34, 52], ["DMSO", "CHEMICAL", 54, 58], ["methods2-Phenylethanol", "CHEMICAL", 156, 178], ["phenethy alcohol", "CHEMICAL", 180, 196], ["2\u2032-hydroxyacetophenone", "CHEMICAL", 199, 221], ["o-hydroxyacetophenone", "CHEMICAL", 223, 244], ["isoeugenol 2-hydroxycinnamic acid", "CHEMICAL", 247, 280], ["3,4-dimethoxycinnamic acid", "CHEMICAL", 282, 308], ["4-hydroxy-3-methoxycinnamic acid", "CHEMICAL", 310, 342], ["ferulic acid", "CHEMICAL", 344, 356], ["4-hydroxycoumarin", "CHEMICAL", 359, 376], ["7-hydroxycoumarin", "CHEMICAL", 378, 395], ["p-cymene", "CHEMICAL", 397, 405], ["4-allylanisole", "CHEMICAL", 407, 421], ["ethylcinnamate", "CHEMICAL", 423, 437], ["cinnamylacetate", "CHEMICAL", 442, 457], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 34, 52], ["DMSO", "SIMPLE_CHEMICAL", 54, 58], ["methods2-Phenylethanol", "SIMPLE_CHEMICAL", 156, 178], ["phenethy alcohol", "SIMPLE_CHEMICAL", 180, 196], ["2\u2032-hydroxyacetophenone", "SIMPLE_CHEMICAL", 199, 221], ["o-hydroxyacetophenone", "SIMPLE_CHEMICAL", 223, 244], ["isoeugenol 2-hydroxycinnamic acid", "SIMPLE_CHEMICAL", 247, 280], ["3,4-dimethoxycinnamic acid", "SIMPLE_CHEMICAL", 282, 308], ["4-hydroxy-3-methoxycinnamic acid", "SIMPLE_CHEMICAL", 310, 342], ["ferulic acid", "SIMPLE_CHEMICAL", 344, 356], ["4-hydroxycoumarin", "SIMPLE_CHEMICAL", 359, 376], ["7-hydroxycoumarin", "SIMPLE_CHEMICAL", 378, 395], ["p-cymene", "SIMPLE_CHEMICAL", 397, 405], ["4-allylanisole", "SIMPLE_CHEMICAL", 407, 421], ["ethylcinnamate", "SIMPLE_CHEMICAL", 423, 437], ["cinnamylacetate", "SIMPLE_CHEMICAL", 442, 457], ["Wako", "ORGANISM_SUBSTANCE", 478, 482], ["dimethyl sulfoxide (DMSO", "TREATMENT", 34, 58], ["Materials", "TEST", 142, 151], ["methods2", "TEST", 156, 164], ["Phenylethanol (phenethy alcohol)", "TREATMENT", 165, 197], ["hydroxyacetophenone (o-hydroxyacetophenone)", "TREATMENT", 202, 245], ["isoeugenol", "TREATMENT", 247, 257], ["hydroxycinnamic acid", "TREATMENT", 260, 280], ["dimethoxycinnamic acid", "TREATMENT", 286, 308], ["hydroxy", "TREATMENT", 312, 319], ["methoxycinnamic acid (ferulic acid)", "TREATMENT", 322, 357], ["hydroxycoumarin", "TREATMENT", 361, 376], ["hydroxycoumarin", "TREATMENT", 380, 395], ["p-cymene", "TREATMENT", 397, 405], ["allylanisole", "TREATMENT", 409, 421], ["ethylcinnamate", "TREATMENT", 423, 437], ["cinnamylacetate", "TREATMENT", 442, 457]]], ["Trans-cinnamaldehyde, trans-cinnamic acid, licochalcone-A 4-hydroxy-3-methoxy cinnamaldehyde and cycloheximide (CHX) were purchased from Sigma (St. Louis, MO).", [["Trans-cinnamaldehyde", "CHEMICAL", 0, 20], ["trans-cinnamic acid", "CHEMICAL", 22, 41], ["licochalcone-A 4-hydroxy-3-methoxy cinnamaldehyde", "CHEMICAL", 43, 92], ["cycloheximide", "CHEMICAL", 97, 110], ["CHX", "CHEMICAL", 112, 115], ["Trans-cinnamaldehyde", "CHEMICAL", 0, 20], ["trans-cinnamic acid", "CHEMICAL", 22, 41], ["licochalcone-A 4-hydroxy-3-methoxy cinnamaldehyde", "CHEMICAL", 43, 92], ["cycloheximide", "CHEMICAL", 97, 110], ["CHX", "CHEMICAL", 112, 115], ["Trans-cinnamaldehyde", "SIMPLE_CHEMICAL", 0, 20], ["trans-cinnamic acid", "SIMPLE_CHEMICAL", 22, 41], ["licochalcone-A 4-hydroxy-3-methoxy cinnamaldehyde", "SIMPLE_CHEMICAL", 43, 92], ["cycloheximide", "SIMPLE_CHEMICAL", 97, 110], ["CHX", "SIMPLE_CHEMICAL", 112, 115], ["St. Louis, MO", "ORGANISM", 144, 157], ["cinnamic acid", "TREATMENT", 28, 41], ["licochalcone", "TREATMENT", 43, 55], ["hydroxy", "TREATMENT", 60, 67], ["methoxy cinnamaldehyde", "TREATMENT", 70, 92], ["cycloheximide (CHX", "TREATMENT", 97, 115]]], ["The eight compounds procyanidin A2, procyanidin B1, procyanidin B2, procyanidin C1, procyanidin oligomer, (\u2212)-epicatechin, (+)-catechin and cinnamtannin B1 were purified from CC as described previously (Nonaka et al., 1983).", [["procyanidin A2", "CHEMICAL", 20, 34], ["procyanidin B1, procyanidin B2, procyanidin C1, procyanidin oligomer, (\u2212)-epicatechin", "CHEMICAL", 36, 121], ["catechin", "CHEMICAL", 127, 135], ["cinnamtannin", "CHEMICAL", 140, 152], ["CC", "CHEMICAL", 175, 177], ["procyanidin A2", "CHEMICAL", 20, 34], ["procyanidin B1", "CHEMICAL", 36, 50], ["procyanidin B2", "CHEMICAL", 52, 66], ["procyanidin C1", "CHEMICAL", 68, 82], ["procyanidin", "CHEMICAL", 84, 95], ["(\u2212)-epicatechin", "CHEMICAL", 106, 121], ["(+)-catechin", "CHEMICAL", 123, 135], ["cinnamtannin B1", "CHEMICAL", 140, 155], ["procyanidin A2", "SIMPLE_CHEMICAL", 20, 34], ["procyanidin B1", "SIMPLE_CHEMICAL", 36, 50], ["procyanidin B2", "SIMPLE_CHEMICAL", 52, 66], ["procyanidin C1", "SIMPLE_CHEMICAL", 68, 82], ["procyanidin oligomer", "SIMPLE_CHEMICAL", 84, 104], ["(\u2212)-epicatechin", "SIMPLE_CHEMICAL", 106, 121], ["(+)-catechin", "SIMPLE_CHEMICAL", 123, 135], ["cinnamtannin B1", "SIMPLE_CHEMICAL", 140, 155], ["CC", "CELL", 175, 177], ["procyanidin A2", "TREATMENT", 20, 34], ["procyanidin B1", "TREATMENT", 36, 50], ["procyanidin B2", "TREATMENT", 52, 66], ["procyanidin C1", "TREATMENT", 68, 82], ["procyanidin oligomer", "TREATMENT", 84, 104], ["catechin", "TREATMENT", 127, 135], ["cinnamtannin B1", "TREATMENT", 140, 155]]], ["These chemicals were dissolved in DMSO at 100 mg/ml or 100 mM.Infection of pseudoviruses ::: Materials and methodsPseudotyped lentiviruses were prepared as described previously (Yang et al., 2004).", [["DMSO", "CHEMICAL", 34, 38], ["DMSO", "CHEMICAL", 34, 38], ["DMSO", "SIMPLE_CHEMICAL", 34, 38], ["lentiviruses", "ORGANISM", 126, 138], ["DMSO", "TREATMENT", 34, 38], ["Infection of pseudoviruses", "PROBLEM", 62, 88], ["methodsPseudotyped lentiviruses", "PROBLEM", 107, 138], ["Pseudotyped lentiviruses", "OBSERVATION", 114, 138]]], ["HEK293T cells were cotransfected with HIV-1-based lentiviral DNA and plasmids encoding full-length SARS-S (G.J. Nabel, National Institutes of Health, Bethesda, MD) or VSV-G (Naldini et al., 1996).", [["HEK293T cells", "ANATOMY", 0, 13], ["plasmids", "ANATOMY", 69, 77], ["HEK293T cells", "CELL", 0, 13], ["HIV-1", "ORGANISM", 38, 43], ["lentiviral", "ORGANISM", 50, 60], ["DNA", "CELLULAR_COMPONENT", 61, 64], ["VSV", "ORGANISM", 167, 170], ["HEK293T cells", "CELL_LINE", 0, 13], ["HIV-1-based lentiviral DNA", "DNA", 38, 64], ["plasmids", "DNA", 69, 77], ["HIV-1", "SPECIES", 38, 43], ["HIV-1", "SPECIES", 38, 43], ["HEK293T cells", "PROBLEM", 0, 13], ["HIV", "TEST", 38, 41], ["lentiviral DNA", "TREATMENT", 50, 64]]], ["The p24 Gag antigen levels were measured using an HIV-1 p24 Antigen Assay kit (ZeptoMetrix Corporation, New York).", [["p24 Gag antigen", "GENE_OR_GENE_PRODUCT", 4, 19], ["p24 Gag antigen", "PROTEIN", 4, 19], ["HIV-1", "SPECIES", 50, 55], ["HIV-1", "SPECIES", 50, 55], ["The p24 Gag antigen levels", "TEST", 0, 26], ["an HIV", "TEST", 47, 53]]], ["Five ng (p24) of the generated HIV/SARS-CoV S or HIV/VSVG were infected in HepG2 cells (1 \u00d7 104cells/well in 96-well plates).", [["VSVG", "ANATOMY", 53, 57], ["HepG2 cells", "ANATOMY", 75, 86], ["cells", "ANATOMY", 95, 100], ["p24", "GENE_OR_GENE_PRODUCT", 9, 12], ["HIV", "ORGANISM", 31, 34], ["SARS-CoV S", "ORGANISM", 35, 45], ["HIV", "ORGANISM", 49, 52], ["VSVG", "GENE_OR_GENE_PRODUCT", 53, 57], ["HepG2 cells", "CELL", 75, 86], ["cells", "CELL", 95, 100], ["p24", "PROTEIN", 9, 12], ["HepG2 cells", "CELL_LINE", 75, 86], ["HIV", "SPECIES", 31, 34], ["HIV", "SPECIES", 49, 52], ["HIV", "SPECIES", 31, 34], ["SARS-CoV", "SPECIES", 35, 43], ["HIV", "SPECIES", 49, 52], ["Five ng (p24", "TEST", 0, 12], ["the generated HIV/SARS", "TEST", 17, 39], ["CoV S", "TEST", 40, 45], ["HIV/VSVG", "PROBLEM", 49, 57], ["HepG2 cells", "TEST", 75, 86], ["cells", "TEST", 95, 100]]], ["After 12 h of cultivation, the cells were washed twice with DMEM which was then replaced with complete medium.", [["cells", "ANATOMY", 31, 36], ["cells", "CELL", 31, 36], ["cultivation", "TREATMENT", 14, 25], ["the cells", "TREATMENT", 27, 36], ["DMEM", "TREATMENT", 60, 64]]], ["Forty-eight hours after infection, the luciferase activity was measured by Mithras LB940 (Berthold Technologies GmbH & Co KG, Germany) according to the Manufacturer's instructions.Inhibition of the pseudovirus infection ::: Materials and methodsThe supernatants containing 5 ng (p24) of the HIV/SARS-CoV S or HIV/VSVG pseudoviruses were mixed with or without the reagents at different concentrations and were then added to HepG2 cells.", [["supernatants", "ANATOMY", 249, 261], ["HepG2 cells", "ANATOMY", 423, 434], ["infection", "DISEASE", 24, 33], ["pseudovirus infection", "DISEASE", 198, 219], ["luciferase", "GENE_OR_GENE_PRODUCT", 39, 49], ["pseudovirus", "ORGANISM", 198, 209], ["p24", "GENE_OR_GENE_PRODUCT", 279, 282], ["HIV/SARS-CoV S", "ORGANISM", 291, 305], ["HIV", "ORGANISM", 309, 312], ["VSVG", "ORGANISM", 313, 317], ["HepG2 cells", "CELL", 423, 434], ["luciferase", "PROTEIN", 39, 49], ["p24", "PROTEIN", 279, 282], ["HepG2 cells", "CELL_LINE", 423, 434], ["HIV", "SPECIES", 291, 294], ["HIV", "SPECIES", 309, 312], ["HIV", "SPECIES", 291, 294], ["HIV", "SPECIES", 309, 312], ["infection", "PROBLEM", 24, 33], ["the luciferase activity", "TEST", 35, 58], ["the pseudovirus infection", "PROBLEM", 194, 219], ["The supernatants", "TREATMENT", 245, 261], ["the HIV/SARS-CoV S", "TEST", 287, 305], ["HIV/VSVG pseudoviruses", "PROBLEM", 309, 331], ["the reagents", "TREATMENT", 359, 371], ["HepG2 cells", "TREATMENT", 423, 434], ["infection", "OBSERVATION", 24, 33], ["pseudovirus", "ANATOMY", 198, 209], ["infection", "OBSERVATION", 210, 219]]], ["The DMSO solvent was also used for a control.", [["DMSO", "CHEMICAL", 4, 8], ["DMSO", "CHEMICAL", 4, 8], ["DMSO", "SIMPLE_CHEMICAL", 4, 8], ["The DMSO solvent", "TREATMENT", 0, 16]]], ["After 12 h infection the cells were washed twice with DMEM which was then replaced with complete medium without the reagents.", [["cells", "ANATOMY", 25, 30], ["infection", "DISEASE", 11, 20], ["cells", "CELL", 25, 30], ["12 h infection the cells", "PROBLEM", 6, 30], ["DMEM", "TREATMENT", 54, 58], ["the reagents", "TREATMENT", 112, 124], ["infection", "OBSERVATION", 11, 20]]], ["The relative luciferase activities were calculated as percentages of the control culture-background.", [["luciferase", "GENE_OR_GENE_PRODUCT", 13, 23], ["luciferase", "PROTEIN", 13, 23], ["the control culture", "TEST", 69, 88], ["luciferase activities", "OBSERVATION", 13, 34]]], ["The 50% inhibition concentration (IC50) of the reagents was determined from a curve relating the luciferase activities to the concentration of the reagents (Y. Xu et al., 2000).Inhibition of the pseudovirus infection ::: Materials and methodsTo evaluate which step of virus replication was inhibited by the reagents, we examined the effects in an additional study in which the reagents were added on the cells at \u22121 or 12 h after HIV/SARS-CoV S infection because 12 h were required to obtain stable luciferase activities (Yang et al., 2004).", [["cells", "ANATOMY", 404, 409], ["pseudovirus infection", "DISEASE", 195, 216], ["infection", "DISEASE", 445, 454], ["luciferase", "GENE_OR_GENE_PRODUCT", 97, 107], ["pseudovirus", "ORGANISM", 195, 206], ["cells", "CELL", 404, 409], ["HIV", "ORGANISM", 430, 433], ["SARS-CoV S", "ORGANISM", 434, 444], ["luciferase", "GENE_OR_GENE_PRODUCT", 499, 509], ["luciferase", "PROTEIN", 97, 107], ["luciferase", "PROTEIN", 499, 509], ["HIV", "SPECIES", 430, 433], ["SARS-CoV", "SPECIES", 434, 442], ["The 50% inhibition concentration (IC50)", "TREATMENT", 0, 39], ["the reagents", "TREATMENT", 43, 55], ["a curve", "TEST", 76, 83], ["the pseudovirus infection", "PROBLEM", 191, 216], ["virus replication", "PROBLEM", 268, 285], ["an additional study", "TEST", 344, 363], ["HIV", "PROBLEM", 430, 433], ["SARS", "PROBLEM", 434, 438], ["CoV S infection", "PROBLEM", 439, 454], ["pseudovirus", "ANATOMY", 195, 206], ["infection", "OBSERVATION", 207, 216]]], ["Furthermore, the cells were pretreated with various concentrations of the reagents for 1 h followed by washing twice, and were challenged with pseudovirus to determine whether the reagents work on the cells or on the viruses.Inhibition assay for wtSARS-CoV infection ::: Materials and methodsThe wtSARS-CoV strain PUMC01 F5 (GenBank accession no. AY350750) was used for the assay.", [["cells", "ANATOMY", 17, 22], ["cells", "ANATOMY", 201, 206], ["infection", "DISEASE", 257, 266], ["AY350750", "CHEMICAL", 347, 355], ["AY350750", "CHEMICAL", 347, 355], ["cells", "CELL", 17, 22], ["cells", "CELL", 201, 206], ["wtSARS-CoV", "GENE_OR_GENE_PRODUCT", 246, 256], ["wtSARS-CoV", "ORGANISM", 296, 306], ["PUMC01 F5", "CELL", 314, 323], ["wtSARS-CoV strain PUMC01 F5", "DNA", 296, 323], ["wtSARS-CoV", "SPECIES", 246, 256], ["wtSARS-CoV", "SPECIES", 296, 306], ["the reagents", "TREATMENT", 70, 82], ["pseudovirus", "TREATMENT", 143, 154], ["the viruses", "PROBLEM", 213, 224], ["Inhibition assay", "TEST", 225, 241], ["wtSARS", "PROBLEM", 246, 252], ["CoV infection", "PROBLEM", 253, 266], ["methods", "TEST", 285, 292], ["The wtSARS", "TEST", 292, 302], ["the assay", "TEST", 370, 379], ["infection", "OBSERVATION", 257, 266]]], ["We performed a plaque reduction assay in which 100 times the 50% cell culture infective doses (CCID50) of wtSARS-CoV was added with 100 \u03bcl of each reagent for 0 or 60 min at 37 \u00b0C and then transferred onto 6-well plates (1 \u00d7 106cells/well) with the VeroE6 cells.", [["plaque", "ANATOMY", 15, 21], ["cell", "ANATOMY", 65, 69], ["cells", "ANATOMY", 228, 233], ["VeroE6 cells", "ANATOMY", 249, 261], ["plaque reduction", "DISEASE", 15, 31], ["cell", "CELL", 65, 69], ["wtSARS-CoV", "GENE_OR_GENE_PRODUCT", 106, 116], ["cells", "CELL", 228, 233], ["VeroE6 cells", "CELL", 249, 261], ["VeroE6 cells", "CELL_LINE", 249, 261], ["wtSARS-CoV", "SPECIES", 106, 116], ["a plaque reduction assay", "TREATMENT", 13, 37], ["the 50% cell culture infective doses", "TREATMENT", 57, 93], ["wtSARS", "TEST", 106, 112], ["CoV", "TEST", 113, 116], ["the VeroE6 cells", "TREATMENT", 245, 261], ["plaque", "OBSERVATION", 15, 21]]], ["The DMSO solvent was also used as a control.", [["DMSO", "CHEMICAL", 4, 8], ["DMSO", "CHEMICAL", 4, 8], ["DMSO", "SIMPLE_CHEMICAL", 4, 8], ["The DMSO solvent", "TREATMENT", 0, 16], ["DMSO solvent", "OBSERVATION", 4, 16]]], ["After 1 h of infection, the cells were washed twice by DMEM, and then 2% agarose was added onto the cell surface.", [["cells", "ANATOMY", 28, 33], ["cell surface", "ANATOMY", 100, 112], ["infection", "DISEASE", 13, 22], ["cells", "CELL", 28, 33], ["agarose", "SIMPLE_CHEMICAL", 73, 80], ["cell surface", "CELLULAR_COMPONENT", 100, 112], ["infection", "PROBLEM", 13, 22], ["the cells", "TREATMENT", 24, 33], ["2% agarose", "TREATMENT", 70, 80], ["infection", "OBSERVATION", 13, 22], ["cell surface", "OBSERVATION", 100, 112]]], ["A 2% secondary agarose layer with 0.05% neutral red dye was added on the third day after incubation.", [["agarose", "SIMPLE_CHEMICAL", 15, 22], ["neutral red dye", "SIMPLE_CHEMICAL", 40, 55], ["A 2% secondary agarose layer", "TREATMENT", 0, 28], ["0.05% neutral red dye", "TREATMENT", 34, 55], ["layer", "OBSERVATION_MODIFIER", 23, 28]]], ["The numbers of plaques were counted after adding neutral red dye.", [["plaques", "ANATOMY", 15, 22], ["plaques", "DISEASE", 15, 22], ["plaques", "PATHOLOGICAL_FORMATION", 15, 22], ["red dye", "SIMPLE_CHEMICAL", 57, 64], ["plaques", "PROBLEM", 15, 22], ["neutral red dye", "TREATMENT", 49, 64], ["numbers", "OBSERVATION_MODIFIER", 4, 11], ["plaques", "OBSERVATION", 15, 22]]], ["The inhibitory concentrations for a 50% plaque reduction (IC50) were determined from a curve relating the plaque number to the concentrations of the reagents.Cytotoxicity assay ::: Materials and methodsIn all experiments, we chose the optimal concentration of each reagent that yielded a cell viability of more than 90%.", [["plaque", "ANATOMY", 40, 46], ["plaque", "ANATOMY", 106, 112], ["cell", "ANATOMY", 288, 292], ["plaque", "PATHOLOGICAL_FORMATION", 40, 46], ["cell", "CELL", 288, 292], ["The inhibitory concentrations", "TREATMENT", 0, 29], ["a 50% plaque reduction", "TREATMENT", 34, 56], ["a curve", "TEST", 85, 92], ["the reagents", "TREATMENT", 145, 157], ["Cytotoxicity assay", "TEST", 158, 176], ["each reagent", "TREATMENT", 260, 272], ["a cell viability", "TEST", 286, 302], ["plaque", "OBSERVATION", 106, 112], ["cell viability", "OBSERVATION", 288, 302]]], ["The cytotoxic analysis of the reagents for HepG2 was performed using a cell counting kit-8 (Dojindo Laboratories, Kumamoto, Japan) in the same conditions as described for the pseudovirus infection.", [["HepG2", "ANATOMY", 43, 48], ["cell", "ANATOMY", 71, 75], ["pseudovirus infection", "DISEASE", 175, 196], ["HepG2", "CELL", 43, 48], ["cell", "CELL", 71, 75], ["pseudovirus", "ORGANISM", 175, 186], ["HepG2", "CELL_LINE", 43, 48], ["The cytotoxic analysis", "TEST", 0, 22], ["HepG2", "TEST", 43, 48], ["a cell counting kit", "TEST", 69, 88], ["the pseudovirus infection", "PROBLEM", 171, 196], ["infection", "OBSERVATION", 187, 196]]], ["For VeroE6 the extracts were incubated with the cells for 72 h and the viabilities were determined using Cell Titer 96 Aqueous Non-radioactive Cell Proliferation Assay Kits (Promega).", [["extracts", "ANATOMY", 15, 23], ["cells", "ANATOMY", 48, 53], ["Cell", "ANATOMY", 105, 109], ["Cell", "ANATOMY", 143, 147], ["VeroE6", "SIMPLE_CHEMICAL", 4, 10], ["extracts", "ORGANISM_SUBSTANCE", 15, 23], ["cells", "CELL", 48, 53], ["Cell", "CELL", 105, 109], ["VeroE6 the extracts", "TREATMENT", 4, 23], ["the cells", "TREATMENT", 44, 53], ["the viabilities", "TEST", 67, 82], ["Cell Titer", "TEST", 105, 115], ["Aqueous Non-radioactive Cell Proliferation Assay Kits (Promega)", "TREATMENT", 119, 182], ["Non-radioactive Cell Proliferation", "OBSERVATION", 127, 161]]], ["The 50% growth reduction (CC50) was calculated.", [["The 50% growth reduction", "TREATMENT", 0, 24], ["growth", "OBSERVATION_MODIFIER", 8, 14], ["reduction", "OBSERVATION_MODIFIER", 15, 24]]], ["The viabilities of Jurkat cells were determined by the trypan blue dye exclusion method.", [["Jurkat cells", "ANATOMY", 19, 31], ["trypan blue", "CHEMICAL", 55, 66], ["trypan blue", "CHEMICAL", 55, 66], ["Jurkat cells", "CELL", 19, 31], ["trypan blue dye", "SIMPLE_CHEMICAL", 55, 70], ["Jurkat cells", "CELL_LINE", 19, 31], ["Jurkat cells", "PROBLEM", 19, 31], ["the trypan blue dye", "TREATMENT", 51, 70], ["Jurkat cells", "OBSERVATION", 19, 31]]], ["Selective index was calculated as CC50/IC50 as described elsewhere (Baba et al., 1987).Flow cytometric analysis ::: Materials and methodsTo investigate whether the compounds affect the expression of ACE2 on the surface of HepG2 cells, the cells were either left untreated or were pretreated with CCE, CC/Fr.2, CFE (0.1 mg/ml) or three compounds (procyanidin A2, procyanidin B1 and cinnamtannin B1 at 100 \u03bcM) in 37 \u00b0C for 60 min.", [["surface", "ANATOMY", 211, 218], ["HepG2 cells", "ANATOMY", 222, 233], ["cells", "ANATOMY", 239, 244], ["CCE", "CHEMICAL", 296, 299], ["CC", "CHEMICAL", 301, 303], ["Fr.2", "CHEMICAL", 304, 308], ["CFE", "CHEMICAL", 310, 313], ["procyanidin A2, procyanidin B1", "CHEMICAL", 346, 376], ["cinnamtannin B1", "CHEMICAL", 381, 396], ["CCE", "CHEMICAL", 296, 299], ["procyanidin A2", "CHEMICAL", 346, 360], ["procyanidin B1", "CHEMICAL", 362, 376], ["cinnamtannin B1", "CHEMICAL", 381, 396], ["ACE2", "GENE_OR_GENE_PRODUCT", 199, 203], ["surface", "CELLULAR_COMPONENT", 211, 218], ["HepG2 cells", "CELL", 222, 233], ["cells", "CELL", 239, 244], ["CCE", "SIMPLE_CHEMICAL", 296, 299], ["Fr.2", "SIMPLE_CHEMICAL", 304, 308], ["CFE", "SIMPLE_CHEMICAL", 310, 313], ["procyanidin A2", "SIMPLE_CHEMICAL", 346, 360], ["procyanidin B1", "SIMPLE_CHEMICAL", 362, 376], ["cinnamtannin B1", "SIMPLE_CHEMICAL", 381, 396], ["ACE2", "PROTEIN", 199, 203], ["HepG2 cells", "CELL_LINE", 222, 233], ["Selective index", "TEST", 0, 15], ["Flow cytometric analysis", "TEST", 87, 111], ["the compounds", "PROBLEM", 160, 173], ["ACE2", "PROBLEM", 199, 203], ["HepG2 cells", "TREATMENT", 222, 233], ["CCE", "TEST", 296, 299], ["CFE", "TEST", 310, 313], ["procyanidin A2", "TREATMENT", 346, 360], ["procyanidin B1", "TREATMENT", 362, 376], ["cinnamtannin B1", "TREATMENT", 381, 396]]], ["The DMSO solvent was also used as a control.", [["DMSO", "CHEMICAL", 4, 8], ["DMSO", "CHEMICAL", 4, 8], ["DMSO", "SIMPLE_CHEMICAL", 4, 8], ["The DMSO solvent", "TREATMENT", 0, 16], ["DMSO solvent", "OBSERVATION", 4, 16]]], ["After washing with PBS, the cells were detached by treatment with 10 mM EDTA for 10 min.", [["cells", "ANATOMY", 28, 33], ["EDTA", "CHEMICAL", 72, 76], ["cells", "CELL", 28, 33], ["EDTA", "SIMPLE_CHEMICAL", 72, 76], ["PBS", "TREATMENT", 19, 22], ["10 mM EDTA", "TREATMENT", 66, 76]]], ["The detached cells were reacted with Biotinylated Anti-human ACE-2 ectodomain Antibody (R&D Systems).", [["cells", "ANATOMY", 13, 18], ["cells", "CELL", 13, 18], ["ACE-2", "GENE_OR_GENE_PRODUCT", 61, 66], ["Biotinylated Anti-human ACE-2 ectodomain Antibody", "PROTEIN", 37, 86], ["The detached cells", "PROBLEM", 0, 18], ["Biotinylated Anti-human ACE", "TREATMENT", 37, 64], ["detached cells", "OBSERVATION", 4, 18]]], ["After reaction with phycoerythrin (PE) streptavidin (BD Pharmingen), the cells were washed and subjected to flow cytometry analysis.Flow cytometric analysis ::: Materials and methodsFor the TfR and CD59 staining, the Jurkat cells and HepG2 cells were used for the assay.", [["cells", "ANATOMY", 73, 78], ["Jurkat cells", "ANATOMY", 217, 229], ["HepG2 cells", "ANATOMY", 234, 245], ["PE", "CHEMICAL", 35, 37], ["phycoerythrin", "SIMPLE_CHEMICAL", 20, 33], ["PE", "SIMPLE_CHEMICAL", 35, 37], ["streptavidin", "SIMPLE_CHEMICAL", 39, 51], ["BD Pharmingen", "SIMPLE_CHEMICAL", 53, 66], ["cells", "CELL", 73, 78], ["TfR", "GENE_OR_GENE_PRODUCT", 190, 193], ["CD59", "GENE_OR_GENE_PRODUCT", 198, 202], ["Jurkat cells", "CELL", 217, 229], ["HepG2 cells", "CELL", 234, 245], ["phycoerythrin (PE) streptavidin", "PROTEIN", 20, 51], ["BD Pharmingen", "PROTEIN", 53, 66], ["TfR", "PROTEIN", 190, 193], ["CD59", "PROTEIN", 198, 202], ["Jurkat cells", "CELL_LINE", 217, 229], ["HepG2 cells", "CELL_LINE", 234, 245], ["phycoerythrin (PE) streptavidin (BD Pharmingen", "TREATMENT", 20, 66], ["the cells", "TREATMENT", 69, 78], ["flow cytometry analysis", "TEST", 108, 131], ["Flow cytometric analysis", "TEST", 132, 156], ["methods", "TREATMENT", 175, 182], ["the TfR", "TEST", 186, 193], ["CD59 staining", "TEST", 198, 211], ["the Jurkat cells", "TEST", 213, 229], ["HepG2 cells", "TREATMENT", 234, 245], ["the assay", "TEST", 260, 269], ["PE", "OBSERVATION", 35, 37], ["flow cytometry", "OBSERVATION", 108, 122], ["Jurkat cells", "OBSERVATION", 217, 229]]], ["Jurkat cells were incubated with the extracts at different concentrations with or without 10 \u03bcg/ml of cycloheximide or at 100 \u03bcg/ml of each extract for various periods (or 5\u201360 min) at 37 or 4 \u00b0C followed by washing twice with cold PBS containing 1% BSA.", [["Jurkat cells", "ANATOMY", 0, 12], ["extracts", "ANATOMY", 37, 45], ["extract", "ANATOMY", 140, 147], ["cycloheximide", "CHEMICAL", 102, 115], ["cycloheximide", "CHEMICAL", 102, 115], ["Jurkat cells", "CELL", 0, 12], ["extracts", "ORGANISM_SUBSTANCE", 37, 45], ["cycloheximide", "SIMPLE_CHEMICAL", 102, 115], ["BSA", "SIMPLE_CHEMICAL", 250, 253], ["Jurkat cells", "CELL_LINE", 0, 12], ["Jurkat cells", "PROBLEM", 0, 12], ["cycloheximide", "TREATMENT", 102, 115], ["cold PBS", "TREATMENT", 227, 235]]], ["Ten \u03bcl of PE-anti-TfR (BD Biosciences) and 10 \u03bcl of FITC-anti-CD59 (BD Biosciences) were incubated with 5 \u00d7 105cells for 30 min at 4 \u00b0C. After washing, the cells were analyzed by Cytomics (Beckman Coulter, Fullerton, CA).", [["cells", "ANATOMY", 156, 161], ["PE", "CHEMICAL", 10, 12], ["FITC", "CHEMICAL", 52, 56], ["TfR", "GENE_OR_GENE_PRODUCT", 18, 21], ["FITC-anti-CD59", "GENE_OR_GENE_PRODUCT", 52, 66], ["cells", "CELL", 156, 161], ["anti", "PROTEIN", 13, 17], ["TfR", "PROTEIN", 18, 21], ["BD Biosciences", "PROTEIN", 23, 37], ["FITC", "PROTEIN", 52, 56], ["anti", "PROTEIN", 57, 61], ["CD59", "PROTEIN", 62, 66], ["BD Biosciences", "PROTEIN", 68, 82], ["PE", "PROBLEM", 10, 12], ["anti-TfR (BD Biosciences", "TREATMENT", 13, 37], ["FITC", "TEST", 52, 56], ["PE", "OBSERVATION", 10, 12]]], ["The HepG2 cells were cultured in 12-well plates one day before treatment.", [["HepG2 cells", "ANATOMY", 4, 15], ["HepG2 cells", "CELL", 4, 15], ["HepG2 cells", "CELL_LINE", 4, 15], ["The HepG2 cells", "TEST", 0, 15], ["treatment", "TREATMENT", 63, 72], ["HepG2", "ANATOMY", 4, 9]]], ["After the extracts were added for 60 min, the cells were washed twice by PBS then detached by treatment with 10 mM EDTA for 10 min.", [["extracts", "ANATOMY", 10, 18], ["cells", "ANATOMY", 46, 51], ["EDTA", "CHEMICAL", 115, 119], ["extracts", "ORGANISM_SUBSTANCE", 10, 18], ["cells", "CELL", 46, 51], ["EDTA", "SIMPLE_CHEMICAL", 115, 119], ["the extracts", "TREATMENT", 6, 18], ["the cells", "TREATMENT", 42, 51], ["10 mM EDTA", "TREATMENT", 109, 119]]], ["The recovered cells were reacted with PE-anti-TfR (BD Biosciences) and of FITC-anti-CD59 (BD Biosciences).", [["cells", "ANATOMY", 14, 19], ["FITC", "CHEMICAL", 74, 78], ["cells", "CELL", 14, 19], ["TfR", "GENE_OR_GENE_PRODUCT", 46, 49], ["FITC-anti-CD59", "GENE_OR_GENE_PRODUCT", 74, 88], ["PE", "PROTEIN", 38, 40], ["anti", "PROTEIN", 41, 45], ["TfR", "PROTEIN", 46, 49], ["BD Biosciences", "PROTEIN", 51, 65], ["FITC", "PROTEIN", 74, 78], ["anti", "PROTEIN", 79, 83], ["CD59", "PROTEIN", 84, 88], ["BD Biosciences", "PROTEIN", 90, 104], ["The recovered cells", "PROBLEM", 0, 19], ["PE", "PROBLEM", 38, 40], ["BD Biosciences", "TEST", 51, 65], ["FITC", "TEST", 74, 78], ["PE", "OBSERVATION", 38, 40]]], ["After washing, the cells were analyzed by Cytomics (Beckman Coulter, Fullerton, CA).Internalization of fluorescent transferrin-A488 ::: Materials and methodsIn order to observe the internalization of transferrin, the Jurkat cells were washed twice with cold PBS and 5 \u00d7 105cells were incubated in 200 \u03bcl PBS containing different concentrations of the extracts on ice for 30 min in polystyrene round-bottom tubes (Falcon 352058).", [["cells", "ANATOMY", 19, 24], ["Jurkat cells", "ANATOMY", 217, 229], ["extracts", "ANATOMY", 351, 359], ["Falcon 352058", "CHEMICAL", 413, 426], ["polystyrene", "CHEMICAL", 381, 392], ["cells", "CELL", 19, 24], ["transferrin-A488", "SIMPLE_CHEMICAL", 115, 131], ["transferrin", "GENE_OR_GENE_PRODUCT", 200, 211], ["Jurkat cells", "CELL", 217, 229], ["extracts", "ORGANISM_SUBSTANCE", 351, 359], ["fluorescent transferrin", "PROTEIN", 103, 126], ["A488", "PROTEIN", 127, 131], ["transferrin", "PROTEIN", 200, 211], ["Jurkat cells", "CELL_LINE", 217, 229], ["fluorescent transferrin", "TEST", 103, 126], ["the internalization of transferrin", "TREATMENT", 177, 211], ["the Jurkat cells", "TREATMENT", 213, 229], ["cold PBS", "TREATMENT", 253, 261], ["ice", "TREATMENT", 363, 366], ["polystyrene round-bottom tubes", "TREATMENT", 381, 411], ["bottom tubes", "OBSERVATION", 399, 411]]], ["Then, A488-labeled transferrin (Molecular Probes) was added at a final concentration of 50 \u03bcg/ml and incubated for another 30 min on ice.", [["A488", "CHEMICAL", 6, 10], ["A488", "SIMPLE_CHEMICAL", 6, 10], ["transferrin", "GENE_OR_GENE_PRODUCT", 19, 30], ["Molecular Probes", "SIMPLE_CHEMICAL", 32, 48], ["A488", "PROTEIN", 6, 10], ["transferrin", "PROTEIN", 19, 30], ["Molecular Probes", "PROTEIN", 32, 48], ["transferrin (Molecular Probes", "TREATMENT", 19, 48]]], ["The treated cells were washed twice with cold PBS, resuspended at 107cells/ml in cold PBS in the presence or absence of various concentrations of extracts and incubated at 37 \u00b0C for 15 min (Crotzer et al., 2004).", [["cells", "ANATOMY", 12, 17], ["extracts", "ANATOMY", 146, 154], ["cells", "CELL", 12, 17], ["extracts", "ORGANISM_SUBSTANCE", 146, 154], ["treated cells", "CELL_LINE", 4, 17], ["The treated cells", "TREATMENT", 0, 17], ["cold PBS", "TREATMENT", 41, 49]]], ["Internalization was stopped by incubating the cells on ice and adding cold PBS.", [["cells", "ANATOMY", 46, 51], ["cells", "CELL", 46, 51], ["Internalization", "TREATMENT", 0, 15], ["ice", "TREATMENT", 55, 58], ["cold PBS", "TREATMENT", 70, 78]]], ["The cells were then fixed with 4% paraformaldehyde and plated on poly-l-lysine-treated cover slips (Sigma\u2013Aldrich).", [["cells", "ANATOMY", 4, 9], ["poly-l-lysine", "CHEMICAL", 65, 78], ["paraformaldehyde", "CHEMICAL", 34, 50], ["poly-l-lysine", "CHEMICAL", 65, 78], ["cells", "CELL", 4, 9], ["paraformaldehyde", "SIMPLE_CHEMICAL", 34, 50], ["poly-l-lysine", "SIMPLE_CHEMICAL", 65, 78], ["The cells", "TREATMENT", 0, 9], ["4% paraformaldehyde", "TREATMENT", 31, 50], ["poly-l-lysine", "TREATMENT", 65, 78]]], ["Cells were viewed using a Zeiss LSM510 microscope, and a single section through the middle of the cell is shown.Inhibition of pseudovirus infection ::: ResultsFirst, we screened the extracts of the 7 medicinal herbs by HIV/SARS-CoV S pseudovirus infection and only two, CCE (Cinnamomi Cortex Extract) and CFE (Caryophylli Flos Extract), apparently showed low IC50 (<100 \u03bcg/ml) with slight and moderate SIs against HIV/SARS-CoV S pseudovirus (Table 1), and these inhibitory activities were dose-dependent (Fig. 2A).", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 98, 102], ["extracts", "ANATOMY", 182, 190], ["pseudovirus infection", "DISEASE", 126, 147], ["HIV/SARS-CoV S pseudovirus infection", "DISEASE", 219, 255], ["CCE", "CHEMICAL", 270, 273], ["CFE", "CHEMICAL", 305, 308], ["Cells", "CELL", 0, 5], ["cell", "CELL", 98, 102], ["pseudovirus", "ORGANISM", 126, 137], ["extracts", "ORGANISM_SUBSTANCE", 182, 190], ["HIV", "ORGANISM", 219, 222], ["SARS-CoV S pseudovirus", "ORGANISM", 223, 245], ["CCE", "SIMPLE_CHEMICAL", 270, 273], ["CFE", "SIMPLE_CHEMICAL", 305, 308], ["Caryophylli Flos Extract", "ORGANISM", 310, 334], ["HIV", "ORGANISM", 414, 417], ["SARS-CoV S pseudovirus", "ORGANISM", 418, 440], ["Zeiss LSM510 microscope", "DNA", 26, 49], ["HIV", "SPECIES", 219, 222], ["CoV S pseudovirus", "SPECIES", 228, 245], ["HIV", "SPECIES", 414, 417], ["CoV S pseudovirus", "SPECIES", 423, 440], ["HIV", "SPECIES", 219, 222], ["SARS-CoV S pseudovirus", "SPECIES", 223, 245], ["HIV", "SPECIES", 414, 417], ["SARS-CoV S pseudovirus", "SPECIES", 418, 440], ["a Zeiss LSM510 microscope", "TEST", 24, 49], ["a single section", "TREATMENT", 55, 71], ["pseudovirus infection", "PROBLEM", 126, 147], ["HIV/SARS", "PROBLEM", 219, 227], ["CoV S pseudovirus infection", "PROBLEM", 228, 255], ["CCE", "TEST", 270, 273], ["Cinnamomi Cortex Extract", "TEST", 275, 299], ["CFE (Caryophylli Flos Extract", "TEST", 305, 334], ["low IC50", "PROBLEM", 355, 363], ["slight and moderate SIs", "PROBLEM", 382, 405], ["HIV/SARS", "PROBLEM", 414, 422], ["CoV S pseudovirus", "PROBLEM", 423, 440], ["middle", "ANATOMY_MODIFIER", 84, 90], ["cell", "ANATOMY", 98, 102], ["pseudovirus", "OBSERVATION_MODIFIER", 126, 137], ["infection", "OBSERVATION", 138, 147], ["infection", "OBSERVATION", 246, 255], ["moderate", "OBSERVATION_MODIFIER", 393, 401]]], ["It is of note that both CCE and CFE also inhibited the infection of HIV/VSVG pseudovirus (Fig. 2B).", [["CCE", "CHEMICAL", 24, 27], ["CFE", "CHEMICAL", 32, 35], ["infection", "DISEASE", 55, 64], ["CCE", "CHEMICAL", 24, 27], ["CFE", "CHEMICAL", 32, 35], ["CCE", "SIMPLE_CHEMICAL", 24, 27], ["CFE", "SIMPLE_CHEMICAL", 32, 35], ["HIV", "ORGANISM", 68, 71], ["VSVG pseudovirus", "ORGANISM", 72, 88], ["Fig. 2B", "ORGANISM", 90, 97], ["HIV", "SPECIES", 68, 71], ["HIV/VSVG pseudovirus", "SPECIES", 68, 88], ["CFE", "TEST", 32, 35], ["the infection", "PROBLEM", 51, 64], ["HIV/VSVG pseudovirus", "PROBLEM", 68, 88], ["infection", "OBSERVATION", 55, 64]]], ["To characterize the responsible substance(s), we separated the four fractions from CC and CF using aqueous ethanol (Fr.1), ethylacetate (Fr.4) and n-butanol (Fr.2) extraction methods (Fig. 1).", [["CC", "CHEMICAL", 83, 85], ["ethanol", "CHEMICAL", 107, 114], ["Fr.1", "CHEMICAL", 116, 120], ["ethylacetate", "CHEMICAL", 123, 135], ["Fr.4", "CHEMICAL", 137, 141], ["n-butanol", "CHEMICAL", 147, 156], ["Fr.2", "CHEMICAL", 158, 162], ["ethanol", "CHEMICAL", 107, 114], ["ethylacetate", "CHEMICAL", 123, 135], ["Fr.4", "CHEMICAL", 137, 141], ["n-butanol", "CHEMICAL", 147, 156], ["ethanol", "SIMPLE_CHEMICAL", 107, 114], ["Fr.1", "SIMPLE_CHEMICAL", 116, 120], ["ethylacetate", "SIMPLE_CHEMICAL", 123, 135], ["Fr.4", "SIMPLE_CHEMICAL", 137, 141], ["n-butanol", "SIMPLE_CHEMICAL", 147, 156], ["Fr.2", "SIMPLE_CHEMICAL", 158, 162], ["aqueous ethanol (Fr.1)", "TREATMENT", 99, 121], ["ethylacetate (Fr.4)", "TREATMENT", 123, 142], ["n-butanol (Fr.2) extraction methods", "TREATMENT", 147, 182]]], ["The IC50 of CC/Fr.2 was the lowest among the four fractions of CC, although all fractions showed slight inhibitory activities (Table 1).", [["CC", "CHEMICAL", 12, 14], ["CC", "CHEMICAL", 63, 65], ["CC", "SIMPLE_CHEMICAL", 63, 65], ["all fractions", "TEST", 76, 89], ["slight inhibitory activities", "PROBLEM", 97, 125], ["slight", "OBSERVATION_MODIFIER", 97, 103], ["inhibitory activities", "OBSERVATION", 104, 125]]], ["The dose-dependent inhibition of CC/Fr.2 was also confirmed using both HIV/SARS-CoV S and HIV/VSVG pseudovirus infection (Fig. 2A and B).", [["CC", "CHEMICAL", 33, 35], ["pseudovirus infection", "DISEASE", 99, 120], ["HIV/SARS-CoV S", "ORGANISM", 71, 85], ["HIV", "ORGANISM", 90, 93], ["VSVG pseudovirus", "ORGANISM", 94, 110], ["B", "GENE_OR_GENE_PRODUCT", 134, 135], ["B", "PROTEIN", 134, 135], ["HIV", "SPECIES", 90, 93], ["HIV", "SPECIES", 71, 74], ["SARS-CoV", "SPECIES", 75, 83], ["HIV/VSVG pseudovirus", "SPECIES", 90, 110], ["both HIV/SARS", "PROBLEM", 66, 79], ["CoV S", "TEST", 80, 85], ["HIV", "PROBLEM", 90, 93], ["VSVG pseudovirus infection", "PROBLEM", 94, 120]]], ["In the case of the CF fractions, CF/Fr.2, CF/Fr.3 and CF/Fr.4 showed moderate inhibitory activities (Table 1).Inhibition of pseudovirus infection ::: ResultsPseudoviruses replicate in infected cells in a single cycle manner, and the luciferase activities are not solely dependent on the entry but also on transcription and protein synthesis.", [["cells", "ANATOMY", 193, 198], ["Fr.4", "CHEMICAL", 57, 61], ["pseudovirus infection", "DISEASE", 124, 145], ["pseudovirus", "ORGANISM", 124, 135], ["cells", "CELL", 193, 198], ["luciferase", "GENE_OR_GENE_PRODUCT", 233, 243], ["infected cells", "CELL_TYPE", 184, 198], ["luciferase", "PROTEIN", 233, 243], ["CF", "TEST", 42, 44], ["CF", "TEST", 54, 56], ["moderate inhibitory activities", "PROBLEM", 69, 99], ["pseudovirus infection", "PROBLEM", 124, 145], ["ResultsPseudoviruses", "TREATMENT", 150, 170], ["infected cells", "PROBLEM", 184, 198], ["the luciferase activities", "TEST", 229, 254], ["transcription and protein synthesis", "TREATMENT", 305, 340], ["moderate", "OBSERVATION_MODIFIER", 69, 77], ["pseudovirus", "OBSERVATION_MODIFIER", 124, 135], ["infection", "OBSERVATION", 136, 145], ["infected cells", "OBSERVATION", 184, 198]]], ["Therefore, the inhibitory activities of CCE and CFE were also examined at different times by adding them to the culture 1 h before infection or 12 h after infection by HIV/SARS-CoV S. The results showed that inhibition occurred only in the former case (data not shown) suggesting that they inhibited the HIV/SARS-CoV S infection only during the early steps of virus replication.", [["CCE", "CHEMICAL", 40, 43], ["CFE", "CHEMICAL", 48, 51], ["infection", "DISEASE", 131, 140], ["infection", "DISEASE", 155, 164], ["infection", "DISEASE", 319, 328], ["CCE", "SIMPLE_CHEMICAL", 40, 43], ["CFE", "SIMPLE_CHEMICAL", 48, 51], ["HIV", "ORGANISM", 168, 171], ["HIV", "ORGANISM", 304, 307], ["SARS-CoV S", "ORGANISM", 308, 318], ["HIV", "SPECIES", 168, 171], ["HIV", "SPECIES", 304, 307], ["HIV/SARS-CoV S.", "SPECIES", 168, 183], ["HIV", "SPECIES", 304, 307], ["CCE", "TEST", 40, 43], ["the culture", "TEST", 108, 119], ["infection", "PROBLEM", 131, 140], ["infection", "PROBLEM", 155, 164], ["HIV/SARS-CoV S.", "TEST", 168, 183], ["the HIV/SARS-CoV S infection", "PROBLEM", 300, 328], ["virus replication", "TREATMENT", 360, 377], ["infection", "OBSERVATION", 319, 328]]], ["Furthermore, pretreatment of HepG2 cells by CCE and CC/Fr.2 showed apparent inhibitory effects on HIV/SARS-CoV S pseudovirus (IC50S were 283.4 \u00b1 16.3 and 149.5 \u00b1 13.5 \u03bcg/ml, respectively), however the other fractions of CC, CFE and its fractions (data not shown) did not show inhibition after pretreatment.", [["HepG2 cells", "ANATOMY", 29, 40], ["CCE", "CHEMICAL", 44, 47], ["CC", "CHEMICAL", 52, 54], ["Fr.2", "CHEMICAL", 55, 59], ["CC", "CHEMICAL", 220, 222], ["CFE", "CHEMICAL", 224, 227], ["HepG2 cells", "CELL", 29, 40], ["CCE", "CELL", 44, 47], ["CC/Fr.2", "SIMPLE_CHEMICAL", 52, 59], ["HIV/SARS-CoV S pseudovirus", "ORGANISM", 98, 124], ["CC", "SIMPLE_CHEMICAL", 220, 222], ["CFE", "SIMPLE_CHEMICAL", 224, 227], ["HepG2 cells", "CELL_LINE", 29, 40], ["HIV", "SPECIES", 98, 101], ["CoV S pseudovirus", "SPECIES", 107, 124], ["HIV/SARS-CoV S pseudovirus", "SPECIES", 98, 124], ["HepG2 cells", "TEST", 29, 40], ["CCE and CC/Fr.2", "TEST", 44, 59], ["apparent inhibitory effects", "PROBLEM", 67, 94], ["HIV/SARS", "PROBLEM", 98, 106], ["CoV S pseudovirus", "TEST", 107, 124], ["IC50S", "TEST", 126, 131], ["CC", "TEST", 220, 222], ["CFE", "TEST", 224, 227], ["its fractions", "TEST", 232, 245]]], ["Also they showed similar effects on HIV/VSVG pseudovirus by pretreatment of HepG2 cells.", [["HepG2 cells", "ANATOMY", 76, 87], ["HIV", "ORGANISM", 36, 39], ["VSVG pseudovirus", "ORGANISM", 40, 56], ["HepG2 cells", "CELL", 76, 87], ["HepG2 cells", "CELL_LINE", 76, 87], ["HIV", "SPECIES", 36, 39], ["HIV/VSVG pseudovirus", "SPECIES", 36, 56], ["HIV/VSVG pseudovirus", "PROBLEM", 36, 56], ["HepG2 cells", "PROBLEM", 76, 87], ["HepG2 cells", "OBSERVATION", 76, 87]]], ["Based on the above results, we hypothesized that CC/Fr.2 and CCE may inhibit virus entry by acting on the cells.", [["cells", "ANATOMY", 106, 111], ["CC", "CHEMICAL", 49, 51], ["Fr.2", "CHEMICAL", 52, 56], ["CCE", "CHEMICAL", 61, 64], ["Fr.2", "GENE_OR_GENE_PRODUCT", 52, 56], ["CCE", "SIMPLE_CHEMICAL", 61, 64], ["cells", "CELL", 106, 111], ["CC/Fr.2", "TEST", 49, 56], ["CCE", "TEST", 61, 64], ["virus entry", "PROBLEM", 77, 88]]], ["The inhibitory activity of CC/Fr.2 was always more prominent than that of CCE indicating that CC/Fr.2 contained the entry inhibitor that acted on the cells.Inhibition of wtSARS-CoV infection ::: ResultsWe examined the inhibitory effects of the selected extracts, CCE and CFE, using a quantitative assay (plaque reduction assay) for the infection of wtSARS-CoV.", [["cells", "ANATOMY", 150, 155], ["extracts", "ANATOMY", 253, 261], ["plaque", "ANATOMY", 304, 310], ["CC", "CHEMICAL", 27, 29], ["CCE", "CHEMICAL", 74, 77], ["CC", "CHEMICAL", 94, 96], ["Fr.2", "CHEMICAL", 97, 101], ["infection", "DISEASE", 181, 190], ["CCE", "CHEMICAL", 263, 266], ["CFE", "CHEMICAL", 271, 274], ["infection", "DISEASE", 336, 345], ["CCE", "CHEMICAL", 74, 77], ["CC/Fr.2", "SIMPLE_CHEMICAL", 27, 34], ["CCE", "SIMPLE_CHEMICAL", 74, 77], ["Fr.2", "SIMPLE_CHEMICAL", 97, 101], ["cells", "CELL", 150, 155], ["wtSARS-CoV", "GENE_OR_GENE_PRODUCT", 170, 180], ["extracts", "ORGANISM_SUBSTANCE", 253, 261], ["CCE", "SIMPLE_CHEMICAL", 263, 266], ["CFE", "SIMPLE_CHEMICAL", 271, 274], ["wtSARS-CoV", "GENE_OR_GENE_PRODUCT", 349, 359], ["wtSARS-CoV", "SPECIES", 170, 180], ["wtSARS-CoV", "SPECIES", 349, 359], ["CC/Fr.2", "TEST", 27, 34], ["CC/Fr.2", "PROBLEM", 94, 101], ["the entry inhibitor", "TREATMENT", 112, 131], ["wtSARS", "TEST", 170, 176], ["CoV infection", "PROBLEM", 177, 190], ["CFE", "TEST", 271, 274], ["a quantitative assay (plaque reduction assay", "TREATMENT", 282, 326], ["the infection of wtSARS", "PROBLEM", 332, 355], ["CoV", "PROBLEM", 356, 359], ["more prominent", "OBSERVATION_MODIFIER", 46, 60], ["CoV", "ANATOMY", 177, 180], ["infection", "OBSERVATION", 181, 190], ["infection", "OBSERVATION", 336, 345]]], ["In this assay CCE inhibited wtSARS-CoV infection when the viruses were mixed with the herbs and added onto the target cells, but CFE showed only weak inhibitory activity (Table 2).", [["cells", "ANATOMY", 118, 123], ["CCE", "CHEMICAL", 14, 17], ["CFE", "CHEMICAL", 129, 132], ["CCE", "SIMPLE_CHEMICAL", 14, 17], ["wtSARS-CoV", "GENE_OR_GENE_PRODUCT", 28, 38], ["cells", "CELL", 118, 123], ["CFE", "SIMPLE_CHEMICAL", 129, 132], ["target cells", "CELL_TYPE", 111, 123], ["CFE", "CELL_LINE", 129, 132], ["wtSARS-CoV", "SPECIES", 28, 38], ["this assay CCE", "TEST", 3, 17], ["wtSARS", "PROBLEM", 28, 34], ["CoV infection", "PROBLEM", 35, 48], ["the viruses", "PROBLEM", 54, 65], ["the herbs", "TREATMENT", 82, 91], ["CFE", "TEST", 129, 132], ["weak inhibitory activity", "PROBLEM", 145, 169], ["CoV", "OBSERVATION_MODIFIER", 35, 38], ["infection", "OBSERVATION", 39, 48]]], ["The IC50S counted by plaque numbers of the wtSARS-CoV, which were pretreated (1 h) with CCE, CC/Fr.2 or compounds (procyanidin A2, procyanidin B1 and cinnamtannin B1), were not different from those in which the viruses were added simultaneously with drugs (0 h) (P> 0.05).", [["plaque", "ANATOMY", 21, 27], ["CCE", "CHEMICAL", 88, 91], ["CC", "CHEMICAL", 93, 95], ["Fr.2", "CHEMICAL", 96, 100], ["procyanidin A2, procyanidin B1 and cinnamtannin B1", "CHEMICAL", 115, 165], ["procyanidin A2", "CHEMICAL", 115, 129], ["procyanidin B1", "CHEMICAL", 131, 145], ["cinnamtannin B1", "CHEMICAL", 150, 165], ["wtSARS-CoV", "GENE_OR_GENE_PRODUCT", 43, 53], ["CCE", "SIMPLE_CHEMICAL", 88, 91], ["Fr.2", "SIMPLE_CHEMICAL", 96, 100], ["procyanidin A2", "SIMPLE_CHEMICAL", 115, 129], ["procyanidin B1", "SIMPLE_CHEMICAL", 131, 145], ["cinnamtannin B1", "SIMPLE_CHEMICAL", 150, 165], ["IC50S", "DNA", 4, 9], ["wtSARS-CoV", "SPECIES", 43, 53], ["The IC50S", "TEST", 0, 9], ["CCE", "TEST", 88, 91], ["CC", "TEST", 93, 95], ["procyanidin A2", "TREATMENT", 115, 129], ["procyanidin B1", "TREATMENT", 131, 145], ["cinnamtannin B1", "TREATMENT", 150, 165], ["drugs", "TREATMENT", 250, 255], ["IC50S", "OBSERVATION_MODIFIER", 4, 9], ["plaque", "OBSERVATION_MODIFIER", 21, 27], ["numbers", "OBSERVATION_MODIFIER", 28, 35], ["CoV", "ANATOMY", 50, 53], ["viruses", "OBSERVATION", 211, 218]]], ["Therefore we could not prove virucidal effects of the compounds, and analyzed their inhibitory activities by adding the mixtures of compounds and the virus (0 h) to target cells.", [["cells", "ANATOMY", 172, 177], ["cells", "CELL", 172, 177], ["target cells", "CELL_TYPE", 165, 177], ["the mixtures of compounds", "TREATMENT", 116, 141], ["the virus", "PROBLEM", 146, 155]]], ["Among the four fractions of CC, CC/Fr.2 showed moderate inhibitory activities in the plaque reduction assay, suggesting that CC/Fr.2 contained more biologically active substances (Table 2).", [["plaque", "ANATOMY", 85, 91], ["CC", "CHEMICAL", 28, 30], ["CC", "CHEMICAL", 32, 34], ["Fr.2", "CHEMICAL", 35, 39], ["CC", "CHEMICAL", 125, 127], ["Fr.2", "CHEMICAL", 128, 132], ["CC", "SIMPLE_CHEMICAL", 28, 30], ["Fr.2", "SIMPLE_CHEMICAL", 35, 39], ["plaque", "PATHOLOGICAL_FORMATION", 85, 91], ["Fr.2", "SIMPLE_CHEMICAL", 128, 132], ["CC, CC/Fr.2", "TEST", 28, 39], ["moderate inhibitory activities", "PROBLEM", 47, 77], ["the plaque reduction assay", "PROBLEM", 81, 107], ["CC/Fr.2", "TEST", 125, 132], ["moderate", "OBSERVATION_MODIFIER", 47, 55], ["inhibitory activities", "OBSERVATION", 56, 77], ["plaque", "OBSERVATION", 85, 91]]], ["Unexpectedly, the four fractions of CF, as well as CFE, did not inhibit wtSARS-CoV infection (Table 2).The effects of chemicals ::: ResultsBecause CCE may contain specific compounds that inhibit virus infection through clathrin-dependent endocytosis, we tried to identify the compounds.", [["CFE", "CHEMICAL", 51, 54], ["infection", "DISEASE", 83, 92], ["CCE", "CHEMICAL", 147, 150], ["infection", "DISEASE", 201, 210], ["wtSARS-CoV", "GENE_OR_GENE_PRODUCT", 72, 82], ["CCE", "SIMPLE_CHEMICAL", 147, 150], ["clathrin", "GENE_OR_GENE_PRODUCT", 219, 227], ["clathrin", "PROTEIN", 219, 227], ["wtSARS-CoV", "SPECIES", 72, 82], ["CF", "PROBLEM", 36, 38], ["CoV infection", "PROBLEM", 79, 92], ["specific compounds", "PROBLEM", 163, 181], ["virus infection", "PROBLEM", 195, 210], ["dependent endocytosis", "PROBLEM", 228, 249], ["infection", "OBSERVATION", 83, 92], ["dependent", "OBSERVATION_MODIFIER", 228, 237], ["endocytosis", "OBSERVATION", 238, 249]]], ["Several compounds reported to be present in CC and other derivatives have also been studied (Heide, 1972, Nonaka et al., 1983).", [["CC", "CHEMICAL", 44, 46], ["CC", "SIMPLE_CHEMICAL", 44, 46]]], ["Among these chemicals, trans-cinnamic acid, 2-phenylethanol (phenethy alcohol) and 2-hydroxycinnamic acid showed slight suppressive effects [selectivity index (SI) > 5] on HIV/SARS-CoV S pseudovirus infection (Table 3).", [["trans-cinnamic acid", "CHEMICAL", 23, 42], ["2-phenylethanol", "CHEMICAL", 44, 59], ["phenethy alcohol", "CHEMICAL", 61, 77], ["2-hydroxycinnamic acid", "CHEMICAL", 83, 105], ["HIV/SARS-CoV S pseudovirus infection", "DISEASE", 172, 208], ["trans-cinnamic acid", "CHEMICAL", 23, 42], ["2-phenylethanol", "CHEMICAL", 44, 59], ["phenethy alcohol", "CHEMICAL", 61, 77], ["2-hydroxycinnamic acid", "CHEMICAL", 83, 105], ["trans-cinnamic acid", "SIMPLE_CHEMICAL", 23, 42], ["2-phenylethanol", "SIMPLE_CHEMICAL", 44, 59], ["phenethy alcohol", "SIMPLE_CHEMICAL", 61, 77], ["2-hydroxycinnamic acid", "SIMPLE_CHEMICAL", 83, 105], ["HIV", "ORGANISM", 172, 175], ["SARS-CoV S pseudovirus", "ORGANISM", 176, 198], ["HIV", "SPECIES", 172, 175], ["CoV S pseudovirus", "SPECIES", 181, 198], ["HIV/SARS-CoV S pseudovirus", "SPECIES", 172, 198], ["cinnamic acid", "TEST", 29, 42], ["hydroxycinnamic acid", "TEST", 85, 105], ["slight suppressive effects", "PROBLEM", 113, 139], ["selectivity index (SI)", "PROBLEM", 141, 163], ["HIV/SARS", "PROBLEM", 172, 180], ["CoV S pseudovirus infection", "PROBLEM", 181, 208], ["infection", "OBSERVATION", 199, 208]]], ["However, these chemicals did not show any anti-SARS-CoV activities in wtSARS-CoV infection even at the highest optimal concentrations (data not shown).", [["infection", "DISEASE", 81, 90], ["anti-SARS-CoV", "GENE_OR_GENE_PRODUCT", 42, 55], ["wtSARS-CoV", "ORGANISM", 70, 80], ["wtSARS-CoV", "SPECIES", 70, 80], ["wtSARS", "PROBLEM", 70, 76], ["CoV infection", "PROBLEM", 77, 90], ["infection", "OBSERVATION", 81, 90]]], ["In the case of the eight compounds fractionated from CC, we examined all by pseudovirus and wtSARS-CoV infection.", [["CC", "CHEMICAL", 53, 55], ["infection", "DISEASE", 103, 112], ["pseudovirus", "ORGANISM", 76, 87], ["wtSARS-CoV", "ORGANISM", 92, 102], ["wtSARS-CoV", "SPECIES", 92, 102], ["wtSARS", "PROBLEM", 92, 98], ["CoV infection", "PROBLEM", 99, 112], ["CoV", "ANATOMY", 99, 102], ["infection", "OBSERVATION", 103, 112]]], ["Among these compounds, procyanidin A2, procyanidin B1 and cinnamtannin B1 showed slight or moderate inhibitory effects in both assays (Table 4).ACE2 expression after treatment by extracts and compounds ::: ResultsThe HepG2 cells which were treated by CCE, CC/Fr.2, CFE (0.1 mg/ml) or three compounds (procyanidin A2, procyanidin B1 and cinnamtannin B1 at 100 \u03bcM) in 37 \u00b0C for 60 min were used for flow cytometry analysis.", [["extracts", "ANATOMY", 179, 187], ["HepG2 cells", "ANATOMY", 217, 228], ["procyanidin A2", "CHEMICAL", 23, 37], ["procyanidin B1", "CHEMICAL", 39, 53], ["cinnamtannin B1", "CHEMICAL", 58, 73], ["CCE", "CHEMICAL", 251, 254], ["CC", "CHEMICAL", 256, 258], ["Fr.2", "CHEMICAL", 259, 263], ["CFE", "CHEMICAL", 265, 268], ["procyanidin A2, procyanidin B1", "CHEMICAL", 301, 331], ["cinnamtannin B1", "CHEMICAL", 336, 351], ["procyanidin A2", "CHEMICAL", 23, 37], ["procyanidin B1", "CHEMICAL", 39, 53], ["cinnamtannin B1", "CHEMICAL", 58, 73], ["procyanidin A2", "CHEMICAL", 301, 315], ["procyanidin B1", "CHEMICAL", 317, 331], ["cinnamtannin B1", "CHEMICAL", 336, 351], ["procyanidin A2", "SIMPLE_CHEMICAL", 23, 37], ["procyanidin B1", "SIMPLE_CHEMICAL", 39, 53], ["cinnamtannin B1", "SIMPLE_CHEMICAL", 58, 73], ["ACE2", "GENE_OR_GENE_PRODUCT", 144, 148], ["extracts", "ORGANISM_SUBSTANCE", 179, 187], ["HepG2 cells", "CELL", 217, 228], ["CCE", "SIMPLE_CHEMICAL", 251, 254], ["Fr.2", "SIMPLE_CHEMICAL", 259, 263], ["CFE", "SIMPLE_CHEMICAL", 265, 268], ["procyanidin A2", "SIMPLE_CHEMICAL", 301, 315], ["procyanidin B1", "SIMPLE_CHEMICAL", 317, 331], ["cinnamtannin B1", "SIMPLE_CHEMICAL", 336, 351], ["ACE2", "PROTEIN", 144, 148], ["HepG2 cells", "CELL_LINE", 217, 228], ["procyanidin A2", "TREATMENT", 23, 37], ["procyanidin B1", "TREATMENT", 39, 53], ["cinnamtannin B1", "TEST", 58, 73], ["moderate inhibitory effects", "PROBLEM", 91, 118], ["The HepG2 cells", "TEST", 213, 228], ["CFE", "TEST", 265, 268], ["procyanidin A2", "TREATMENT", 301, 315], ["procyanidin B1", "TREATMENT", 317, 331], ["cinnamtannin B1", "TREATMENT", 336, 351], ["flow cytometry analysis", "TEST", 397, 420], ["slight", "OBSERVATION_MODIFIER", 81, 87], ["moderate", "OBSERVATION_MODIFIER", 91, 99], ["inhibitory effects", "OBSERVATION", 100, 118]]], ["Both the positive percentages and MFI of PE-anti-ACE2 were analyzed.", [["ACE2", "GENE_OR_GENE_PRODUCT", 49, 53], ["ACE2", "PROTEIN", 49, 53], ["MFI", "TEST", 34, 37], ["PE", "TEST", 41, 43], ["anti-ACE2", "TREATMENT", 44, 53], ["positive", "OBSERVATION_MODIFIER", 9, 17], ["percentages", "OBSERVATION_MODIFIER", 18, 29], ["PE", "OBSERVATION", 41, 43]]], ["There was no significant difference for both parameters between treated cells and untreated control.", [["cells", "ANATOMY", 72, 77], ["cells", "CELL", 72, 77], ["treated cells", "CELL_LINE", 64, 77], ["significant difference", "PROBLEM", 13, 35], ["untreated control", "TREATMENT", 82, 99], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION", 25, 35]]], ["The percentages and MFI of non-treated cells were 35.5 \u00b1 2.6%, 635.7 \u00b1 36.2, and those of treated cells were 34.3 \u00b1 2.3% to 39.9 \u00b1 2.8%, 601.3 \u00b1 25.2 to 699.0 \u00b1 40.4, respectively.Influence on the expression of TfR on Jurkat cell surface by the herbal treatment. ::: ResultsBecause both CCE and CFE inhibited not only the SARS-CoV infection but also that of HIV/VSVG, we suspected that they may act through shared endocytic pathways of the viruses, and both viruses are known to enter into cells via clathrin-dependent endocytic pathways (Sun et al., 2005, Inoue et al., 2007).", [["cells", "ANATOMY", 39, 44], ["cells", "ANATOMY", 98, 103], ["Jurkat cell surface", "ANATOMY", 218, 237], ["cells", "ANATOMY", 490, 495], ["CCE", "CHEMICAL", 287, 290], ["CFE", "CHEMICAL", 295, 298], ["SARS", "DISEASE", 322, 326], ["infection", "DISEASE", 331, 340], ["cells", "CELL", 39, 44], ["cells", "CELL", 98, 103], ["TfR", "GENE_OR_GENE_PRODUCT", 211, 214], ["Jurkat cell", "CELL", 218, 229], ["surface", "CELLULAR_COMPONENT", 230, 237], ["CFE", "SIMPLE_CHEMICAL", 295, 298], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 322, 330], ["HIV", "ORGANISM", 358, 361], ["VSVG", "GENE_OR_GENE_PRODUCT", 362, 366], ["cells", "CELL", 490, 495], ["clathrin", "GENE_OR_GENE_PRODUCT", 500, 508], ["TfR", "PROTEIN", 211, 214], ["clathrin", "PROTEIN", 500, 508], ["HIV", "SPECIES", 358, 361], ["SARS-CoV", "SPECIES", 322, 330], ["HIV", "SPECIES", 358, 361], ["The percentages", "TEST", 0, 15], ["non-treated cells", "TEST", 27, 44], ["TfR on Jurkat cell surface", "TREATMENT", 211, 237], ["the herbal treatment", "TREATMENT", 241, 261], ["the SARS", "PROBLEM", 318, 326], ["CoV infection", "PROBLEM", 327, 340], ["HIV/VSVG", "PROBLEM", 358, 366], ["the viruses", "PROBLEM", 436, 447], ["both viruses", "PROBLEM", 453, 465], ["percentages", "OBSERVATION_MODIFIER", 4, 15], ["Jurkat cell", "OBSERVATION", 218, 229], ["infection", "OBSERVATION", 331, 340], ["viruses", "OBSERVATION", 440, 447]]], ["TfR is considered to be a marker of clathrin-mediated endocytosis and CD59 is a marker of clathrin-independent endocytosis (Mellman, 1996, Naslavsky et al., 2004).", [["TfR", "GENE_OR_GENE_PRODUCT", 0, 3], ["clathrin", "GENE_OR_GENE_PRODUCT", 36, 44], ["CD59", "GENE_OR_GENE_PRODUCT", 70, 74], ["clathrin", "GENE_OR_GENE_PRODUCT", 90, 98], ["TfR", "PROTEIN", 0, 3], ["clathrin", "PROTEIN", 36, 44], ["CD59", "PROTEIN", 70, 74], ["clathrin", "PROTEIN", 90, 98], ["TfR", "TREATMENT", 0, 3], ["CD59", "TEST", 70, 74], ["considered to be", "UNCERTAINTY", 7, 23]]], ["As expected, CC/Fr.2 and CCE up-regulated the TfR expression on Jurkat cell in dose- and time-dependent manners (Fig. 3A and C).", [["Jurkat cell", "ANATOMY", 64, 75], ["CC", "CHEMICAL", 13, 15], ["CCE", "CHEMICAL", 25, 28], ["Fr.2", "GENE_OR_GENE_PRODUCT", 16, 20], ["CCE", "CELL", 25, 28], ["TfR", "GENE_OR_GENE_PRODUCT", 46, 49], ["Jurkat cell", "CELL", 64, 75], ["TfR", "PROTEIN", 46, 49], ["Jurkat cell", "CELL_LINE", 64, 75], ["CCE", "TEST", 25, 28], ["Jurkat cell", "OBSERVATION", 64, 75]]], ["Furthermore, neither CC/Fr.3, CC/Fr.4 (Fig. 3) nor CFE and its fractions (data not shown) influenced the TfR expression.", [["CC", "CHEMICAL", 21, 23], ["CC", "CHEMICAL", 30, 32], ["CFE", "CHEMICAL", 51, 54], ["CFE", "CANCER", 51, 54], ["TfR", "GENE_OR_GENE_PRODUCT", 105, 108], ["CFE", "PROTEIN", 51, 54], ["TfR", "PROTEIN", 105, 108], ["neither CC/Fr.3", "TEST", 13, 28], ["CC", "TEST", 30, 32], ["CFE", "TEST", 51, 54]]], ["The enhanced expressions of TfR on Jurkat cells by CC/Fr.2 could not be explained by enhanced protein synthesis, because the up-regulation was also observed when the cells were incubated with CHX.", [["Jurkat cells", "ANATOMY", 35, 47], ["cells", "ANATOMY", 166, 171], ["CC", "CHEMICAL", 51, 53], ["CHX", "CHEMICAL", 192, 195], ["CHX", "CHEMICAL", 192, 195], ["TfR", "GENE_OR_GENE_PRODUCT", 28, 31], ["Jurkat cells", "CELL", 35, 47], ["CC", "CELL", 51, 53], ["Fr.2", "GENE_OR_GENE_PRODUCT", 54, 58], ["cells", "CELL", 166, 171], ["CHX", "SIMPLE_CHEMICAL", 192, 195], ["TfR", "PROTEIN", 28, 31], ["Jurkat cells", "CELL_LINE", 35, 47], ["TfR on Jurkat cells", "TREATMENT", 28, 47], ["enhanced protein synthesis", "PROBLEM", 85, 111], ["CHX", "TREATMENT", 192, 195]]], ["No up-regulation of TfR was seen when the Jurkat cells were incubated with CCE at 4 \u00b0C. The up-regulation of only TfR was also found in treated HepG2 cells by CCE and CC/Fr.2 (MFI of untreated cells was 404.7 \u00b1 25.5, and 628.3 \u00b1 37.1 and 759.0 \u00b1 42.0 for CCE and CC/Fr.2, respectively).", [["Jurkat cells", "ANATOMY", 42, 54], ["HepG2 cells", "ANATOMY", 144, 155], ["cells", "ANATOMY", 193, 198], ["CCE", "CHEMICAL", 75, 78], ["CC", "CHEMICAL", 167, 169], ["CC", "CHEMICAL", 263, 265], ["TfR", "GENE_OR_GENE_PRODUCT", 20, 23], ["Jurkat cells", "CELL", 42, 54], ["CCE", "SIMPLE_CHEMICAL", 75, 78], ["TfR", "GENE_OR_GENE_PRODUCT", 114, 117], ["HepG2 cells", "CELL", 144, 155], ["CCE", "CELL", 159, 162], ["CC/Fr.2", "CELL", 167, 174], ["cells", "CELL", 193, 198], ["TfR", "PROTEIN", 20, 23], ["Jurkat cells", "CELL_LINE", 42, 54], ["TfR", "PROTEIN", 114, 117], ["HepG2 cells", "CELL_LINE", 144, 155], ["up-regulation of TfR", "PROBLEM", 3, 23], ["the Jurkat cells", "PROBLEM", 38, 54], ["HepG2 cells", "TEST", 144, 155], ["CCE", "TEST", 159, 162], ["CC", "TEST", 167, 169], ["untreated cells", "TEST", 183, 198], ["CCE", "TEST", 255, 258], ["CC", "TEST", 263, 265], ["up-regulation", "OBSERVATION_MODIFIER", 3, 16], ["TfR", "OBSERVATION", 20, 23]]], ["In the case of the eight compounds fractionated from CC, we examined all by pseudovirus and wtSARS-CoV infection.", [["CC", "CHEMICAL", 53, 55], ["infection", "DISEASE", 103, 112], ["pseudovirus", "ORGANISM", 76, 87], ["wtSARS-CoV", "ORGANISM", 92, 102], ["wtSARS-CoV", "SPECIES", 92, 102], ["wtSARS", "PROBLEM", 92, 98], ["CoV infection", "PROBLEM", 99, 112], ["CoV", "ANATOMY", 99, 102], ["infection", "OBSERVATION", 103, 112]]], ["Because procyanidin A2, procyanidin B1 and cinnamtannin B1 showed inhibitory effects on SARS virus infection (Table 4), the effects on the expressions of CD59 and TfR on Jurkat cells were examined.", [["Jurkat cells", "ANATOMY", 170, 182], ["procyanidin A2", "CHEMICAL", 8, 22], ["procyanidin B1", "CHEMICAL", 24, 38], ["cinnamtannin B1", "CHEMICAL", 43, 58], ["SARS virus infection", "DISEASE", 88, 108], ["procyanidin A2", "CHEMICAL", 8, 22], ["procyanidin B1", "CHEMICAL", 24, 38], ["cinnamtannin B1", "CHEMICAL", 43, 58], ["procyanidin A2", "SIMPLE_CHEMICAL", 8, 22], ["procyanidin B1", "SIMPLE_CHEMICAL", 24, 38], ["cinnamtannin B1", "SIMPLE_CHEMICAL", 43, 58], ["SARS virus", "ORGANISM", 88, 98], ["CD59", "GENE_OR_GENE_PRODUCT", 154, 158], ["TfR", "GENE_OR_GENE_PRODUCT", 163, 166], ["Jurkat cells", "CELL", 170, 182], ["CD59", "PROTEIN", 154, 158], ["TfR", "PROTEIN", 163, 166], ["Jurkat cells", "CELL_LINE", 170, 182], ["SARS virus", "SPECIES", 88, 98], ["procyanidin A2", "TREATMENT", 8, 22], ["procyanidin B1", "TREATMENT", 24, 38], ["cinnamtannin B1", "TREATMENT", 43, 58], ["inhibitory effects", "PROBLEM", 66, 84], ["SARS virus infection", "PROBLEM", 88, 108], ["CD59", "TEST", 154, 158], ["TfR on Jurkat cells", "TREATMENT", 163, 182], ["Jurkat cells", "OBSERVATION", 170, 182]]], ["Flow cytometric analysis showed that procyanidin A2 and cinnamtannin B1 up-regulated the expression of TfR in dose- and time-dependent manners (Fig. 4).", [["procyanidin A2", "CHEMICAL", 37, 51], ["cinnamtannin", "CHEMICAL", 56, 68], ["procyanidin A2", "CHEMICAL", 37, 51], ["cinnamtannin B1", "CHEMICAL", 56, 71], ["procyanidin A2", "GENE_OR_GENE_PRODUCT", 37, 51], ["cinnamtannin B1", "GENE_OR_GENE_PRODUCT", 56, 71], ["TfR", "GENE_OR_GENE_PRODUCT", 103, 106], ["TfR", "PROTEIN", 103, 106], ["Flow cytometric analysis", "TEST", 0, 24], ["procyanidin A2", "TREATMENT", 37, 51], ["procyanidin A2", "OBSERVATION", 37, 51]]], ["Procyanidin B1 did not affect the expression of CD59 and TfR, even though it inhibited the infection of wtSARS-CoV with a SI of about 15.Internalization of fluorescent transferrin-A488 ::: ResultsBecause TfR is a recycling molecule in cells, we considered that interference by CCE and CC/Fr.2 with the recycling of TfR resulted in the enhanced expression of TfR on Jurkat cells.", [["cells", "ANATOMY", 235, 240], ["Jurkat cells", "ANATOMY", 365, 377], ["Procyanidin B1", "CHEMICAL", 0, 14], ["infection", "DISEASE", 91, 100], ["CCE", "CHEMICAL", 277, 280], ["CC", "CHEMICAL", 285, 287], ["Procyanidin B1", "CHEMICAL", 0, 14], ["Procyanidin B1", "GENE_OR_GENE_PRODUCT", 0, 14], ["CD59", "GENE_OR_GENE_PRODUCT", 48, 52], ["TfR", "GENE_OR_GENE_PRODUCT", 57, 60], ["wtSARS-CoV", "GENE_OR_GENE_PRODUCT", 104, 114], ["transferrin-A488", "SIMPLE_CHEMICAL", 168, 184], ["TfR", "GENE_OR_GENE_PRODUCT", 204, 207], ["cells", "CELL", 235, 240], ["CCE", "CELL", 277, 280], ["Fr.2", "GENE_OR_GENE_PRODUCT", 288, 292], ["TfR", "GENE_OR_GENE_PRODUCT", 315, 318], ["TfR", "GENE_OR_GENE_PRODUCT", 358, 361], ["Jurkat cells", "CELL", 365, 377], ["CD59", "PROTEIN", 48, 52], ["TfR", "PROTEIN", 57, 60], ["wtSARS", "PROTEIN", 104, 110], ["fluorescent transferrin", "PROTEIN", 156, 179], ["A488", "PROTEIN", 180, 184], ["TfR", "PROTEIN", 204, 207], ["Fr.2", "PROTEIN", 288, 292], ["TfR", "PROTEIN", 315, 318], ["TfR", "PROTEIN", 358, 361], ["Jurkat cells", "CELL_LINE", 365, 377], ["wtSARS-CoV", "SPECIES", 104, 114], ["Procyanidin B1", "TREATMENT", 0, 14], ["CD59", "TEST", 48, 52], ["TfR", "TEST", 57, 60], ["the infection of wtSARS", "PROBLEM", 87, 110], ["fluorescent transferrin", "TEST", 156, 179], ["a recycling molecule in cells", "PROBLEM", 211, 240], ["the recycling of TfR", "TREATMENT", 298, 318], ["TfR on Jurkat cells", "TREATMENT", 358, 377], ["infection", "OBSERVATION", 91, 100], ["Jurkat cells", "OBSERVATION", 365, 377]]], ["The Tfn-A488 was used for detection of the internalization, which is a step of endocytosis.", [["Tfn-A488", "GENE_OR_GENE_PRODUCT", 4, 12], ["Tfn", "PROTEIN", 4, 7], ["A488", "PROTEIN", 8, 12], ["the internalization", "PROBLEM", 39, 58], ["endocytosis", "OBSERVATION", 79, 90]]], ["At 37 \u00b0C incubation the Tfn-A488 was internalized into Jurkat cells in the absence of the herbs after 15 min (Fig. 5, middle panel).", [["Jurkat cells", "ANATOMY", 55, 67], ["Tfn-A488", "CHEMICAL", 24, 32], ["Tfn-A488", "SIMPLE_CHEMICAL", 24, 32], ["Jurkat cells", "CELL", 55, 67], ["Tfn", "PROTEIN", 24, 27], ["A488", "PROTEIN", 28, 32], ["Jurkat cells", "CELL_LINE", 55, 67], ["the Tfn", "TEST", 20, 27], ["the herbs", "TREATMENT", 86, 95], ["Jurkat cells", "OBSERVATION", 55, 67]]], ["We examined whether the extracts interfered with the internalization of Tfn-A488 in Jurkat cells.", [["extracts", "ANATOMY", 24, 32], ["Tfn-A488", "ANATOMY", 72, 80], ["Jurkat cells", "ANATOMY", 84, 96], ["extracts", "ORGANISM_SUBSTANCE", 24, 32], ["Tfn-A488", "GENE_OR_GENE_PRODUCT", 72, 80], ["Jurkat cells", "CELL", 84, 96], ["Tfn", "PROTEIN", 72, 75], ["A488", "PROTEIN", 76, 80], ["Jurkat cells", "CELL_LINE", 84, 96], ["the extracts", "PROBLEM", 20, 32], ["Tfn-A488 in Jurkat cells", "TREATMENT", 72, 96], ["Jurkat cells", "OBSERVATION", 84, 96]]], ["CCE and all its fractions except for CC/Fr.4 blocked the internalization of Tfn-A488 at 100 \u03bcg/ml (Table 5), and no internalization was observed when CC/Fr.2 was added at a relatively low concentration (10 \u03bcg/ml), which is close to the IC50 for the wild-type infection (7.8 \u03bcg/ml).", [["CCE", "CHEMICAL", 0, 3], ["CC", "CHEMICAL", 37, 39], ["Fr.4", "CHEMICAL", 40, 44], ["Tfn-A488", "CHEMICAL", 76, 84], ["CC", "CHEMICAL", 150, 152], ["Fr.2", "CHEMICAL", 153, 157], ["infection", "DISEASE", 259, 268], ["CCE", "SIMPLE_CHEMICAL", 0, 3], ["Fr.4", "SIMPLE_CHEMICAL", 40, 44], ["Tfn-A488", "SIMPLE_CHEMICAL", 76, 84], ["Fr.2", "SIMPLE_CHEMICAL", 153, 157], ["CCE", "TEST", 0, 3], ["the internalization of Tfn", "TREATMENT", 53, 79], ["a relatively low concentration", "TREATMENT", 171, 201], ["the IC50", "TREATMENT", 232, 240], ["the wild-type infection", "PROBLEM", 245, 268]]], ["CFE and the other fractions had no effect on the internalization (Table 5) even at a concentration (100 \u03bcg/ml) higher than the IC50 for HIV/SARS-CoV S pseudovirus infection (Table 5).", [["CFE", "CHEMICAL", 0, 3], ["HIV/SARS-CoV S pseudovirus infection", "DISEASE", 136, 172], ["CFE", "SIMPLE_CHEMICAL", 0, 3], ["HIV", "ORGANISM", 136, 139], ["SARS-CoV S pseudovirus", "ORGANISM", 140, 162], ["CoV S pseudovirus", "SPECIES", 145, 162], ["HIV/SARS-CoV S pseudovirus", "SPECIES", 136, 162], ["CFE", "TEST", 0, 3], ["the other fractions", "TEST", 8, 27], ["HIV", "PROBLEM", 136, 139], ["SARS", "PROBLEM", 140, 144], ["CoV S pseudovirus infection", "PROBLEM", 145, 172], ["infection", "OBSERVATION", 163, 172]]], ["Finally, no procyanidins inhibited the internalization at the optimal concentration.Discussion ::: ResultsWe used a pseudovirus to evaluate the anti-SARS-CoV activities of medicinal herbs using luciferase as a reporter.", [["procyanidins", "CHEMICAL", 12, 24], ["procyanidins", "CHEMICAL", 12, 24], ["procyanidins", "SIMPLE_CHEMICAL", 12, 24], ["luciferase", "GENE_OR_GENE_PRODUCT", 194, 204], ["luciferase", "PROTEIN", 194, 204], ["procyanidins", "TREATMENT", 12, 24], ["a pseudovirus", "TEST", 114, 127], ["medicinal herbs", "TREATMENT", 172, 187]]], ["The 7 kinds of medicinal herbs which were recommended to be used for SARS patients (Liu et al., 2006) were examined for their effects on HIV/SARS-CoV S pseudovirus infection.", [["SARS", "DISEASE", 69, 73], ["HIV/SARS-CoV S pseudovirus infection", "DISEASE", 137, 173], ["patients", "ORGANISM", 74, 82], ["HIV", "ORGANISM", 137, 140], ["SARS-CoV S pseudovirus", "ORGANISM", 141, 163], ["patients", "SPECIES", 74, 82], ["HIV", "SPECIES", 137, 140], ["CoV S pseudovirus", "SPECIES", 146, 163], ["HIV/SARS-CoV S pseudovirus", "SPECIES", 137, 163], ["medicinal herbs", "TREATMENT", 15, 30], ["HIV/SARS", "PROBLEM", 137, 145], ["CoV S pseudovirus infection", "PROBLEM", 146, 173], ["infection", "OBSERVATION", 164, 173]]], ["Two herbal extracts (CCE and CFE) showed slightly or moderate inhibitory activities on both HIV/SARS-CoV S and HIV/VSVG pseudovirus infection.Discussion ::: ResultsWe evaluated the anti-virus activities of the fractionated extracts and found that CC/Fr.1, CC/Fr.2 and all four fractions of CF showed slightly or moderate inhibitory activities against pseudovirus in the infection assay (Table 1).", [["extracts", "ANATOMY", 11, 19], ["extracts", "ANATOMY", 223, 231], ["CCE", "CHEMICAL", 21, 24], ["CFE", "CHEMICAL", 29, 32], ["HIV/SARS-CoV S and HIV/VSVG pseudovirus infection", "DISEASE", 92, 141], ["CC", "CHEMICAL", 247, 249], ["Fr.1", "CHEMICAL", 250, 254], ["CC", "CHEMICAL", 256, 258], ["Fr.2", "CHEMICAL", 259, 263], ["infection", "DISEASE", 370, 379], ["CCE", "SIMPLE_CHEMICAL", 21, 24], ["CFE", "SIMPLE_CHEMICAL", 29, 32], ["HIV", "ORGANISM", 92, 95], ["SARS-CoV S", "ORGANISM", 96, 106], ["HIV", "ORGANISM", 111, 114], ["VSVG pseudovirus", "ORGANISM", 115, 131], ["extracts", "ORGANISM_SUBSTANCE", 223, 231], ["Fr.2", "SIMPLE_CHEMICAL", 259, 263], ["pseudovirus", "ORGANISM", 351, 362], ["HIV", "SPECIES", 92, 95], ["HIV", "SPECIES", 111, 114], ["HIV/SARS-CoV", "SPECIES", 92, 104], ["HIV/VSVG pseudovirus", "SPECIES", 111, 131], ["Two herbal extracts", "TEST", 0, 19], ["CCE and CFE", "TEST", 21, 32], ["slightly or moderate inhibitory activities", "PROBLEM", 41, 83], ["both HIV/SARS", "PROBLEM", 87, 100], ["CoV S", "PROBLEM", 101, 106], ["HIV", "PROBLEM", 111, 114], ["VSVG pseudovirus infection", "PROBLEM", 115, 141], ["the fractionated extracts", "TEST", 206, 231], ["CC", "TEST", 247, 249], ["CC/Fr.2", "TEST", 256, 263], ["all four fractions of CF", "TEST", 268, 292], ["moderate inhibitory activities", "PROBLEM", 312, 342], ["pseudovirus", "PROBLEM", 351, 362], ["the infection assay", "PROBLEM", 366, 385], ["moderate", "OBSERVATION_MODIFIER", 53, 61], ["infection", "OBSERVATION", 132, 141], ["moderate", "OBSERVATION_MODIFIER", 312, 320], ["infection", "OBSERVATION", 370, 379]]], ["Because HIV-based pseudovirus RNA should be reverse transcribed followed by integration to make the reporter gene product, we examined whether these inhibitors could inhibit wild-type infection.", [["infection", "DISEASE", 184, 193], ["HIV", "ORGANISM", 8, 11], ["pseudovirus", "ORGANISM", 18, 29], ["pseudovirus RNA", "RNA", 18, 33], ["HIV", "SPECIES", 8, 11], ["HIV", "SPECIES", 8, 11], ["pseudovirus", "SPECIES", 18, 29], ["HIV-based pseudovirus RNA", "PROBLEM", 8, 33], ["these inhibitors", "TREATMENT", 143, 159], ["type infection", "PROBLEM", 179, 193], ["infection", "OBSERVATION", 184, 193]]], ["In the plaque reduction assay of wtSARS-CoV infection, the SIs of CC/Fr.1 and CC/Fr.2 were found to be moderate; however, CFE and its fractions did not show significant inhibitory activities.", [["plaque", "ANATOMY", 7, 13], ["plaque reduction", "DISEASE", 7, 23], ["infection", "DISEASE", 44, 53], ["CC", "CHEMICAL", 66, 68], ["CC", "CHEMICAL", 78, 80], ["CFE", "CHEMICAL", 122, 125], ["CFE", "CHEMICAL", 122, 125], ["plaque", "PATHOLOGICAL_FORMATION", 7, 13], ["wtSARS-CoV", "GENE_OR_GENE_PRODUCT", 33, 43], ["CFE", "SIMPLE_CHEMICAL", 122, 125], ["wtSARS-CoV", "SPECIES", 33, 43], ["wtSARS", "PROBLEM", 33, 39], ["CoV infection", "PROBLEM", 40, 53], ["the SIs of CC/Fr.1", "TEST", 55, 73], ["CC/Fr.2", "TEST", 78, 85], ["CFE", "TEST", 122, 125], ["its fractions", "TEST", 130, 143], ["significant inhibitory activities", "PROBLEM", 157, 190], ["plaque", "OBSERVATION", 7, 13], ["CoV", "OBSERVATION_MODIFIER", 40, 43], ["infection", "OBSERVATION", 44, 53], ["moderate", "OBSERVATION", 103, 111]]], ["We believe CCE may inhibit the early steps of SARS-CoV infection, based on the time of addition study and on the plaque reduction assay in the wild-type infection.", [["plaque", "ANATOMY", 113, 119], ["CCE", "CHEMICAL", 11, 14], ["SARS-CoV infection", "DISEASE", 46, 64], ["infection", "DISEASE", 153, 162], ["CCE", "SIMPLE_CHEMICAL", 11, 14], ["SARS-CoV", "ORGANISM", 46, 54], ["plaque", "PATHOLOGICAL_FORMATION", 113, 119], ["SARS-CoV", "SPECIES", 46, 54], ["SARS", "PROBLEM", 46, 50], ["CoV infection", "PROBLEM", 51, 64], ["addition study", "TEST", 87, 101], ["the plaque reduction assay", "TEST", 109, 135], ["type infection", "PROBLEM", 148, 162], ["CoV", "OBSERVATION_MODIFIER", 51, 54], ["infection", "OBSERVATION", 55, 64], ["infection", "OBSERVATION", 153, 162]]], ["Furthermore, the extract appeared to act on both cells and the virus because it inhibited infection of the cells by pretreatment of the cells or viruses.", [["extract", "ANATOMY", 17, 24], ["cells", "ANATOMY", 49, 54], ["cells", "ANATOMY", 107, 112], ["cells", "ANATOMY", 136, 141], ["infection", "DISEASE", 90, 99], ["cells", "CELL", 49, 54], ["cells", "CELL", 107, 112], ["cells", "CELL", 136, 141], ["the virus", "PROBLEM", 59, 68], ["infection of the cells", "PROBLEM", 90, 112], ["the cells", "PROBLEM", 132, 141], ["viruses", "PROBLEM", 145, 152], ["infection", "OBSERVATION", 90, 99]]], ["The IC50S (283.4 \u00b1 16.3 \u03bcg/ml for CCE and 149.5 \u00b1 13.5 \u03bcg/ml for CC/Fr.2) for pre-treatment of the cells were much higher than those obtained by the experiments in which the reagent was mixed with the virus first (IC50S, 43.1 \u00b1 2.8 \u03bcg/ml for CCE and 7.8 \u00b1 0.3 \u03bcg/ml for CC/Fr.2), although we could not demonstrate virucidal activities in our assay.", [["cells", "ANATOMY", 99, 104], ["CCE", "CHEMICAL", 34, 37], ["CC", "CHEMICAL", 65, 67], ["CCE", "CHEMICAL", 242, 245], ["CC", "CHEMICAL", 270, 272], ["cells", "CELL", 99, 104], ["The IC50S", "TEST", 0, 9], ["CCE", "TEST", 34, 37], ["CC/Fr.2", "TEST", 65, 72], ["pre-treatment of the cells", "PROBLEM", 78, 104], ["the virus", "PROBLEM", 197, 206], ["IC50S", "TEST", 214, 219], ["CCE", "TEST", 242, 245], ["CC/Fr.2", "TEST", 270, 277], ["virucidal", "OBSERVATION", 314, 323]]], ["Because CCE inhibited not only SARS-CoV but also HIV/VSVG pseudovirus infection, we suspected that they might interact with molecules that are important for the entry of both viruses.", [["CCE", "CHEMICAL", 8, 11], ["infection", "DISEASE", 70, 79], ["CCE", "SIMPLE_CHEMICAL", 8, 11], ["SARS-CoV", "ORGANISM", 31, 39], ["HIV", "ORGANISM", 49, 52], ["VSVG pseudovirus", "ORGANISM", 53, 69], ["HIV", "SPECIES", 49, 52], ["SARS-CoV", "SPECIES", 31, 39], ["HIV/VSVG pseudovirus", "SPECIES", 49, 69], ["SARS", "PROBLEM", 31, 35], ["CoV", "PROBLEM", 36, 39], ["HIV", "PROBLEM", 49, 52], ["VSVG pseudovirus infection", "PROBLEM", 53, 79], ["infection", "OBSERVATION", 70, 79], ["viruses", "OBSERVATION", 175, 182]]], ["It is known that VSV and many enveloped viruses must be endocytosed for infection, and they are then transported to early endosomes, late endosomes, and lysosomes using the endocytic pathway.", [["early endosomes", "ANATOMY", 116, 131], ["late endosomes", "ANATOMY", 133, 147], ["lysosomes", "ANATOMY", 153, 162], ["infection", "DISEASE", 72, 81], ["VSV", "ORGANISM", 17, 20], ["endosomes", "CELLULAR_COMPONENT", 122, 131], ["late endosomes", "CELLULAR_COMPONENT", 133, 147], ["lysosomes", "CELLULAR_COMPONENT", 153, 162], ["VSV", "SPECIES", 17, 20], ["VSV", "PROBLEM", 17, 20], ["many enveloped viruses", "PROBLEM", 25, 47], ["infection", "PROBLEM", 72, 81], ["VSV", "OBSERVATION", 17, 20], ["enveloped", "OBSERVATION_MODIFIER", 30, 39], ["viruses", "OBSERVATION", 40, 47], ["infection", "OBSERVATION", 72, 81]]], ["VSV is well-known to infect cells in a pH-dependent manner and was shown to utilize the clathrin-mediated endocytic pathway upon infection.", [["cells", "ANATOMY", 28, 33], ["infection", "DISEASE", 129, 138], ["VSV", "ORGANISM", 0, 3], ["cells", "CELL", 28, 33], ["clathrin", "GENE_OR_GENE_PRODUCT", 88, 96], ["clathrin", "PROTEIN", 88, 96], ["VSV", "SPECIES", 0, 3], ["the clathrin", "TREATMENT", 84, 96], ["infection", "PROBLEM", 129, 138], ["infection", "OBSERVATION", 129, 138]]], ["We have also reported that SARS-CoV entry is clathrin-dependent.", [["SARS", "DISEASE", 27, 31], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 27, 35], ["clathrin", "GENE_OR_GENE_PRODUCT", 45, 53], ["clathrin", "PROTEIN", 45, 53], ["SARS-CoV", "SPECIES", 27, 35], ["SARS", "PROBLEM", 27, 31]]], ["We therefore examined whether CCE or CFE could interfere with the recycling of TfR.Discussion ::: ResultsAs we expected, CCE and CC/Fr.2 but not CFE up-regulated the TfR expression in time- and dose-dependent manners despite the presence of CHX (Fig. 3), and the TfR-inducing activity of CC/Fr.2 was higher than that of CCE.", [["CCE", "CHEMICAL", 30, 33], ["CFE", "CHEMICAL", 37, 40], ["CC", "CHEMICAL", 129, 131], ["CFE", "CHEMICAL", 145, 148], ["CHX", "CHEMICAL", 241, 244], ["CC", "CHEMICAL", 288, 290], ["CCE", "CHEMICAL", 320, 323], ["CHX", "CHEMICAL", 241, 244], ["CCE", "SIMPLE_CHEMICAL", 30, 33], ["CFE", "SIMPLE_CHEMICAL", 37, 40], ["CCE", "CELL", 121, 124], ["CFE", "CELL", 145, 148], ["TfR", "GENE_OR_GENE_PRODUCT", 166, 169], ["CHX", "SIMPLE_CHEMICAL", 241, 244], ["TfR", "GENE_OR_GENE_PRODUCT", 263, 266], ["CCE", "CELL", 320, 323], ["TfR", "PROTEIN", 166, 169], ["TfR", "PROTEIN", 263, 266], ["CCE", "TEST", 30, 33], ["CCE", "TEST", 121, 124], ["CFE", "TEST", 145, 148], ["CHX", "PROBLEM", 241, 244], ["the TfR", "TEST", 259, 266], ["CC/Fr.2", "TREATMENT", 288, 295]]], ["These results suggested that the anti-virus activity of CC/Fr.2, but not that of CFE, might be related to the endocytic pathway of viruses.", [["CC", "CHEMICAL", 56, 58], ["CFE", "CHEMICAL", 81, 84], ["Fr.2", "GENE_OR_GENE_PRODUCT", 59, 63], ["CFE", "CELL", 81, 84], ["CC", "PROTEIN", 56, 58], ["Fr.2", "PROTEIN", 59, 63], ["CFE", "PROTEIN", 81, 84], ["CC/Fr.2", "TEST", 56, 63], ["CFE", "PROBLEM", 81, 84], ["viruses", "PROBLEM", 131, 138], ["viruses", "OBSERVATION", 131, 138]]], ["TfR is a well-known clathrin-mediated recycling molecule, and interference with its recycling may enhance the TfR expression on the cell surface.", [["cell surface", "ANATOMY", 132, 144], ["TfR", "GENE_OR_GENE_PRODUCT", 0, 3], ["clathrin", "GENE_OR_GENE_PRODUCT", 20, 28], ["TfR", "GENE_OR_GENE_PRODUCT", 110, 113], ["cell surface", "CELLULAR_COMPONENT", 132, 144], ["TfR", "PROTEIN", 0, 3], ["clathrin-mediated recycling molecule", "PROTEIN", 20, 56], ["TfR", "PROTEIN", 110, 113], ["recycling molecule", "OBSERVATION", 38, 56], ["cell surface", "OBSERVATION", 132, 144]]], ["Therefore, we hypothesized that CC/Fr.2 may have both biological activities via its effect on clathrin pathways.", [["CC", "CHEMICAL", 32, 34], ["Fr.2", "CHEMICAL", 35, 39], ["Fr.2", "GENE_OR_GENE_PRODUCT", 35, 39], ["clathrin", "GENE_OR_GENE_PRODUCT", 94, 102], ["clathrin", "PROTEIN", 94, 102], ["clathrin pathways", "TREATMENT", 94, 111]]], ["In fact, CC/Fr.2 inhibited the internalization of TfR at a relatively low concentration 10 \u03bcg/ml (Table 5).Discussion ::: ResultsIt is well-known that CC contains large amounts of proanthocyanidins (Prior and Gu, 2005), also known as condensed tannin, which has been accredited with a variety of beneficial effects on health (Beecher, 2004).", [["CC", "CHEMICAL", 9, 11], ["Fr.2", "CHEMICAL", 12, 16], ["CC", "CHEMICAL", 151, 153], ["proanthocyanidins", "CHEMICAL", 180, 197], ["proanthocyanidins", "CHEMICAL", 180, 197], ["Fr.2", "SIMPLE_CHEMICAL", 12, 16], ["TfR", "GENE_OR_GENE_PRODUCT", 50, 53], ["proanthocyanidins", "SIMPLE_CHEMICAL", 180, 197], ["tannin", "SIMPLE_CHEMICAL", 244, 250], ["TfR", "PROTEIN", 50, 53], ["the internalization of TfR", "TREATMENT", 27, 53], ["a relatively low concentration", "TREATMENT", 57, 87], ["proanthocyanidins", "TREATMENT", 180, 197], ["large", "OBSERVATION_MODIFIER", 163, 168], ["amounts", "OBSERVATION_MODIFIER", 169, 176], ["condensed tannin", "OBSERVATION", 234, 250]]], ["Tannins and related compounds were reported to possess anti-HIV activity (Lee et al., 1992, H.X. Xu et al., 2000).", [["Tannins", "CHEMICAL", 0, 7], ["Tannins", "CHEMICAL", 0, 7], ["Tannins", "SIMPLE_CHEMICAL", 0, 7], ["anti-HIV", "CANCER", 55, 63], ["Tannins", "TREATMENT", 0, 7]]], ["Proantocyanidins are reported to have anti-HIV and anti-HSV activities (De Bruyne et al., 1999).", [["Proantocyanidins", "CHEMICAL", 0, 16], ["Proantocyanidins", "CHEMICAL", 0, 16], ["Proantocyanidins", "SIMPLE_CHEMICAL", 0, 16], ["anti-HIV", "CANCER", 38, 46], ["anti-HSV", "SPECIES", 51, 59], ["Proantocyanidins", "TREATMENT", 0, 16], ["anti-HIV", "TREATMENT", 38, 46]]], ["Therefore, we examined 8 compounds isolated from CC for various biological activities and found that three compounds that were structurally very similar showed inhibitory activities on SARS-CoV infection (Fig. 6) and two of them caused up-regulation of TfR expression.", [["CC", "CHEMICAL", 49, 51], ["SARS-CoV infection", "DISEASE", 185, 203], ["CC", "SIMPLE_CHEMICAL", 49, 51], ["SARS-CoV", "ORGANISM", 185, 193], ["TfR", "GENE_OR_GENE_PRODUCT", 253, 256], ["TfR", "PROTEIN", 253, 256], ["SARS-CoV", "SPECIES", 185, 193], ["inhibitory activities", "PROBLEM", 160, 181], ["SARS", "PROBLEM", 185, 189], ["CoV infection", "PROBLEM", 190, 203], ["TfR expression", "PROBLEM", 253, 267], ["TfR expression", "OBSERVATION", 253, 267]]], ["The structures of procyanidins B1 and B2 are closely related to each other except for the configuration at the C-3\u2032 position, but procyanidins B2 did not inhibit SARS-CoV infection nor up-regulate TfR expression (data not shown).", [["procyanidins B2", "CHEMICAL", 130, 145], ["SARS-CoV infection", "DISEASE", 162, 180], ["procyanidins B1 and B2", "CHEMICAL", 18, 40], ["procyanidins B2", "CHEMICAL", 130, 145], ["procyanidins B1", "GENE_OR_GENE_PRODUCT", 18, 33], ["B2", "GENE_OR_GENE_PRODUCT", 38, 40], ["procyanidins B2", "SIMPLE_CHEMICAL", 130, 145], ["SARS-CoV", "ORGANISM", 162, 170], ["TfR", "GENE_OR_GENE_PRODUCT", 197, 200], ["B1", "PROTEIN", 31, 33], ["B2", "PROTEIN", 38, 40], ["C-3\u2032 position", "DNA", 111, 124], ["TfR", "PROTEIN", 197, 200], ["SARS-CoV", "SPECIES", 162, 170], ["procyanidins B1 and B2", "TREATMENT", 18, 40], ["procyanidins B2", "PROBLEM", 130, 145], ["SARS", "PROBLEM", 162, 166], ["CoV infection", "PROBLEM", 167, 180], ["procyanidins B1", "OBSERVATION", 18, 33], ["CoV", "OBSERVATION_MODIFIER", 167, 170], ["infection", "OBSERVATION", 171, 180]]], ["These data strongly suggest that the anti-SARS-CoV activities in CC/Fr.1 and CC/Fr.2 could be explained by procyanidins.", [["CC", "CHEMICAL", 65, 67], ["CC", "CHEMICAL", 77, 79], ["procyanidins", "CHEMICAL", 107, 119], ["anti-SARS-CoV", "GENE_OR_GENE_PRODUCT", 37, 50], ["CC/Fr.1", "CELL", 65, 72], ["procyanidins", "SIMPLE_CHEMICAL", 107, 119], ["the anti-SARS", "TEST", 33, 46], ["procyanidins", "TREATMENT", 107, 119]]], ["In fact, procyanidins were detected in Fr.1 and Fr.2 but not in Fr.3 (Tanaka, unpublished observation March 12, 2008).", [["procyanidins", "CHEMICAL", 9, 21], ["procyanidins", "GENE_OR_GENE_PRODUCT", 9, 21], ["procyanidins", "TREATMENT", 9, 21], ["procyanidins", "OBSERVATION", 9, 21]]], ["However, none of the procyanidins inhibited the internalization of TfR at the optimal concentration (data not shown), suggesting they may not act on the TfR recycling pathway directly.", [["procyanidins", "CHEMICAL", 21, 33], ["procyanidins", "CHEMICAL", 21, 33], ["procyanidins", "SIMPLE_CHEMICAL", 21, 33], ["TfR", "GENE_OR_GENE_PRODUCT", 67, 70], ["TfR", "GENE_OR_GENE_PRODUCT", 153, 156], ["TfR", "PROTEIN", 67, 70], ["TfR", "PROTEIN", 153, 156], ["the procyanidins", "TREATMENT", 17, 33], ["TfR", "TREATMENT", 67, 70]]], ["It was also demonstrated that the compounds did not affect ACE2 expression which is a SARS-CoV receptor.", [["ACE2", "GENE_OR_GENE_PRODUCT", 59, 63], ["SARS-CoV receptor", "GENE_OR_GENE_PRODUCT", 86, 103], ["ACE2", "PROTEIN", 59, 63], ["SARS-CoV receptor", "PROTEIN", 86, 103]]], ["A previous study indicated that procyanidin A2 has the highest SI (24) against HIV suggesting that it has a virucidal effect (De Bruyne et al., 1999).", [["procyanidin A2", "CHEMICAL", 32, 46], ["procyanidin A2", "CHEMICAL", 32, 46], ["procyanidin A2", "GENE_OR_GENE_PRODUCT", 32, 46], ["HIV", "ORGANISM", 79, 82], ["HIV", "SPECIES", 79, 82], ["HIV", "SPECIES", 79, 82], ["A previous study", "TEST", 0, 16], ["procyanidin A2", "TREATMENT", 32, 46], ["HIV", "PROBLEM", 79, 82], ["a virucidal effect", "PROBLEM", 106, 124], ["virucidal", "OBSERVATION_MODIFIER", 108, 117]]], ["Therefore it is possible that Fr.2 may contain both endocytosis inhibitor(s) and procyanidins, although we could not identify the substances which could inhibit endocytosis.", [["Fr.2", "CHEMICAL", 30, 34], ["procyanidins", "CHEMICAL", 81, 93], ["Fr.2", "SIMPLE_CHEMICAL", 30, 34], ["procyanidins", "SIMPLE_CHEMICAL", 81, 93], ["procyanidins", "TREATMENT", 81, 93]]], ["The up-regulation of TfR by procyanidin is a puzzling phenomenon discovered in this experiment.", [["procyanidin", "CHEMICAL", 28, 39], ["procyanidin", "CHEMICAL", 28, 39], ["TfR", "GENE_OR_GENE_PRODUCT", 21, 24], ["procyanidin", "GENE_OR_GENE_PRODUCT", 28, 39], ["TfR", "PROTEIN", 21, 24], ["procyanidin", "TREATMENT", 28, 39], ["a puzzling phenomenon", "PROBLEM", 43, 64], ["up-regulation", "OBSERVATION_MODIFIER", 4, 17]]], ["It is known that proanthocyanidins and their related compounds have chelating activities (Scalbert et al., 2000) and depletion of Fe in cells or medium causes up-regulation of the TfR transcript.", [["cells", "ANATOMY", 136, 141], ["proanthocyanidins", "CHEMICAL", 17, 34], ["Fe", "CHEMICAL", 130, 132], ["proanthocyanidins", "CHEMICAL", 17, 34], ["Fe", "CHEMICAL", 130, 132], ["proanthocyanidins", "SIMPLE_CHEMICAL", 17, 34], ["Fe", "SIMPLE_CHEMICAL", 130, 132], ["cells", "CELL", 136, 141], ["TfR", "GENE_OR_GENE_PRODUCT", 180, 183], ["Fe", "PROTEIN", 130, 132], ["TfR transcript", "RNA", 180, 194], ["proanthocyanidins", "TREATMENT", 17, 34], ["depletion of Fe in cells", "TREATMENT", 117, 141], ["the TfR transcript", "TREATMENT", 176, 194], ["proanthocyanidins", "OBSERVATION", 17, 34]]], ["However, the up-regulation of mRNA was observed 24 h after the chelators were added (Xu et al., 2008).", [["chelators", "SIMPLE_CHEMICAL", 63, 72], ["mRNA", "RNA", 30, 34], ["the chelators", "TREATMENT", 59, 72]]], ["Iron chelation by clinically relevant anthracyclines causes an alteration in the expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking (Xu et al., 2008).", [["intracellular", "ANATOMY", 140, 153], ["Iron", "CHEMICAL", 0, 4], ["anthracyclines", "CHEMICAL", 38, 52], ["iron", "CHEMICAL", 154, 158], ["Iron", "CHEMICAL", 0, 4], ["anthracyclines", "CHEMICAL", 38, 52], ["iron", "CHEMICAL", 154, 158], ["Iron", "SIMPLE_CHEMICAL", 0, 4], ["anthracyclines", "SIMPLE_CHEMICAL", 38, 52], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 140, 153], ["iron", "SIMPLE_CHEMICAL", 154, 158], ["iron-regulated genes", "DNA", 95, 115], ["Iron chelation", "TREATMENT", 0, 14], ["anthracyclines", "TREATMENT", 38, 52], ["an alteration", "PROBLEM", 60, 73], ["iron-regulated genes", "PROBLEM", 95, 115], ["atypical changes in intracellular iron distribution", "PROBLEM", 120, 171], ["alteration", "OBSERVATION_MODIFIER", 63, 73], ["iron-regulated genes", "OBSERVATION", 95, 115], ["atypical", "OBSERVATION_MODIFIER", 120, 128], ["intracellular iron distribution", "OBSERVATION", 140, 171]]], ["We could see the up-regulation within 15 min after the addition of procyanidins (Fig. 4) and it is also known that transferrin are the principal plasma proteins that bind wine catechins (Brunet et al., 2002), therefore, the swift up-regulation of TfR may be caused by depletion of Tfn in the medium.", [["plasma", "ANATOMY", 145, 151], ["wine catechins", "CHEMICAL", 171, 185], ["procyanidins", "CHEMICAL", 67, 79], ["catechins", "CHEMICAL", 176, 185], ["procyanidins", "SIMPLE_CHEMICAL", 67, 79], ["transferrin", "GENE_OR_GENE_PRODUCT", 115, 126], ["plasma", "ORGANISM_SUBSTANCE", 145, 151], ["wine catechins", "SIMPLE_CHEMICAL", 171, 185], ["TfR", "GENE_OR_GENE_PRODUCT", 247, 250], ["Tfn", "GENE_OR_GENE_PRODUCT", 281, 284], ["transferrin", "PROTEIN", 115, 126], ["plasma proteins", "PROTEIN", 145, 160], ["TfR", "PROTEIN", 247, 250], ["Tfn", "PROTEIN", 281, 284], ["procyanidins (Fig.", "TREATMENT", 67, 85], ["the swift up-regulation of TfR", "TREATMENT", 220, 250], ["Tfn in the medium", "TREATMENT", 281, 298], ["depletion", "OBSERVATION", 268, 277], ["Tfn", "OBSERVATION_MODIFIER", 281, 284]]], ["It is of note that \u03b1-interferon induces depletion of the intracellular iron content and up-regulation of functional TfR on human epidermoid cancer KB cells (Caraglia et al., 1994), and has also anti-SARS activities (Paragas et al., 2005, Tan et al., 2004, Barnard et al., 2006).", [["intracellular", "ANATOMY", 57, 70], ["epidermoid cancer KB cells", "ANATOMY", 129, 155], ["\u03b1-interferon", "CHEMICAL", 19, 31], ["iron", "CHEMICAL", 71, 75], ["epidermoid cancer", "DISEASE", 129, 146], ["\u03b1-interferon", "CHEMICAL", 19, 31], ["iron", "CHEMICAL", 71, 75], ["\u03b1-interferon", "GENE_OR_GENE_PRODUCT", 19, 31], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 57, 70], ["iron", "SIMPLE_CHEMICAL", 71, 75], ["TfR", "GENE_OR_GENE_PRODUCT", 116, 119], ["human", "ORGANISM", 123, 128], ["epidermoid cancer KB cells", "CELL", 129, 155], ["\u03b1-interferon", "PROTEIN", 19, 31], ["TfR", "PROTEIN", 116, 119], ["human epidermoid cancer KB cells", "CELL_LINE", 123, 155], ["human", "SPECIES", 123, 128], ["human", "SPECIES", 123, 128], ["the intracellular iron content", "PROBLEM", 53, 83], ["functional TfR", "PROBLEM", 105, 119], ["human epidermoid cancer KB cells", "PROBLEM", 123, 155], ["intracellular iron content", "OBSERVATION", 57, 83]]], ["Although, the relationships between these two activities are not clear, the higher SI of procyanidin A2 could be explained by its up-regulation of TfR.Discussion ::: ResultsIn this study we found that CC/Fr.2 contains inhibitors of SARS virus infection.", [["procyanidin A2", "CHEMICAL", 89, 103], ["CC", "CHEMICAL", 201, 203], ["SARS virus infection", "DISEASE", 232, 252], ["procyanidin A2", "CHEMICAL", 89, 103], ["procyanidin A2", "GENE_OR_GENE_PRODUCT", 89, 103], ["SARS virus", "ORGANISM", 232, 242], ["procyanidin A2", "PROTEIN", 89, 103], ["SARS virus", "SPECIES", 232, 242], ["procyanidin A2", "TREATMENT", 89, 103], ["this study", "TEST", 176, 186], ["CC", "TEST", 201, 203], ["inhibitors", "TREATMENT", 218, 228], ["SARS virus infection", "PROBLEM", 232, 252], ["clear", "OBSERVATION", 65, 70], ["SARS virus", "OBSERVATION", 232, 242]]], ["The fraction also inhibited the internalization of TfR indicating the interference of clathrin-dependent endocytosis.", [["TfR", "GENE_OR_GENE_PRODUCT", 51, 54], ["clathrin", "GENE_OR_GENE_PRODUCT", 86, 94], ["TfR", "PROTEIN", 51, 54], ["clathrin", "PROTEIN", 86, 94], ["the internalization of TfR", "TREATMENT", 28, 54], ["clathrin-dependent endocytosis", "PROBLEM", 86, 116], ["dependent", "OBSERVATION_MODIFIER", 95, 104], ["endocytosis", "OBSERVATION", 105, 116]]], ["The fraction also contained procyanidins which could have a virucidal effect and some of them showed up-regulation of TfR, probably by depleting transferrin and/or iron from the culture.", [["procyanidins", "CHEMICAL", 28, 40], ["iron", "CHEMICAL", 164, 168], ["procyanidins", "CHEMICAL", 28, 40], ["iron", "CHEMICAL", 164, 168], ["procyanidins", "SIMPLE_CHEMICAL", 28, 40], ["TfR", "GENE_OR_GENE_PRODUCT", 118, 121], ["transferrin", "GENE_OR_GENE_PRODUCT", 145, 156], ["iron", "SIMPLE_CHEMICAL", 164, 168], ["TfR", "PROTEIN", 118, 121], ["transferrin", "PROTEIN", 145, 156], ["procyanidins", "TREATMENT", 28, 40], ["a virucidal effect", "PROBLEM", 58, 76], ["up-regulation of TfR", "PROBLEM", 101, 121], ["depleting transferrin", "PROBLEM", 135, 156], ["iron", "TREATMENT", 164, 168], ["the culture", "TEST", 174, 185], ["procyanidins", "OBSERVATION_MODIFIER", 28, 40], ["virucidal effect", "OBSERVATION", 60, 76]]], ["The novel and complex biological activities of CC could lead to the amelioration of symptoms of a number of virus-infected diseases, including SARS.", [["CC", "CHEMICAL", 47, 49], ["virus-infected diseases", "DISEASE", 108, 131], ["SARS", "DISEASE", 143, 147], ["CC", "MULTI-TISSUE_STRUCTURE", 47, 49], ["symptoms", "PROBLEM", 84, 92], ["virus", "PROBLEM", 108, 113], ["infected diseases", "PROBLEM", 114, 131], ["SARS", "PROBLEM", 143, 147], ["infected", "OBSERVATION_MODIFIER", 114, 122], ["diseases", "OBSERVATION", 123, 131]]]], "ab26f03fd219a3da07426f56fecfcc0a20cb0a4e": [["Stranded whole transcriptome library preparation and sequencing of IFN samplesWhole transcriptome libraries were constructed using the TruSeq Stranded Total RNA with Ribo-Zero Gold (Illumina, San Diego, CA) and sequenced on a Genome Analyzer IIx using GA v5 sequencing reagents, similarly to infected CC founder mice lung samples.", [["lung samples", "ANATOMY", 317, 329], ["CC", "CHEMICAL", 301, 303], ["CC", "CELL", 301, 303], ["mice", "ORGANISM", 312, 316], ["lung samples", "CANCER", 317, 329], ["IFN samples", "PROTEIN", 67, 78], ["Zero Gold", "DNA", 171, 180], ["mice", "SPECIES", 312, 316], ["mice", "SPECIES", 312, 316], ["Stranded whole transcriptome library preparation", "TREATMENT", 0, 48], ["IFN samples", "TEST", 67, 78], ["Whole transcriptome libraries", "TREATMENT", 78, 107], ["the TruSeq Stranded Total RNA", "TREATMENT", 131, 160], ["Ribo", "TEST", 166, 170], ["a Genome Analyzer IIx", "TREATMENT", 224, 245], ["GA v5 sequencing reagents", "TREATMENT", 252, 277], ["lung", "ANATOMY", 317, 321]]], ["Raw reads were processed and aligned to the C57BL/6J transcriptome as described for infected samples.", [["samples", "ANATOMY", 93, 100], ["C57BL/6J", "ORGANISM", 44, 52], ["samples", "CANCER", 93, 100], ["the C57BL/6J transcriptome", "TREATMENT", 40, 66], ["infected samples", "PROBLEM", 84, 100]]], ["In total, 35,785 genes, including 17,894 lncRNA (50%), were quantified with at least one read count across the experiment.", [["35,785 genes", "DNA", 10, 22], ["17,894 lncRNA", "DNA", 34, 47], ["lncRNA", "TEST", 41, 47]]], ["Data normalization and DE analysis was performed with similar criteria than for infected samples, with 273 DE genes including 206 coding and 67 lncRNAs.Alignments of reads to the mouse reference genome.To verify the accuracy of transcript quantification after alignment to each CC founder transcriptome, we compared the results from this pipeline to alignment to the mouse reference genome for three C57BL/6J samples.", [["samples", "ANATOMY", 89, 96], ["C57BL/6J samples", "ANATOMY", 400, 416], ["CC", "CHEMICAL", 278, 280], ["samples", "CANCER", 89, 96], ["mouse", "ORGANISM", 179, 184], ["mouse", "ORGANISM", 367, 372], ["C57BL/6J samples", "ORGANISM", 400, 416], ["DE genes", "DNA", 107, 115], ["lncRNAs", "DNA", 144, 151], ["mouse reference genome", "DNA", 179, 201], ["mouse reference genome", "DNA", 367, 389], ["mouse", "SPECIES", 179, 184], ["mouse", "SPECIES", 367, 372], ["mouse", "SPECIES", 179, 184], ["mouse", "SPECIES", 367, 372], ["Data normalization", "TEST", 0, 18], ["DE analysis", "TEST", 23, 34], ["infected samples", "PROBLEM", 80, 96], ["transcript quantification", "TEST", 228, 253], ["three C57BL/6J samples", "TREATMENT", 394, 416]]], ["Reads that were unmapped to mouse ribosomal sequences and to viral sequences were aligned to the mouse reference genome (Mus_musculus.GRCm38.70, downloaded from Ensembl) using the gapped aligner software TopHat2 (1) with the following options \"--solexa-quals --library-type fr-firststrand -r 200 --matestd-dev 60 --no-novel-juncs -o\".", [["ribosomal", "ANATOMY", 34, 43], ["mouse", "ORGANISM", 28, 33], ["ribosomal", "CELLULAR_COMPONENT", 34, 43], ["mouse", "ORGANISM", 97, 102], ["mouse ribosomal sequences", "DNA", 28, 53], ["viral sequences", "DNA", 61, 76], ["mouse reference genome", "DNA", 97, 119], ["Mus_musculus", "DNA", 121, 133], ["mouse", "SPECIES", 28, 33], ["mouse", "SPECIES", 97, 102], ["mouse", "SPECIES", 28, 33], ["mouse", "SPECIES", 97, 102], ["mouse ribosomal sequences", "TEST", 28, 53], ["viral sequences", "TEST", 61, 76], ["GRCm", "TEST", 134, 138], ["solexa", "TEST", 246, 252]]], ["Ensembl_70 transcript annotations were supplied to allow the mapping of reads spanning known splicing junctions.", [["Ensembl_70", "GENE_OR_GENE_PRODUCT", 0, 10], ["the mapping", "TEST", 57, 68], ["splicing junctions", "OBSERVATION", 93, 111]]], ["We then estimated the levels of gene expression for Ensembl-annotated genes using the HTSeq software (2) with the following flags \"--mode=union --stranded=reverse --idattr=gene_id\".Alignments of reads to viral genomeTo quantify viral infection, we mapped the reads to the PR8 genome and transcriptome; and to MA15 genome and transcriptome, using the SOAP2 aligner with the same options than used for alignment to mouse transcriptomes (\"-m 20 -x 500 -r 2 -v 2\").", [["viral infection", "DISEASE", 228, 243], ["PR8", "ORGANISM", 272, 275], ["mouse", "ORGANISM", 413, 418], ["Ensembl-annotated genes", "DNA", 52, 75], ["viral genome", "DNA", 204, 216], ["PR8 genome", "DNA", 272, 282], ["MA15 genome", "DNA", 309, 320], ["SOAP2 aligner", "DNA", 350, 363], ["mouse", "SPECIES", 413, 418], ["mouse", "SPECIES", 413, 418], ["viral infection", "PROBLEM", 228, 243], ["the SOAP2 aligner", "TREATMENT", 346, 363], ["viral genome", "OBSERVATION", 204, 216], ["viral", "OBSERVATION_MODIFIER", 228, 233], ["infection", "OBSERVATION", 234, 243]]], ["For SARS-CoV MA15, viral genome was retrieved from GenBank (GenBank accession no. DQ497008.1).", [["SARS-CoV MA15", "GENE_OR_GENE_PRODUCT", 4, 17], ["SARS-CoV MA15", "DNA", 4, 17], ["viral genome", "DNA", 19, 31], ["SARS-CoV MA15", "SPECIES", 4, 17], ["SARS", "PROBLEM", 4, 8], ["viral genome", "PROBLEM", 19, 31], ["viral genome", "OBSERVATION", 19, 31]]], ["Reverse complement of the genomic viral RNA sequence was used to quantify MA15 anti-genome, and the following annotation was used to quantify each viral mRNA : SARS-MA15_ORF1ab Benchmark study of correlation methods.Alignments of reads to viral genomeWe evaluated several parametric and non-parametric correlation methods to determine the optimal method for detecting co-expressed coding genes sharing similar functions.Alignments of reads to viral genomeSeven unsigned co-expression networks were inferred using Pearson's, Spearman's and In total, 11 different co-expression networks were evaluated against 2 reference networks.Alignments of reads to viral genomeThe GO-based iso-ontological reference network was obtained by linking genes with at least one shared GO biological process (BP).", [["MA15", "GENE_OR_GENE_PRODUCT", 74, 78], ["genomic viral RNA sequence", "DNA", 26, 52], ["MA15 anti-genome", "DNA", 74, 90], ["viral mRNA", "RNA", 147, 157], ["viral genomeWe", "DNA", 239, 253], ["co-expressed coding genes", "DNA", 368, 393], ["viral genome", "DNA", 652, 664], ["iso-ontological reference network", "DNA", 677, 710], ["MA15", "SPECIES", 74, 78], ["the genomic viral RNA sequence", "TEST", 22, 52], ["viral genomeWe", "TEST", 239, 253], ["BP", "TEST", 789, 791], ["viral genome", "OBSERVATION", 652, 664]]], ["We considered 1205 GO BPs that were inferred from experimental evidence (\"IMP\": inferred from mutant phenotype, and \"IDA\": inferred from direct assay) and had more than 10 and less than 300 genes.", [["GO BPs", "TEST", 19, 25], ["mutant phenotype", "PROBLEM", 94, 110]]], ["The Reactome-based iso-pathway reference network was obtained by linking genes with at least one shared Reactome pathway.MONOCLdb modules functional descriptionFor each co-expression module, we provide a brief description of functional enrichment results and expression profiles.", [["iso-pathway reference network", "DNA", 19, 48], ["MONOCLdb modules", "DNA", 121, 137]]], ["Fig 4B, ES PAGE were defined as -log 10 p-value calculated by PAGE test which assess whether neighbor genes were among the most positively correlated (for enhancer-like lncRNA) or negatively correlated (for inhibitor lncRNA) genes.", [["enhancer-like lncRNA", "GENE_OR_GENE_PRODUCT", 155, 175], ["neighbor genes", "DNA", 93, 107], ["enhancer", "DNA", 155, 163], ["lncRNA", "DNA", 169, 175], ["inhibitor lncRNA) genes", "DNA", 207, 230], ["PAGE test", "TEST", 62, 71]]], ["ES PAGE was calculated only for lncRNAs with more than 3 coding neighbors; otherwise this score was set arbitrarily to 0.", [["lncRNAs", "DNA", 32, 39], ["this score", "TEST", 85, 95]]], ["The x-axis represents the arithmetic mean of bicor coefficient between a given lncRNA and all its coding neighbor genes. lncRNAs with highest specificity for correlation with coding neighbor genes, or the most correlated with their neighbor genes (mean bicor) are indicated with their names.", [["bicor coefficient", "DNA", 45, 62], ["lncRNA", "DNA", 79, 85], ["coding neighbor genes", "DNA", 98, 119], ["lncRNAs", "DNA", 121, 128], ["coding neighbor genes", "DNA", 175, 196], ["neighbor genes", "DNA", 232, 246], ["bicor", "DNA", 253, 258], ["lncRNA", "OBSERVATION", 79, 85]]], ["Table S1 .", [["S1", "ANATOMY", 6, 8]]], ["ES: Enrichment score (ES) defined as -log 10 p-value calculated by exact Fisher's test.", [["Enrichment score", "TEST", 4, 20], ["exact Fisher's test", "TEST", 67, 86]]], ["Table S2 . lncRNA and transcription factor binding motif present in their promoter for lncRNA coexpressed with genes sharing the same binding motif.", [["lncRNA and transcription factor binding motif", "DNA", 11, 56], ["lncRNA", "DNA", 87, 93], ["binding motif", "DNA", 134, 147], ["lncRNA", "OBSERVATION", 11, 17]]], ["Number of replicates used in the analysis for each biological condition.", [["the analysis", "TEST", 29, 41]]], ["In total, 120 samples were analyzed, with n=2-3 replicates for infected conditions, and n=2 replicates for mocks.", [["samples", "ANATOMY", 14, 21], ["infected conditions", "PROBLEM", 63, 82]]], ["For five biological conditions, denoted with \"3*\", three replicates were used for the whole analysis, except for DE analysis for which only two replicates were used (see Methods).", [["the whole analysis", "TEST", 82, 100], ["DE analysis", "TEST", 113, 124]]]], "66a121f435558b3caa6c32ec9b6764f27619192b": [["3Introduction: 20Positive sense RNA viruses rely heavily on host cell factors for all aspects of their life 21 cycle.", [["cell", "ANATOMY", 65, 69], ["host cell", "CELL", 60, 69], ["host cell factors", "PROTEIN", 60, 77], ["20Positive sense RNA viruses", "PROBLEM", 15, 43], ["host cell factors", "TREATMENT", 60, 77], ["host cell", "OBSERVATION_MODIFIER", 60, 69]]], ["They replicate on host derived membranous vesicles that are induced 22Introduction: 20following viral infection, the formation of which requires the activity of key membrane 23 bound viral enzymes (Altan-Bonnet, 2017) .", [["membranous vesicles", "ANATOMY", 31, 50], ["membrane", "ANATOMY", 165, 173], ["viral infection", "DISEASE", 96, 111], ["membranous vesicles", "CELLULAR_COMPONENT", 31, 50], ["membrane", "CELLULAR_COMPONENT", 165, 173], ["membrane 23 bound viral enzymes", "PROTEIN", 165, 196], ["host derived membranous vesicles", "PROBLEM", 18, 50], ["viral infection", "PROBLEM", 96, 111], ["viral enzymes", "TEST", 183, 196], ["membranous vesicles", "OBSERVATION", 31, 50], ["viral", "OBSERVATION_MODIFIER", 96, 101], ["infection", "OBSERVATION", 102, 111]]], ["Within the membrane bound viral 24 replication complex, translation of the viral genome and the synthesis of new viral 25 RNA occurs in a highly coordinated process.", [["membrane", "ANATOMY", 11, 19], ["membrane", "CELLULAR_COMPONENT", 11, 19], ["membrane bound viral 24 replication complex", "PROTEIN", 11, 54], ["viral genome", "DNA", 75, 87], ["viral 25 RNA", "RNA", 113, 125], ["the viral genome", "PROBLEM", 71, 87], ["new viral 25 RNA", "PROBLEM", 109, 125], ["viral genome", "OBSERVATION", 75, 87], ["highly coordinated", "OBSERVATION_MODIFIER", 138, 156], ["process", "OBSERVATION", 157, 164]]], ["Positive sense RNA viruses have 26 evolved novel gene expression mechanisms that enable them to overcome the 27 genome size limitations that accompany error-prone replication and which might 28 restrict their overall coding capacity (Firth and Brierley, 2012) .", [["Positive sense RNA viruses", "PROBLEM", 0, 26], ["error-prone replication", "TREATMENT", 151, 174], ["sense RNA viruses", "OBSERVATION", 9, 26], ["size", "OBSERVATION_MODIFIER", 119, 123]]], ["In addition, viral 29 modification of the host cell translation machinery often provides a competitive 30 advantage allowing for the efficient translation of viral RNA in an environment where 31 competing cellular RNAs are in abundance (McCormick and Khaperskyy, 2017) .", [["cell", "ANATOMY", 47, 51], ["cellular", "ANATOMY", 205, 213], ["cell", "CELL", 47, 51], ["cellular", "CELL", 205, 213], ["viral RNA", "RNA", 158, 167], ["cellular RNAs", "RNA", 205, 218], ["the host cell translation machinery", "TREATMENT", 38, 73], ["viral RNA", "PROBLEM", 158, 167], ["host cell", "OBSERVATION", 42, 51], ["viral RNA", "OBSERVATION", 158, 167], ["cellular RNAs", "OBSERVATION", 205, 218]]], ["32Introduction: 20This ability to compete with cellular RNAs is particularly important for the initiation of 33 infection where the incoming viral genome may be present at only a single copy per 34 cell.", [["cellular", "ANATOMY", 47, 55], ["cell", "ANATOMY", 198, 202], ["infection", "DISEASE", 112, 121], ["cellular", "CELL", 47, 55], ["cell", "CELL", 198, 202], ["cellular RNAs", "RNA", 47, 60], ["incoming viral genome", "DNA", 132, 153], ["cellular RNAs", "TREATMENT", 47, 60], ["33 infection", "PROBLEM", 109, 121], ["the incoming viral genome", "PROBLEM", 128, 153], ["infection", "OBSERVATION", 112, 121], ["viral genome", "OBSERVATION", 141, 153]]], ["35Introduction: 20We have previously described a novel paradigm of viral translation that relies on the 36 interaction of host translation initiation factors with a virus-encoded protein (VPg), 37 covalently linked to the 5' end of the genome of members of the Caliciviridae family 38 of positive sense RNA viruses (Chaudhry et al., 2006; Chung et al., 2014; 39 9 In addition, to minimise the impact of gRNAs that may have deleterious effects on 164 long term cell viability and to increase our ability to detect genes that may be 165 important, but not essential, for norovirus-induced cell death, the infection was 166 reduced to 24 hours as compared to 2-10 days post infection in previous studies.", [["cell", "ANATOMY", 460, 464], ["cell", "ANATOMY", 587, 591], ["norovirus", "DISEASE", 569, 578], ["death", "DISEASE", 592, 597], ["infection", "DISEASE", 603, 612], ["infection", "DISEASE", 671, 680], ["VPg", "GENE_OR_GENE_PRODUCT", 188, 191], ["cell", "CELL", 460, 464], ["norovirus", "ORGANISM", 569, 578], ["cell", "CELL", 587, 591], ["host translation initiation factors", "PROTEIN", 122, 157], ["virus-encoded protein", "PROTEIN", 165, 186], ["VPg", "PROTEIN", 188, 191], ["5' end", "DNA", 222, 228], ["Caliciviridae family 38", "PROTEIN", 261, 284], ["gRNAs", "PROTEIN", 403, 408], ["viral translation", "PROBLEM", 67, 84], ["a virus", "PROBLEM", 163, 170], ["positive sense RNA viruses", "PROBLEM", 288, 314], ["gRNAs", "TREATMENT", 403, 408], ["deleterious effects", "PROBLEM", 423, 442], ["164 long term cell viability", "PROBLEM", 446, 474], ["norovirus", "PROBLEM", 569, 578], ["cell death", "PROBLEM", 587, 597], ["the infection", "PROBLEM", 599, 612], ["infection", "PROBLEM", 671, 680], ["previous studies", "TEST", 684, 700], ["long term cell", "OBSERVATION_MODIFIER", 450, 464], ["infection", "OBSERVATION", 671, 680]]], ["167 BV-2-Cas9 expressing cells were infected with lentiviruses carrying the Brie gRNA 168 library carrying 78,637 independent guide RNAs to 19,674 genes (Doench et al., 169 2016) .", [["BV-2-Cas9", "ANATOMY", 4, 13], ["cells", "ANATOMY", 25, 30], ["BV-2-Cas9", "CELL", 4, 13], ["cells", "CELL", 25, 30], ["lentiviruses", "ORGANISM", 50, 62], ["BV-2-Cas9 expressing cells", "CELL_LINE", 4, 30], ["Brie gRNA 168 library", "DNA", 76, 97], ["19,674 genes", "DNA", 140, 152], ["BV", "TEST", 4, 6], ["Cas9 expressing cells", "PROBLEM", 9, 30]]], ["The transduced cells were then infected with two MNV strains, CW3 and 170 CR6, which cause acute and persistent infections in immunocompetent mice 171 respectively (Nice et al., 2012; Thackray et al., 2007) , and guide RNA abundance 172 compared to mock infected cells at 24 hours post infection as illustrated in Fig 3A.", [["cells", "ANATOMY", 15, 20], ["cells", "ANATOMY", 263, 268], ["infections", "DISEASE", 112, 122], ["infection", "DISEASE", 286, 295], ["cells", "CELL", 15, 20], ["MNV", "ORGANISM", 49, 52], ["CR6", "GENE_OR_GENE_PRODUCT", 74, 77], ["mice", "ORGANISM", 142, 146], ["cells", "CELL", 263, 268], ["transduced cells", "CELL_LINE", 4, 20], ["mock infected cells", "CELL_TYPE", 249, 268], ["mice", "SPECIES", 142, 146], ["mice", "SPECIES", 142, 146], ["The transduced cells", "PROBLEM", 0, 20], ["CW3", "TEST", 62, 65], ["CR6", "TEST", 74, 77], ["acute and persistent infections", "PROBLEM", 91, 122], ["infected cells", "PROBLEM", 254, 268], ["infection", "PROBLEM", 286, 295], ["transduced cells", "OBSERVATION", 4, 20], ["acute", "OBSERVATION_MODIFIER", 91, 96], ["persistent", "OBSERVATION_MODIFIER", 101, 111], ["infections", "OBSERVATION", 112, 122], ["infected cells", "OBSERVATION", 254, 268], ["infection", "OBSERVATION", 286, 295]]], ["173 being negatively selected (Fig 3B) , whereas for MNV-CW3 279 and 19 genes were 179 positively and negatively selected respectively ( Fig 3B) .", [["MNV-CW3 279 and 19 genes", "DNA", 53, 77], ["MNV-CW3", "SPECIES", 53, 60], ["MNV", "TEST", 53, 56], ["CW3", "TEST", 57, 60]]], ["In most cases, there was a 180 clear correlation between the datasets obtained using either strain ( Fig 3C) .", [["the datasets", "TEST", 57, 69], ["strain ( Fig 3C", "TREATMENT", 92, 107]]], ["STARS 181 analysis was used to ranks genes with positive and negative values (Table S4 ).", [["STARS 181", "DNA", 0, 9], ["STARS 181 analysis", "TEST", 0, 18]]], ["In 182 both screens, the MNV receptor Cd300lf was the most highly positively selected 183 gene identified, in agreement with previous reports (Haga et al., 2016; Orchard et al., 184 2016) .", [["MNV", "ORGANISM", 25, 28], ["Cd300lf", "GENE_OR_GENE_PRODUCT", 38, 45], ["MNV receptor Cd300lf", "PROTEIN", 25, 45], ["183 gene", "DNA", 86, 94], ["the MNV receptor Cd300lf", "TEST", 21, 45]]], ["The second most highly enriched gene was G3BP1, a gene also identified in 185 one of the two previous CRISPR screens performed on norovirus infected cells 186 .", [["cells", "ANATOMY", 149, 154], ["norovirus infected", "DISEASE", 130, 148], ["G3BP1", "GENE_OR_GENE_PRODUCT", 41, 46], ["norovirus", "ORGANISM", 130, 139], ["cells", "CELL", 149, 154], ["G3BP1", "DNA", 41, 46], ["CRISPR screens", "DNA", 102, 116], ["CRISPR screens", "TEST", 102, 116], ["norovirus infected cells", "PROBLEM", 130, 154]]], ["187 188 A comparison of the data obtained from all three approaches allowed us to identify 189 several host proteins that were common to all screens (Table S5) .", [["A comparison of the data", "TEST", 8, 32]]], ["G3BP1, the core 190 stress granule component was identified in all three screens as a potential host 191 factor essential for norovirus infection.", [["stress granule", "ANATOMY", 20, 34], ["norovirus infection", "DISEASE", 126, 145], ["G3BP1", "GENE_OR_GENE_PRODUCT", 0, 5], ["stress granule", "CELLULAR_COMPONENT", 20, 34], ["norovirus", "ORGANISM", 126, 135], ["G3BP1", "PROTEIN", 0, 5], ["core 190 stress granule component", "PROTEIN", 11, 44], ["191 factor", "PROTEIN", 101, 111], ["norovirus", "SPECIES", 126, 135], ["the core 190 stress granule component", "PROBLEM", 7, 44], ["norovirus infection", "PROBLEM", 126, 145], ["granule component", "OBSERVATION", 27, 44], ["infection", "OBSERVATION", 136, 145]]], ["G3BP1 was found to be associated with the 192 MNV and NV VPg proteins (Fig 1D) , enriched in viral replication complexes purified 193 using either NS1/2 or NS4 flag tagged viruses ( Fig 2D) and identified in a CRISPR 194 screen using two different MNV strains as a putative pro-viral factor involved in the 195 norovirus life cycle ( Fig 3C) .", [["G3BP1", "GENE_OR_GENE_PRODUCT", 0, 5], ["NS1/2", "ORGANISM", 147, 152], ["NS4", "GENE_OR_GENE_PRODUCT", 156, 159], ["MNV", "ORGANISM", 248, 251], ["G3BP1", "PROTEIN", 0, 5], ["192 MNV and NV VPg proteins", "PROTEIN", 42, 69], ["Fig 1D", "PROTEIN", 71, 77], ["viral replication complexes", "PROTEIN", 93, 120], ["NS1", "PROTEIN", 147, 150], ["NS4", "PROTEIN", 156, 159], ["pro-viral factor", "PROTEIN", 274, 290], ["NV", "SPECIES", 54, 56], ["MNV", "SPECIES", 248, 251], ["NV VPg proteins", "TEST", 54, 69], ["viral replication complexes", "TREATMENT", 93, 120], ["NS1", "TREATMENT", 147, 150], ["a CRISPR", "TEST", 208, 216], ["two different MNV strains", "PROBLEM", 234, 259], ["a putative pro-viral factor", "TEST", 263, 290], ["viral replication", "OBSERVATION", 93, 110]]], ["196G3BP1 is essential for murine norovirus replication 198To validate the importance of G3BP1 in the norovirus life cycle we generated G3BP1 199 deficient BV-2 cell lines ( Fig 4A) and examined the impact of G3BP1 ablation on 200 MNV infection.", [["BV-2 cell lines", "ANATOMY", 155, 170], ["MNV infection", "DISEASE", 230, 243], ["196G3BP1", "GENE_OR_GENE_PRODUCT", 0, 8], ["murine norovirus", "ORGANISM", 26, 42], ["G3BP1", "GENE_OR_GENE_PRODUCT", 88, 93], ["BV-2 cell lines", "CELL", 155, 170], ["Fig 4A", "CELL", 173, 179], ["G3BP1", "GENE_OR_GENE_PRODUCT", 208, 213], ["196G3BP1", "PROTEIN", 0, 8], ["G3BP1", "PROTEIN", 88, 93], ["G3BP1 199 deficient BV-2 cell lines", "CELL_LINE", 135, 170], ["G3BP1", "PROTEIN", 208, 213], ["murine", "SPECIES", 26, 32], ["MNV", "SPECIES", 230, 233], ["murine norovirus replication", "TREATMENT", 26, 54], ["G3BP1", "TREATMENT", 88, 93], ["BV", "TEST", 155, 157], ["G3BP1 ablation", "TREATMENT", 208, 222], ["MNV infection", "PROBLEM", 230, 243], ["200 MNV", "OBSERVATION_MODIFIER", 226, 233], ["infection", "OBSERVATION", 234, 243]]], ["Western blotting confirmed the loss of G3BP1 in the three lines 201 tested and we noted that at in some cases, a concomitant increase in G3BP2 202 expression was observed as has been previously noted (Kedersha et al., 2016) .", [["G3BP1", "GENE_OR_GENE_PRODUCT", 39, 44], ["G3BP2 202", "GENE_OR_GENE_PRODUCT", 137, 146], ["G3BP1", "PROTEIN", 39, 44], ["lines 201", "CELL_LINE", 58, 67], ["G3BP2 202", "PROTEIN", 137, 146], ["Western blotting", "TEST", 0, 16], ["the loss of G3BP1", "PROBLEM", 27, 44], ["a concomitant increase in G3BP2", "PROBLEM", 111, 142], ["concomitant", "OBSERVATION_MODIFIER", 113, 124], ["increase", "OBSERVATION_MODIFIER", 125, 133]]], ["A 203 clear defect was observed in the ability to replicate to produce infectious virus in 204 three independently selected \u0394G3BP1 cell lines ( Fig 4B) .", [["\u0394G3BP1 cell lines", "ANATOMY", 124, 141], ["\u0394G3BP1 cell lines", "CELL", 124, 141], ["Fig 4B", "CELL", 144, 150], ["\u0394G3BP1 cell lines", "CELL_LINE", 124, 141], ["A 203 clear defect", "PROBLEM", 0, 18], ["infectious virus", "PROBLEM", 71, 87], ["clear", "OBSERVATION_MODIFIER", 6, 11], ["defect", "OBSERVATION", 12, 18], ["infectious", "OBSERVATION", 71, 81], ["cell lines", "OBSERVATION", 131, 141]]], ["This effect was mirrored by 205 an inability to induce cytopathic effect leading to virus-induced cell death ( Fig 4C) .", [["cell", "ANATOMY", 98, 102], ["death", "DISEASE", 103, 108], ["cell", "CELL", 98, 102], ["cytopathic effect", "PROBLEM", 55, 72], ["virus", "PROBLEM", 84, 89], ["induced cell death", "PROBLEM", 90, 108], ["cell death", "OBSERVATION", 98, 108]]], ["In 206 contrast, the ability of encephalomyocarditis virus (EMCV) to infect and cause cell 207 death was unaffected by the deletion of G3BP1( Fig 4C) .", [["cell", "ANATOMY", 86, 90], ["death", "DISEASE", 95, 100], ["encephalomyocarditis virus", "ORGANISM", 32, 58], ["EMCV", "ORGANISM", 60, 64], ["cell 207", "CELL", 86, 94], ["G3BP1", "GENE_OR_GENE_PRODUCT", 135, 140], ["G3BP1", "PROTEIN", 135, 140], ["encephalomyocarditis virus", "SPECIES", 32, 58], ["encephalomyocarditis virus", "SPECIES", 32, 58], ["EMCV", "SPECIES", 60, 64], ["encephalomyocarditis virus", "PROBLEM", 32, 58], ["cell 207 death", "PROBLEM", 86, 100], ["encephalomyocarditis", "OBSERVATION", 32, 52]]], ["These data confirm that 208 cells lacking G3BP1 are highly resistant to norovirus infection.", [["cells", "ANATOMY", 28, 33], ["norovirus infection", "DISEASE", 72, 91], ["cells", "CELL", 28, 33], ["G3BP1", "GENE_OR_GENE_PRODUCT", 42, 47], ["norovirus", "ORGANISM", 72, 81], ["208 cells", "CELL_LINE", 24, 33], ["G3BP1", "PROTEIN", 42, 47], ["These data", "TEST", 0, 10], ["208 cells lacking G3BP1", "PROBLEM", 24, 47], ["norovirus infection", "PROBLEM", 72, 91], ["norovirus", "OBSERVATION", 72, 81]]], ["209G3BP1 is essential for human norovirus replication in cell culture 211To determine if the G3BP1 was also essential for HuNoV, we examined the impact 212 of loss of G3BP1 on human norovirus replication in cell culture using the Norwalk 213 virus replicon.", [["cell culture", "ANATOMY", 57, 69], ["cell culture", "ANATOMY", 207, 219], ["209G3BP1", "GENE_OR_GENE_PRODUCT", 0, 8], ["human", "ORGANISM", 26, 31], ["cell", "CELL", 57, 61], ["G3BP1", "GENE_OR_GENE_PRODUCT", 93, 98], ["HuNoV", "GENE_OR_GENE_PRODUCT", 122, 127], ["G3BP1", "GENE_OR_GENE_PRODUCT", 167, 172], ["human", "ORGANISM", 176, 181], ["cell", "CELL", 207, 211], ["Norwalk 213 virus replicon", "ORGANISM", 230, 256], ["209G3BP1", "PROTEIN", 0, 8], ["G3BP1", "PROTEIN", 93, 98], ["HuNoV", "PROTEIN", 122, 127], ["G3BP1", "PROTEIN", 167, 172], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 176, 181], ["human", "SPECIES", 26, 31], ["human norovirus", "SPECIES", 176, 191], ["Norwalk 213 virus", "SPECIES", 230, 247], ["human norovirus replication", "TREATMENT", 26, 53], ["cell culture", "TEST", 57, 69], ["the G3BP1", "TEST", 89, 98], ["HuNoV", "PROBLEM", 122, 127], ["loss of G3BP1", "PROBLEM", 159, 172], ["human norovirus replication", "TREATMENT", 176, 203], ["cell culture", "TEST", 207, 219], ["the Norwalk 213 virus replicon", "TREATMENT", 226, 256]]], ["To establish the experimental system, we first confirmed that the 214 presence of VPg on the 5' end of the Norwalk RNA was essential for the replication 215 of the replicon RNA and for the capacity to form G418 resistant colonies.", [["colonies", "ANATOMY", 221, 229], ["G418", "CHEMICAL", 206, 210], ["VPg", "GENE_OR_GENE_PRODUCT", 82, 85], ["VPg", "PROTEIN", 82, 85], ["5' end", "RNA", 93, 99], ["Norwalk RNA", "RNA", 107, 118], ["replicon RNA", "RNA", 164, 176], ["G418 resistant colonies", "CELL_LINE", 206, 229], ["VPg", "TEST", 82, 85], ["the Norwalk RNA", "TREATMENT", 103, 118], ["the replicon RNA", "TREATMENT", 160, 176], ["the capacity", "PROBLEM", 185, 197], ["G418 resistant colonies", "PROBLEM", 206, 229]]], ["216G3BP1 is essential for human norovirus replication in cell culture 211Transfection of replicon RNA, purified from replicon containing cells, into BHK cells 217 readily resulted in the formation of antibiotic resistant cell colonies ( Fig 5A) .", [["cell culture", "ANATOMY", 57, 69], ["cells", "ANATOMY", 137, 142], ["BHK cells", "ANATOMY", 149, 158], ["cell colonies", "ANATOMY", 221, 234], ["216G3BP1", "CHEMICAL", 0, 8], ["216G3BP1", "GENE_OR_GENE_PRODUCT", 0, 8], ["human", "ORGANISM", 26, 31], ["norovirus", "ORGANISM", 32, 41], ["cell", "CELL", 57, 61], ["cells", "CELL", 137, 142], ["BHK cells", "CELL", 149, 158], ["cell colonies", "CELL", 221, 234], ["216G3BP1", "PROTEIN", 0, 8], ["replicon RNA", "RNA", 89, 101], ["BHK cells 217", "CELL_LINE", 149, 162], ["antibiotic resistant cell colonies", "CELL_LINE", 200, 234], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 26, 31], ["human norovirus replication", "TREATMENT", 26, 53], ["cell culture", "TEST", 57, 69], ["Transfection of replicon RNA", "TREATMENT", 73, 101], ["replicon containing cells", "TREATMENT", 117, 142], ["BHK cells", "TEST", 149, 158], ["antibiotic resistant cell colonies", "PROBLEM", 200, 234], ["antibiotic resistant cell colonies", "OBSERVATION", 200, 234]]], ["In 218 contrast, RNA that was proteinase K treated prior to transfection was unable to 219 produce replicon containing colonies.", [["colonies", "ANATOMY", 119, 127], ["K", "CHEMICAL", 41, 42], ["proteinase K", "GENE_OR_GENE_PRODUCT", 30, 42], ["proteinase K", "PROTEIN", 30, 42], ["proteinase K", "TEST", 30, 42], ["transfection", "TEST", 60, 72]]], ["Transfection of replicon RNA into wild type 220 U2OS osteosarcoma cells allowed the formation of replicon-containing colonies, 221 although the efficiency of formation was significantly less than that seen in BHK cells 222 ( Fig 5B) .", [["U2OS osteosarcoma cells", "ANATOMY", 48, 71], ["colonies", "ANATOMY", 117, 125], ["BHK cells", "ANATOMY", 209, 218], ["osteosarcoma", "DISEASE", 53, 65], ["U2OS osteosarcoma cells", "CELL", 48, 71], ["BHK cells", "CELL", 209, 218], ["replicon RNA", "RNA", 16, 28], ["wild type 220 U2OS osteosarcoma cells", "CELL_LINE", 34, 71], ["BHK cells 222", "CELL_LINE", 209, 222], ["Transfection of replicon RNA", "TREATMENT", 0, 28], ["U2OS osteosarcoma cells", "PROBLEM", 48, 71], ["replicon", "TREATMENT", 97, 105], ["BHK cells", "TEST", 209, 218], ["osteosarcoma cells", "OBSERVATION", 53, 71]]], ["CRISPR modified U2OS cells that lacked G3BP1 (Kedersha et al., 2016) 223 were unable to support NV replication, as evident by the lack of antibiotic resistant 224 colonies ( Fig 5B) .", [["U2OS cells", "ANATOMY", 16, 26], ["colonies", "ANATOMY", 163, 171], ["U2OS cells", "CELL", 16, 26], ["G3BP1", "GENE_OR_GENE_PRODUCT", 39, 44], ["NV", "GENE_OR_GENE_PRODUCT", 96, 98], ["U2OS cells", "CELL_LINE", 16, 26], ["antibiotic resistant 224 colonies", "CELL_LINE", 138, 171], ["NV", "SPECIES", 96, 98], ["CRISPR modified U2OS cells", "PROBLEM", 0, 26], ["NV replication", "PROBLEM", 96, 110], ["antibiotic resistant 224 colonies", "PROBLEM", 138, 171], ["U2OS cells", "OBSERVATION", 16, 26]]], ["To further examine the role of G3BP1 in human Norwalk virus 225 replication, WT or G3BP1 deficient U2OS cells were transfected with NV replicon 226G3BP1 is essential for human norovirus replication in cell culture 211VPg-linked RNA, and RNA synthesis monitored overtime following the addition of 227 G418.", [["U2OS cells", "ANATOMY", 99, 109], ["cell", "ANATOMY", 201, 205], ["G418", "CHEMICAL", 300, 304], ["G418", "CHEMICAL", 300, 304], ["G3BP1", "GENE_OR_GENE_PRODUCT", 31, 36], ["human Norwalk virus 225", "ORGANISM", 40, 63], ["G3BP1", "GENE_OR_GENE_PRODUCT", 83, 88], ["U2OS cells", "CELL", 99, 109], ["NV replicon 226G3BP1", "ORGANISM", 132, 152], ["human", "ORGANISM", 170, 175], ["norovirus", "ORGANISM", 176, 185], ["cell", "CELL", 201, 205], ["G3BP1", "PROTEIN", 31, 36], ["G3BP1 deficient U2OS cells", "CELL_LINE", 83, 109], ["NV replicon 226G3BP1", "DNA", 132, 152], ["cell culture 211VPg-linked RNA", "RNA", 201, 231], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 170, 175], ["human Norwalk virus 225", "SPECIES", 40, 63], ["human", "SPECIES", 170, 175], ["WT", "TEST", 77, 79], ["G3BP1 deficient U2OS cells", "PROBLEM", 83, 109], ["NV replicon", "TREATMENT", 132, 143], ["human norovirus replication", "TREATMENT", 170, 197], ["cell culture", "TEST", 201, 213], ["RNA synthesis", "TEST", 237, 250]]], ["While a significant increase in NV viral RNA levels was seen in WT U2OS 228 cells, those lacking G3BP1 were completely unable to support NV RNA synthesis 229 ( Fig 5C) .", [["U2OS 228 cells", "ANATOMY", 67, 81], ["NV", "GENE_OR_GENE_PRODUCT", 32, 34], ["U2OS 228 cells", "CELL", 67, 81], ["G3BP1", "GENE_OR_GENE_PRODUCT", 97, 102], ["NV viral RNA", "RNA", 32, 44], ["WT U2OS 228 cells", "CELL_LINE", 64, 81], ["G3BP1", "PROTEIN", 97, 102], ["NV RNA", "RNA", 137, 143], ["NV", "SPECIES", 32, 34], ["a significant increase", "PROBLEM", 6, 28], ["NV viral RNA levels", "TEST", 32, 51], ["NV RNA synthesis", "TEST", 137, 153], ["significant", "OBSERVATION_MODIFIER", 8, 19], ["increase", "OBSERVATION_MODIFIER", 20, 28], ["viral RNA", "OBSERVATION", 35, 44]]], ["These data indicate that like for MNV, G3BP1 is essential for human 230Norwalk virus replication.", [["MNV", "ORGANISM", 34, 37], ["G3BP1", "GENE_OR_GENE_PRODUCT", 39, 44], ["human", "ORGANISM", 62, 67], ["Norwalk virus", "ORGANISM", 71, 84], ["G3BP1", "PROTEIN", 39, 44], ["human", "SPECIES", 62, 67], ["MNV", "SPECIES", 34, 37], ["human", "SPECIES", 62, 67], ["Norwalk virus", "SPECIES", 71, 84], ["These data", "TEST", 0, 10], ["MNV", "PROBLEM", 34, 37], ["Norwalk virus replication", "TREATMENT", 71, 96], ["virus replication", "OBSERVATION", 79, 96]]], ["231 232The RNA-binding domain of G3BP1 is required for its function in the norovirus 233 life cycle.", [["G3BP1", "GENE_OR_GENE_PRODUCT", 33, 38], ["RNA-binding domain", "PROTEIN", 11, 29], ["G3BP1", "PROTEIN", 33, 38], ["The RNA", "TEST", 7, 14]]], ["234Norwalk virus replication.", [["Norwalk virus", "ORGANISM", 3, 16], ["Norwalk virus", "SPECIES", 3, 16], ["Norwalk virus replication", "TREATMENT", 3, 28], ["virus replication", "OBSERVATION", 11, 28]]], ["231 232To confirm the role of G3BP1 in the norovirus life cycle we examined the ability of full 235 length and truncated versions of G3BP1 to restore norovirus replication in G3BP1 236 knockout cells.", [["G3BP1 236 knockout cells", "ANATOMY", 175, 199], ["G3BP1", "GENE_OR_GENE_PRODUCT", 30, 35], ["G3BP1", "GENE_OR_GENE_PRODUCT", 133, 138], ["norovirus", "ORGANISM", 150, 159], ["G3BP1 236 knockout cells", "CELL", 175, 199], ["G3BP1", "PROTEIN", 30, 35], ["G3BP1", "PROTEIN", 133, 138], ["G3BP1 236 knockout cells", "CELL_LINE", 175, 199], ["G3BP1", "TREATMENT", 133, 138], ["norovirus replication", "PROBLEM", 150, 171], ["norovirus", "OBSERVATION", 150, 159]]], ["A mouse BV-2 G3BP1 knockout cell line was complemented with 237 either full length G3BP1 or variants lacking the RGG or both the RGG and RRM 238 binding domains ( Fig 6A) and the impact on viral replication assessed.", [["BV-2 G3BP1 knockout cell line", "ANATOMY", 8, 37], ["mouse", "ORGANISM", 2, 7], ["BV-2 G3BP1", "CELL", 8, 18], ["cell line", "CELL", 28, 37], ["G3BP1", "GENE_OR_GENE_PRODUCT", 83, 88], ["mouse BV-2 G3BP1 knockout cell line", "CELL_LINE", 2, 37], ["G3BP1", "PROTEIN", 83, 88], ["RGG", "PROTEIN", 113, 116], ["RGG and RRM 238 binding domains", "PROTEIN", 129, 160], ["mouse", "SPECIES", 2, 7], ["mouse", "SPECIES", 2, 7], ["A mouse BV", "TEST", 0, 10], ["variants lacking the RGG", "PROBLEM", 92, 116], ["Fig 6A", "TEST", 163, 169], ["viral replication", "TREATMENT", 189, 206], ["cell line", "OBSERVATION", 28, 37], ["viral replication", "OBSERVATION", 189, 206]]], ["239Norwalk virus replication.", [["Norwalk virus", "ORGANISM", 3, 16], ["Norwalk virus", "SPECIES", 3, 16], ["Norwalk virus replication", "TREATMENT", 3, 28], ["virus replication", "OBSERVATION", 11, 28]]], ["231 232Complementation with full length murine G3BP1 restored the ability of MNV to 240 induce cell death ( Fig 6B) and to produce infectious virus ( Fig 6C) To further define the role of G3BP1 in the norovirus life cycle we examined whether 249 G3BP1 functioned at the level of viral entry or post-entry.", [["cell", "ANATOMY", 95, 99], ["death", "DISEASE", 100, 105], ["murine", "ORGANISM", 40, 46], ["G3BP1", "GENE_OR_GENE_PRODUCT", 47, 52], ["MNV", "ORGANISM", 77, 80], ["cell", "CELL", 95, 99], ["G3BP1", "GENE_OR_GENE_PRODUCT", 188, 193], ["G3BP1", "GENE_OR_GENE_PRODUCT", 246, 251], ["murine G3BP1", "PROTEIN", 40, 52], ["G3BP1", "PROTEIN", 188, 193], ["249 G3BP1", "PROTEIN", 242, 251], ["murine", "SPECIES", 40, 46], ["cell death", "PROBLEM", 95, 105], ["infectious virus", "PROBLEM", 131, 147], ["viral entry", "OBSERVATION", 279, 290]]], ["We therefore bypassed the 250 entry phase of the infection process and transfected viral VPg-linked RNA into WT 251 and two independently generated BV-2 \u0394G3BP1 cell lines and examined the impact 252 on norovirus replication.", [["BV-2 \u0394G3BP1 cell lines", "ANATOMY", 148, 170], ["infection", "DISEASE", 49, 58], ["BV-2 \u0394G3BP1 cell lines", "CELL", 148, 170], ["norovirus", "ORGANISM", 202, 211], ["viral VPg-linked RNA", "RNA", 83, 103], ["WT 251", "CELL_LINE", 109, 115], ["BV-2 \u0394G3BP1 cell lines", "CELL_LINE", 148, 170], ["the infection process", "PROBLEM", 45, 66], ["transfected viral VPg", "PROBLEM", 71, 92], ["WT", "TEST", 109, 111], ["BV", "TEST", 148, 150], ["norovirus replication", "TREATMENT", 202, 223], ["250 entry phase", "OBSERVATION_MODIFIER", 26, 41], ["infection", "OBSERVATION", 49, 58], ["cell lines", "OBSERVATION", 160, 170], ["norovirus", "OBSERVATION", 202, 211]]], ["Transfection of MNV viral VPg-linked RNA into WT cells 253 resulted in high yields of infectious virus ( Fig 7A) and viral proteins ( Fig 7C) .", [["WT cells", "ANATOMY", 46, 54], ["MNV", "ORGANISM", 16, 19], ["WT cells", "CELL", 46, 54], ["infectious virus", "ORGANISM", 86, 102], ["MNV viral VPg-linked RNA", "RNA", 16, 40], ["WT cells 253", "CELL_LINE", 46, 58], ["viral proteins", "PROTEIN", 117, 131], ["MNV", "SPECIES", 16, 19], ["infectious virus", "SPECIES", 86, 102], ["MNV viral VPg", "TEST", 16, 29], ["WT cells", "TEST", 46, 54], ["infectious virus", "PROBLEM", 86, 102], ["viral proteins", "TEST", 117, 131], ["viral VPg", "OBSERVATION", 20, 29], ["infectious", "OBSERVATION", 86, 96]]], ["The 254 levels of infectivity obtained following transfection of \u0394G3BP1 cell lines with MNV 255 viral RNA was comparable to that obtained in WT cells in the presence of the 256 nucleoside analogue 2'-C-methylcytidin (2CMC), a known inhibitor of the norovirus 257 RNA polymerase (Rocha-Pereira et al., 2012; (Fig 7A) .", [["\u0394G3BP1 cell lines", "ANATOMY", 65, 82], ["cells", "ANATOMY", 144, 149], ["nucleoside", "CHEMICAL", 177, 187], ["2'-C-methylcytidin", "CHEMICAL", 197, 215], ["2CMC", "CHEMICAL", 217, 221], ["nucleoside", "CHEMICAL", 177, 187], ["2'-C-methylcytidin", "CHEMICAL", 197, 215], ["2CMC", "CHEMICAL", 217, 221], ["\u0394G3BP1 cell lines", "CELL", 65, 82], ["MNV 255 viral", "ORGANISM", 88, 101], ["WT cells", "CELL", 141, 149], ["2'-C-methylcytidin", "SIMPLE_CHEMICAL", 197, 215], ["2CMC", "SIMPLE_CHEMICAL", 217, 221], ["\u0394G3BP1 cell lines", "CELL_LINE", 65, 82], ["MNV 255 viral RNA", "RNA", 88, 105], ["WT cells", "CELL_LINE", 141, 149], ["norovirus 257 RNA polymerase", "PROTEIN", 249, 277], ["MNV", "SPECIES", 88, 91], ["infectivity", "PROBLEM", 18, 29], ["transfection of \u0394G3BP1 cell lines", "TREATMENT", 49, 82], ["MNV", "TEST", 88, 91], ["viral RNA", "TEST", 96, 105], ["nucleoside analogue", "TEST", 177, 196], ["the norovirus", "TEST", 245, 258], ["RNA polymerase", "TEST", 263, 277], ["Rocha", "TEST", 279, 284]]], ["No viral proteins were 258 detected in either of the \u0394G3BP1 cell lines suggesting a defect at a very early stage 259Norwalk virus replication.", [["\u0394G3BP1 cell lines", "ANATOMY", 53, 70], ["\u0394G3BP1 cell lines", "CELL", 53, 70], ["Norwalk virus", "ORGANISM", 116, 129], ["viral proteins", "PROTEIN", 3, 17], ["\u0394G3BP1 cell lines", "CELL_LINE", 53, 70], ["Norwalk virus", "SPECIES", 116, 129], ["viral proteins", "TEST", 3, 17], ["a defect", "PROBLEM", 82, 90], ["Norwalk virus replication", "TREATMENT", 116, 141], ["viral proteins", "OBSERVATION", 3, 17], ["\u0394G3BP1 cell lines", "OBSERVATION", 53, 70], ["defect", "OBSERVATION", 84, 90], ["virus replication", "OBSERVATION", 124, 141]]], ["Transfection of VPg-linked RNA into the \u0394G3BP1 cell 260 lines reconstituted with WT G3BP1 restored the ability to produce infectious virus 261 ( Fig 7B) and the production of viral proteins (Fig 7D) .", [["\u0394G3BP1 cell 260 lines", "ANATOMY", 40, 61], ["\u0394G3BP1 cell 260 lines", "CELL", 40, 61], ["G3BP1", "GENE_OR_GENE_PRODUCT", 84, 89], ["infectious virus 261", "ORGANISM", 122, 142], ["VPg-linked RNA", "RNA", 16, 30], ["\u0394G3BP1 cell 260 lines", "CELL_LINE", 40, 61], ["WT G3BP1", "PROTEIN", 81, 89], ["viral proteins", "PROTEIN", 175, 189], ["Fig 7D", "PROTEIN", 191, 197], ["infectious virus 261", "SPECIES", 122, 142], ["VPg", "TEST", 16, 19], ["WT G3BP1", "TREATMENT", 81, 89], ["infectious virus", "PROBLEM", 122, 138], ["Fig 7B", "TEST", 145, 151], ["viral proteins", "PROBLEM", 175, 189]]], ["A minor increase in viral 262 infectivity was observed in the \u0394G3BP1 cell line reconstituted with the \u0394RGG 263 construct producing viral titres that were higher than those obtained from the WT 264 complemented line in the presence of 2CMC, suggesting low levels of viral 265 replication ( Fig 7B) .", [["\u0394G3BP1 cell line", "ANATOMY", 62, 78], ["\u0394G3BP1 cell line", "CELL", 62, 78], ["2CMC", "GENE_OR_GENE_PRODUCT", 234, 238], ["\u0394G3BP1 cell line", "CELL_LINE", 62, 78], ["\u0394RGG 263 construct", "DNA", 102, 120], ["WT 264 complemented line", "CELL_LINE", 190, 214], ["A minor increase in viral 262 infectivity", "PROBLEM", 0, 41], ["the \u0394RGG", "TEST", 98, 106], ["viral titres", "TEST", 131, 143], ["the WT", "TEST", 186, 192], ["low levels of viral 265 replication", "PROBLEM", 251, 286], ["minor", "OBSERVATION_MODIFIER", 2, 7], ["increase", "OBSERVATION_MODIFIER", 8, 16], ["viral 262 infectivity", "OBSERVATION", 20, 41], ["cell line", "OBSERVATION", 69, 78], ["viral titres", "OBSERVATION", 131, 143], ["low levels", "OBSERVATION_MODIFIER", 251, 261]]], ["However, the levels of viral proteins produced in this line was 266 below the limit of detection by western blot (Fig 7D) .", [["viral proteins", "PROTEIN", 23, 37], ["viral proteins", "TEST", 23, 37], ["viral proteins", "OBSERVATION", 23, 37]]], ["These data confirm that G3BP1 267 is required for a post entry stage of the norovirus life cycle and that in the absence of 268 G3BP1 only residual norovirus replication is observed.", [["G3BP1 267", "GENE_OR_GENE_PRODUCT", 24, 33], ["G3BP1", "GENE_OR_GENE_PRODUCT", 128, 133], ["G3BP1 267", "PROTEIN", 24, 33], ["268 G3BP1", "PROTEIN", 124, 133], ["These data", "TEST", 0, 10], ["G3BP1", "TEST", 24, 29], ["the norovirus life cycle", "TREATMENT", 72, 96], ["residual norovirus replication", "PROBLEM", 139, 169], ["norovirus", "OBSERVATION", 76, 85], ["residual", "OBSERVATION_MODIFIER", 139, 147], ["norovirus replication", "OBSERVATION", 148, 169]]], ["269G3BP1 is required for viral negative sense RNA synthesis 271To define the precise role of G3BP1 in the early stages of the virus life cycle, we 272 used strand-specific RT-qPCR to quantify the levels of viral positive and negative 273 sense RNA in WT and \u0394G3BP1 cell lines following infection with MNV.", [["\u0394G3BP1 cell lines", "ANATOMY", 258, 275], ["infection", "DISEASE", 286, 295], ["269G3BP1", "GENE_OR_GENE_PRODUCT", 0, 8], ["G3BP1", "GENE_OR_GENE_PRODUCT", 93, 98], ["\u0394G3BP1 cell lines", "CELL", 258, 275], ["MNV", "ORGANISM", 301, 304], ["269G3BP1", "PROTEIN", 0, 8], ["G3BP1", "PROTEIN", 93, 98], ["viral positive and negative 273 sense RNA", "RNA", 206, 247], ["\u0394G3BP1 cell lines", "CELL_LINE", 258, 275], ["MNV", "SPECIES", 301, 304], ["G3BP1", "TREATMENT", 93, 98], ["the levels", "TEST", 192, 202], ["viral positive", "PROBLEM", 206, 220], ["WT", "TEST", 251, 253], ["\u0394G3BP1 cell lines", "TREATMENT", 258, 275], ["infection", "PROBLEM", 286, 295], ["cell lines", "OBSERVATION", 265, 275], ["infection", "OBSERVATION", 286, 295]]], ["As a control, 274 2CMC was included following virus inoculation as illustrated in the experimental time 275 line ( Fig 8A) .", [["2CMC", "CANCER", 18, 22], ["virus inoculation", "TREATMENT", 46, 63]]], ["The production of viral positive sense RNA was reduced to background 276 levels in the absence of G3BP1, comparable to levels observed when the 2CMC was 277 present during the infection (Fig 8B) .", [["infection", "DISEASE", 176, 185], ["G3BP1", "GENE_OR_GENE_PRODUCT", 98, 103], ["viral positive sense RNA", "RNA", 18, 42], ["G3BP1", "PROTEIN", 98, 103], ["viral positive sense RNA", "PROBLEM", 18, 42], ["the infection", "PROBLEM", 172, 185], ["viral", "OBSERVATION_MODIFIER", 18, 23], ["positive", "OBSERVATION", 24, 32]]], ["Viral negative sense RNA synthesis was also 278 reduced to below the detection limit of the assay in \u0394G3BP1 cell lines ( Fig 8C) .", [["\u0394G3BP1 cell lines", "ANATOMY", 101, 118], ["\u0394G3BP1 cell lines", "CELL", 101, 118], ["\u0394G3BP1 cell lines", "CELL_LINE", 101, 118], ["RNA synthesis", "TEST", 21, 34], ["the assay", "TEST", 88, 97], ["negative", "OBSERVATION", 6, 14], ["cell lines", "OBSERVATION", 108, 118]]], ["279G3BP1 is required for viral negative sense RNA synthesis 271Surprisingly, we were able to detect an ~5 fold increase in viral negative sense RNA 280 production at 6 hours post infection of WT cells in the presence of 2CMC, which, 281G3BP1 is required for viral negative sense RNA synthesis 271given that 2CMC was added after the inoculation phase (Fig 8B) , likely represents 282 the first round of viral negative sense RNA synthesis, confirming the sensitivity of the 283 assay.", [["cells", "ANATOMY", 195, 200], ["2CMC", "CHEMICAL", 307, 311], ["2CMC", "CHEMICAL", 220, 224], ["279G3BP1", "GENE_OR_GENE_PRODUCT", 0, 8], ["WT cells", "CELL", 192, 200], ["2CMC", "SIMPLE_CHEMICAL", 220, 224], ["2CMC", "SIMPLE_CHEMICAL", 307, 311], ["279G3BP1", "PROTEIN", 0, 8], ["WT cells", "CELL_TYPE", 192, 200], ["viral negative sense RNA synthesis", "PROBLEM", 25, 59], ["an ~5 fold increase", "PROBLEM", 100, 119], ["viral negative sense RNA", "PROBLEM", 123, 147], ["infection of WT cells", "PROBLEM", 179, 200], ["viral negative sense RNA synthesis", "PROBLEM", 258, 292], ["the inoculation phase", "TEST", 328, 349], ["viral negative sense RNA synthesis", "PROBLEM", 402, 436], ["the sensitivity", "TEST", 449, 464], ["increase", "OBSERVATION_MODIFIER", 111, 119]]], ["Addition of 2CMC during the inoculation phase reduced this background 284 levels (data not shown). presence of low levels of viral infectivity ( Fig 7B) .", [["2CMC", "CHEMICAL", 12, 16], ["2CMC", "SIMPLE_CHEMICAL", 12, 16], ["the inoculation phase", "TEST", 24, 45], ["viral infectivity", "PROBLEM", 125, 142], ["low levels", "OBSERVATION_MODIFIER", 111, 121], ["viral infectivity", "OBSERVATION", 125, 142]]], ["This discrepancy likely reflects the 293 relative sensitivities of the assays and the nature of the strand specific qPCR assay 294 which requires low levels of RNA input to maintain strand specificity.", [["the assays", "TEST", 67, 77], ["the strand specific qPCR assay", "TEST", 96, 126], ["RNA input", "TREATMENT", 160, 169], ["strand specificity", "TEST", 182, 200]]], ["Together these 295 data suggest that the function of G3BP1 is prior to, or at the level of viral negative 296 sense RNA synthesis, with the most logical steps being either viral RNA translation 297 or the formation of viral replication complexes.", [["G3BP1", "GENE_OR_GENE_PRODUCT", 53, 58], ["G3BP1", "PROTEIN", 53, 58], ["viral replication complexes", "PROTEIN", 218, 245], ["the function of G3BP1", "PROBLEM", 37, 58], ["viral RNA translation", "PROBLEM", 172, 193], ["viral replication complexes", "PROBLEM", 218, 245], ["viral replication complexes", "OBSERVATION", 218, 245]]], ["298 299 G3BP1 is required for the association of VPg with 40S ribosomal subunits.", [["G3BP1", "GENE_OR_GENE_PRODUCT", 8, 13], ["VPg", "GENE_OR_GENE_PRODUCT", 49, 52], ["40S ribosomal subunits", "GENE_OR_GENE_PRODUCT", 58, 80], ["G3BP1", "PROTEIN", 8, 13], ["VPg", "PROTEIN", 49, 52], ["40S ribosomal subunits", "PROTEIN", 58, 80], ["VPg", "TREATMENT", 49, 52], ["40S ribosomal subunits", "TREATMENT", 58, 80]]], ["300G3BP1 is required for viral negative sense RNA synthesis 271We have previously shown that norovirus VPg interacts with eIF4G to recruit 301 ribosomal subunits and direct viral translation (Chaudhry et al., 2006; Chung et al., 302 2014) .", [["300G3BP1", "GENE_OR_GENE_PRODUCT", 0, 8], ["norovirus VPg", "ORGANISM", 93, 106], ["eIF4G", "GENE_OR_GENE_PRODUCT", 122, 127], ["300G3BP1", "PROTEIN", 0, 8], ["norovirus VPg", "PROTEIN", 93, 106], ["eIF4G", "PROTEIN", 122, 127], ["301 ribosomal subunits", "PROTEIN", 139, 161], ["norovirus", "SPECIES", 93, 102], ["viral negative sense RNA synthesis", "PROBLEM", 25, 59], ["norovirus VPg", "PROBLEM", 93, 106], ["eIF4G", "TREATMENT", 122, 127], ["ribosomal subunits", "TREATMENT", 143, 161], ["norovirus", "OBSERVATION", 93, 102]]], ["The interaction between VPg and eIF4G occurs via a direct interaction 303 between the highly conserved C-terminal region in VPg and the central HEAT 304 domain of eIF4G (Leen et al., 2016) and does not require any additional cellular 305 cofactors, at least in vitro.", [["cellular", "ANATOMY", 225, 233], ["C", "CHEMICAL", 103, 104], ["VPg", "GENE_OR_GENE_PRODUCT", 24, 27], ["eIF4G", "GENE_OR_GENE_PRODUCT", 32, 37], ["VPg", "CELLULAR_COMPONENT", 124, 127], ["eIF4G", "GENE_OR_GENE_PRODUCT", 163, 168], ["cellular", "CELL", 225, 233], ["VPg", "PROTEIN", 24, 27], ["eIF4G", "PROTEIN", 32, 37], ["C-terminal region", "PROTEIN", 103, 120], ["VPg", "PROTEIN", 124, 127], ["central HEAT 304 domain", "PROTEIN", 136, 159], ["eIF4G", "PROTEIN", 163, 168], ["cellular 305 cofactors", "PROTEIN", 225, 247], ["VPg and eIF4G", "TREATMENT", 24, 37], ["terminal", "ANATOMY_MODIFIER", 105, 113], ["central", "ANATOMY_MODIFIER", 136, 143]]], ["The interaction between the eIF4G HEAT domain and the 306 eIF3 complex plays a central role in the recruitment of the 40S ribosomal subunit for 307 translation initiation (Marcotrigiano:2001uq; Kumar et al., 2016; Villa et al., 2013) .", [["eIF4G", "GENE_OR_GENE_PRODUCT", 28, 33], ["eIF3", "GENE_OR_GENE_PRODUCT", 58, 62], ["eIF4G HEAT domain", "PROTEIN", 28, 45], ["306 eIF3 complex", "PROTEIN", 54, 70], ["40S ribosomal subunit", "PROTEIN", 118, 139], ["the eIF4G HEAT domain", "TREATMENT", 24, 45], ["the 40S ribosomal subunit", "TREATMENT", 114, 139]]], ["308G3BP1 is required for viral negative sense RNA synthesis 271Our proteomics analysis also confirms that the norovirus VPg proteins form a 309 complex that contains multiple components of the 40S subunit ( Fig 1D) and it has 310 been established previously that G3BP1 associates with 40S subunits (Kedersha et 311 al., 2016) .", [["308G3BP1", "GENE_OR_GENE_PRODUCT", 0, 8], ["norovirus VPg", "ORGANISM", 110, 123], ["40S subunit", "GENE_OR_GENE_PRODUCT", 193, 204], ["G3BP1", "GENE_OR_GENE_PRODUCT", 263, 268], ["308G3BP1", "PROTEIN", 0, 8], ["norovirus VPg proteins", "PROTEIN", 110, 132], ["309 complex", "PROTEIN", 140, 151], ["40S subunit", "PROTEIN", 193, 204], ["Fig 1D", "PROTEIN", 207, 213], ["G3BP1", "PROTEIN", 263, 268], ["40S subunits", "PROTEIN", 285, 297], ["Our proteomics analysis", "TEST", 63, 86], ["the norovirus VPg proteins", "PROBLEM", 106, 132], ["norovirus", "OBSERVATION", 110, 119], ["multiple", "OBSERVATION_MODIFIER", 166, 174], ["components", "OBSERVATION_MODIFIER", 175, 185]]], ["To assess a potential role for G3BP1 in the formation of VPg-driven 312 translation complexes in cells, we examined the ability of GFP tagged version of 313 MNV VPg to pull down 40S subunits in the presence and absence of G3BP1.", [["cells", "ANATOMY", 97, 102], ["G3BP1", "GENE_OR_GENE_PRODUCT", 31, 36], ["VPg", "GENE_OR_GENE_PRODUCT", 57, 60], ["cells", "CELL", 97, 102], ["GFP", "GENE_OR_GENE_PRODUCT", 131, 134], ["MNV", "ORGANISM", 157, 160], ["G3BP1", "GENE_OR_GENE_PRODUCT", 222, 227], ["G3BP1", "PROTEIN", 31, 36], ["VPg", "PROTEIN", 57, 60], ["312 translation complexes", "PROTEIN", 68, 93], ["313 MNV VPg", "PROTEIN", 153, 164], ["40S subunits", "PROTEIN", 178, 190], ["G3BP1", "PROTEIN", 222, 227], ["G3BP1", "TREATMENT", 31, 36], ["VPg", "TEST", 57, 60]]], ["GFP-314 tagged WT MNV VPg was readily able to pull down eIF4G, G3BP1 and RpS6, a 315 component of the 40S subunit ( Fig 9A) .", [["GFP-314", "GENE_OR_GENE_PRODUCT", 0, 7], ["WT MNV", "ORGANISM", 15, 21], ["eIF4G", "GENE_OR_GENE_PRODUCT", 56, 61], ["G3BP1", "GENE_OR_GENE_PRODUCT", 63, 68], ["RpS6", "GENE_OR_GENE_PRODUCT", 73, 77], ["40S subunit", "GENE_OR_GENE_PRODUCT", 102, 113], ["GFP-314 tagged WT MNV VPg", "PROTEIN", 0, 25], ["eIF4G", "PROTEIN", 56, 61], ["G3BP1", "PROTEIN", 63, 68], ["RpS6", "PROTEIN", 73, 77], ["315 component", "PROTEIN", 81, 94], ["40S subunit", "PROTEIN", 102, 113], ["Fig 9A", "PROTEIN", 116, 122], ["MNV", "SPECIES", 18, 21], ["GFP", "TEST", 0, 3], ["VPg", "TEST", 22, 25], ["eIF4G", "TEST", 56, 61], ["G3BP1", "TEST", 63, 68], ["RpS6", "TEST", 73, 77]]], ["However, in the absence of G3BP1, the 316 ability to pull down RpS6 was lost ( Fig 9A) .", [["G3BP1", "GENE_OR_GENE_PRODUCT", 27, 32], ["RpS6", "GENE_OR_GENE_PRODUCT", 63, 67], ["G3BP1", "PROTEIN", 27, 32], ["RpS6", "PROTEIN", 63, 67]]], ["Furthermore, we found that disruption of 317 the VPg-eIF4G interaction by the introduction of the F123A mutation into the eIF4G 318 binding domain, also significantly reduced the ability to pull down RpS6 (Fig 9B) .", [["VPg", "GENE_OR_GENE_PRODUCT", 49, 52], ["eIF4G", "GENE_OR_GENE_PRODUCT", 53, 58], ["F123A", "GENE_OR_GENE_PRODUCT", 98, 103], ["RpS6", "GENE_OR_GENE_PRODUCT", 200, 204], ["VPg", "PROTEIN", 49, 52], ["eIF4G", "PROTEIN", 53, 58], ["eIF4G 318 binding domain", "PROTEIN", 122, 146], ["RpS6", "PROTEIN", 200, 204], ["Fig 9B", "PROTEIN", 206, 212]]], ["319G3BP1 is required for viral negative sense RNA synthesis 271These data suggest that the interaction of VPg with eIF4G is important for complex 320 formation with ribosomal proteins and that that G3BP1 contributes in some manner 321 to the formation of this complex. namely in the presence of 2CMC.", [["ribosomal", "ANATOMY", 165, 174], ["2CMC", "CHEMICAL", 295, 299], ["319G3BP1", "GENE_OR_GENE_PRODUCT", 0, 8], ["VPg", "GENE_OR_GENE_PRODUCT", 106, 109], ["eIF4G", "GENE_OR_GENE_PRODUCT", 115, 120], ["ribosomal", "CELLULAR_COMPONENT", 165, 174], ["G3BP1", "GENE_OR_GENE_PRODUCT", 198, 203], ["319G3BP1", "PROTEIN", 0, 8], ["VPg", "PROTEIN", 106, 109], ["eIF4G", "PROTEIN", 115, 120], ["ribosomal proteins", "PROTEIN", 165, 183], ["G3BP1", "PROTEIN", 198, 203], ["VPg with eIF4G", "TREATMENT", 106, 120], ["ribosomal proteins", "PROBLEM", 165, 183]]], ["This approach enabled us to assess only the 328 capacity of the incoming parental viral RNA to assemble into translationally active 329 complexes, a stage often referred to as the \"maiden round\" of RNA virus genome 330 translation.", [["incoming parental viral RNA", "RNA", 64, 91], ["329 complexes", "PROTEIN", 132, 145]]], ["To this aim, cells were infected with MNV in the presence of 2CMC and 331 polysomes profiling on extracts prepared from cells at 4 and 9 hours post infection 332 performed (Fig 10A) .", [["cells", "ANATOMY", 13, 18], ["extracts", "ANATOMY", 97, 105], ["cells", "ANATOMY", 120, 125], ["infection", "DISEASE", 148, 157], ["cells", "CELL", 13, 18], ["MNV", "ORGANISM", 38, 41], ["2CMC", "SIMPLE_CHEMICAL", 61, 65], ["extracts", "ORGANISM_SUBSTANCE", 97, 105], ["cells", "CELL", 120, 125], ["MNV", "SPECIES", 38, 41], ["polysomes profiling", "TEST", 74, 93], ["infection", "PROBLEM", 148, 157]]], ["Quantification of the viral RNA levels in cells in the presence of 333 2CMC confirmed that the absence of G3BP1 has no impact on the overall levels 334 present at the time points examined (data not shown).", [["cells", "ANATOMY", 42, 47], ["G3BP1", "CHEMICAL", 106, 111], ["cells", "CELL", 42, 47], ["G3BP1", "GENE_OR_GENE_PRODUCT", 106, 111], ["G3BP1", "PROTEIN", 106, 111], ["the viral RNA levels", "TEST", 18, 38], ["viral RNA levels", "OBSERVATION", 22, 38]]], ["We noted that even in the 335 presence of 2CMC, which inhibits viral RNA synthesis, there was a small but 336 measurable increase in free 80S ribosomes over time in WT cells but not in cells 337 lacking G3BP1 (Fig 10A) .", [["cells", "ANATOMY", 168, 173], ["cells", "ANATOMY", 185, 190], ["2CMC", "CHEMICAL", 42, 46], ["2CMC", "CHEMICAL", 42, 46], ["2CMC", "SIMPLE_CHEMICAL", 42, 46], ["WT cells", "CELL", 165, 173], ["cells", "CELL", 185, 190], ["G3BP1", "GENE_OR_GENE_PRODUCT", 203, 208], ["viral RNA", "RNA", 63, 72], ["80S ribosomes", "RNA", 138, 151], ["WT cells", "CELL_LINE", 165, 173], ["G3BP1", "PROTEIN", 203, 208], ["viral RNA synthesis", "PROBLEM", 63, 82], ["viral RNA synthesis", "OBSERVATION", 63, 82], ["small", "OBSERVATION_MODIFIER", 96, 101], ["measurable", "OBSERVATION_MODIFIER", 110, 120], ["increase", "OBSERVATION_MODIFIER", 121, 129], ["free", "OBSERVATION_MODIFIER", 133, 137], ["80S ribosomes", "OBSERVATION", 138, 151]]], ["We have previously found that MNV infection results in 338 translation shut off and that this effect is at least partuialkly due to the activity of the 339 NS6 protease (Emmott et al., 2017) .", [["MNV infection", "DISEASE", 30, 43], ["MNV", "ORGANISM", 30, 33], ["NS6", "GENE_OR_GENE_PRODUCT", 156, 159], ["339 NS6 protease", "PROTEIN", 152, 168], ["MNV", "SPECIES", 30, 33], ["MNV infection", "PROBLEM", 30, 43], ["MNV", "OBSERVATION_MODIFIER", 30, 33], ["infection", "OBSERVATION", 34, 43]]], ["The fact we observed 80S accumulation in WT 340 cells, even in the absence of viral RNA synthesis, but not in cells lacking G3BP1, 341G3BP1 is required for viral negative sense RNA synthesis 271indirectly lead us to suspect that translation of viral RNA had occurred in WT cells, indicated that translation in nuclease treated extracts was on average reduced by 364 ~40-50% because of G3BP1 ablation ( Fig 11C) .", [["80S", "ANATOMY", 21, 24], ["WT 340 cells", "ANATOMY", 41, 53], ["cells", "ANATOMY", 110, 115], ["cells", "ANATOMY", 273, 278], ["extracts", "ANATOMY", 327, 335], ["80S", "CELLULAR_COMPONENT", 21, 24], ["WT 340 cells", "CELL", 41, 53], ["cells", "CELL", 110, 115], ["G3BP1", "GENE_OR_GENE_PRODUCT", 124, 129], ["341G3BP1", "GENE_OR_GENE_PRODUCT", 131, 139], ["WT cells", "CELL", 270, 278], ["extracts", "ORGANISM_SUBSTANCE", 327, 335], ["G3BP1", "GENE_OR_GENE_PRODUCT", 385, 390], ["80S", "PROTEIN", 21, 24], ["WT 340 cells", "CELL_LINE", 41, 53], ["G3BP1", "PROTEIN", 124, 129], ["341G3BP1", "PROTEIN", 131, 139], ["viral RNA", "RNA", 244, 253], ["WT cells", "CELL_TYPE", 270, 278], ["nuclease", "PROTEIN", 310, 318], ["G3BP1", "PROTEIN", 385, 390], ["80S accumulation in WT 340 cells", "PROBLEM", 21, 53], ["viral RNA synthesis", "PROBLEM", 78, 97], ["viral negative sense RNA synthesis", "PROBLEM", 156, 190], ["viral RNA", "PROBLEM", 244, 253], ["G3BP1 ablation", "TREATMENT", 385, 399], ["80S accumulation", "OBSERVATION", 21, 37], ["viral RNA synthesis", "OBSERVATION", 78, 97], ["viral RNA", "OBSERVATION", 244, 253]]], ["A similar reduction in in vitro 365 translation was observed across multiple time points (Fig S11C) .", [["A similar reduction", "TREATMENT", 0, 19], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["reduction", "OBSERVATION_MODIFIER", 10, 19]]], ["366367The ability of VPg-linked norovirus RNA to be translated in the presence of 368 increasing amounts of total cellular RNAs was then examined to assess the relative 369 role of G3BP1 under conditions where cellular RNA are present.", [["cellular", "ANATOMY", 114, 122], ["cellular", "ANATOMY", 210, 218], ["366367", "CHEMICAL", 0, 6], ["VPg", "GENE_OR_GENE_PRODUCT", 21, 24], ["norovirus", "ORGANISM", 32, 41], ["cellular", "CELL", 114, 122], ["G3BP1", "GENE_OR_GENE_PRODUCT", 181, 186], ["cellular", "CELL", 210, 218], ["VPg-linked norovirus RNA", "RNA", 21, 45], ["cellular RNAs", "RNA", 114, 127], ["G3BP1", "PROTEIN", 181, 186], ["cellular RNA", "RNA", 210, 222], ["366367", "SPECIES", 0, 6], ["VPg", "TEST", 21, 24], ["linked norovirus RNA", "PROBLEM", 25, 45], ["total cellular RNAs", "TREATMENT", 108, 127], ["cellular RNA", "PROBLEM", 210, 222], ["cellular RNA", "OBSERVATION", 210, 222]]], ["Total RNA isolated 370 from uninfected cells was titrated into the nuclease treated extracts and the impact 371 norovirus VPg-dependent translation examined ( Fig 11D) .", [["cells", "ANATOMY", 39, 44], ["extracts", "ANATOMY", 84, 92], ["cells", "CELL", 39, 44], ["extracts", "ORGANISM_SUBSTANCE", 84, 92], ["norovirus", "ORGANISM", 112, 121], ["VPg", "GENE_OR_GENE_PRODUCT", 122, 125], ["uninfected cells", "CELL_TYPE", 28, 44], ["nuclease", "PROTEIN", 67, 75], ["norovirus VPg", "PROTEIN", 112, 125], ["Total RNA", "TEST", 0, 9], ["uninfected cells", "TREATMENT", 28, 44], ["the nuclease treated extracts", "TREATMENT", 63, 92], ["norovirus VPg", "TREATMENT", 112, 125]]], ["We found that in the 372 presence of cellular RNAs, the translation of norovirus VPg-linked RNA in extracts 373 from \u0394G3BP1 cells is reduced by up to 80% in comparison to extracts from WT cells.", [["cellular", "ANATOMY", 37, 45], ["extracts", "ANATOMY", 99, 107], ["\u0394G3BP1 cells", "ANATOMY", 117, 129], ["extracts", "ANATOMY", 171, 179], ["cells", "ANATOMY", 188, 193], ["cellular", "CELL", 37, 45], ["norovirus", "ORGANISM", 71, 80], ["extracts", "ORGANISM_SUBSTANCE", 99, 107], ["\u0394G3BP1 cells", "CELL", 117, 129], ["extracts", "ORGANISM_SUBSTANCE", 171, 179], ["WT cells", "CELL", 185, 193], ["cellular RNAs", "RNA", 37, 50], ["norovirus VPg-linked RNA", "RNA", 71, 95], ["\u0394G3BP1 cells", "CELL_LINE", 117, 129], ["WT cells", "CELL_TYPE", 185, 193], ["cellular RNAs", "PROBLEM", 37, 50], ["norovirus VPg", "PROBLEM", 71, 84], ["\u0394G3BP1 cells", "TEST", 117, 129], ["cellular RNAs", "OBSERVATION", 37, 50], ["norovirus VPg", "OBSERVATION", 71, 84], ["reduced", "OBSERVATION_MODIFIER", 133, 140], ["WT cells", "OBSERVATION", 185, 193]]], ["374367In agreement with our data using polysome profiling, these data suggest that G3BP1 375 functions to provide a competitive advantage for norovirus VPg-linked RNA under 376367conditions where cellular RNAs are present.Discussion 379In this study, we have used a combination of biochemical and genetic approaches to 380 identify host factors involved in the norovirus life cycle.", [["cellular", "ANATOMY", 196, 204], ["G3BP1 375", "GENE_OR_GENE_PRODUCT", 83, 92], ["norovirus", "ORGANISM", 142, 151], ["cellular", "CELL", 196, 204], ["G3BP1 375", "PROTEIN", 83, 92], ["norovirus VPg-linked RNA", "RNA", 142, 166], ["cellular RNAs", "RNA", 196, 209], ["host factors", "PROTEIN", 332, 344], ["norovirus", "SPECIES", 142, 151], ["polysome profiling", "TEST", 39, 57], ["these data", "TEST", 59, 69], ["norovirus VPg", "TREATMENT", 142, 155], ["cellular RNAs", "PROBLEM", 196, 209], ["this study", "TEST", 239, 249], ["biochemical and genetic approaches", "TREATMENT", 281, 315], ["cellular RNAs", "OBSERVATION", 196, 209]]], ["Our combined approaches 381 resulted in the identification of the core stress granule component G3BP1 as a host 382 protein critical for the replication of both murine and human noroviruses in cell 383 culture.", [["stress granule", "ANATOMY", 71, 85], ["cell", "ANATOMY", 193, 197], ["stress granule", "CELLULAR_COMPONENT", 71, 85], ["G3BP1", "GENE_OR_GENE_PRODUCT", 96, 101], ["murine", "ORGANISM", 161, 167], ["human", "ORGANISM", 172, 177], ["cell 383 culture", "CELL", 193, 209], ["core stress granule component", "PROTEIN", 66, 95], ["G3BP1", "PROTEIN", 96, 101], ["host 382 protein", "PROTEIN", 107, 123], ["cell 383 culture", "CELL_LINE", 193, 209], ["murine", "SPECIES", 161, 167], ["human", "SPECIES", 172, 177], ["human", "SPECIES", 172, 177], ["the core stress granule component", "PROBLEM", 62, 95], ["human noroviruses", "PROBLEM", 172, 189], ["culture", "TEST", 202, 209]]], ["Furthermore, we determined that G3BP1 plays a key role in the processes of 384 norovirus VPg-dependent protein synthesis, uncovering a new function for G3BP1 in 385 facilitating RNA virus genome translation.", [["G3BP1", "CHEMICAL", 32, 37], ["G3BP1", "GENE_OR_GENE_PRODUCT", 32, 37], ["VPg", "GENE_OR_GENE_PRODUCT", 89, 92], ["G3BP1", "GENE_OR_GENE_PRODUCT", 152, 157], ["G3BP1", "PROTEIN", 32, 37], ["384 norovirus VPg", "PROTEIN", 75, 92], ["G3BP1", "PROTEIN", 152, 157], ["norovirus VPg", "PROBLEM", 79, 92], ["dependent protein synthesis", "PROBLEM", 93, 120], ["G3BP1", "TREATMENT", 152, 157]]], ["386Discussion 379The orthogonal approaches used in the current study provide an unprecedented 387 insight into the identity of host factors with potential roles in the norovirus life cycle.", [["386Discussion 379", "CHEMICAL", 0, 17], ["host factors", "PROTEIN", 127, 139], ["the current study", "TEST", 51, 68], ["the norovirus life cycle", "TREATMENT", 164, 188]]], ["388Discussion 379The detailed proteomic analysis of the viral replication and translation complexes 389 formed during MNV infection (Fig 2) resulted in the identification of several host 390 factors with previously identified roles in the MNV life cycle.", [["388Discussion 379", "CHEMICAL", 0, 17], ["MNV infection", "DISEASE", 118, 131], ["MNV", "ORGANISM", 118, 121], ["translation complexes 389", "PROTEIN", 78, 103], ["390 factors", "PROTEIN", 187, 198], ["MNV", "SPECIES", 118, 121], ["The detailed proteomic analysis", "TEST", 17, 48], ["the viral replication", "TREATMENT", 52, 73], ["translation complexes", "TEST", 78, 99], ["MNV infection", "PROBLEM", 118, 131], ["viral replication", "OBSERVATION", 56, 73]]], ["We focused our efforts 391 on G3BP1 as it was identified in all three approaches and was also identified in a 392 CRISPR screen published during this study .", [["G3BP1", "GENE_OR_GENE_PRODUCT", 30, 35], ["G3BP1", "DNA", 30, 35], ["CRISPR screen", "TEST", 114, 127], ["this study", "TEST", 145, 155]]], ["Furthermore, we 393 have previously shown that feline calicivirus (FCV), a relative of noroviruses within 394 the Vesivirus genus, cleaves G3BP1 to inhibit stress granule formation (Humoud et 395 al., 2016) .", [["stress granule", "ANATOMY", 156, 170], ["feline calicivirus", "DISEASE", 47, 65], ["noroviruses", "DISEASE", 87, 98], ["feline calicivirus", "ORGANISM", 47, 65], ["FCV", "ORGANISM", 67, 70], ["G3BP1", "GENE_OR_GENE_PRODUCT", 139, 144], ["stress granule", "CELLULAR_COMPONENT", 156, 170], ["G3BP1", "PROTEIN", 139, 144], ["feline calicivirus", "SPECIES", 47, 65], ["feline calicivirus", "SPECIES", 47, 65], ["FCV", "SPECIES", 67, 70], ["feline calicivirus (FCV", "PROBLEM", 47, 70], ["noroviruses", "PROBLEM", 87, 98], ["stress granule formation", "PROBLEM", 156, 180], ["noroviruses", "OBSERVATION", 87, 98], ["granule formation", "OBSERVATION", 163, 180]]], ["In contrast, MNV infection does not result in G3BP1 cleavage and instead 396 forms cytoplasmic foci the composition of which is distinct from canonical stress 397 granules (Brocard et al., 2018) .", [["cytoplasmic foci", "ANATOMY", 83, 99], ["stress 397 granules", "ANATOMY", 152, 171], ["infection", "DISEASE", 17, 26], ["MNV", "ORGANISM", 13, 16], ["G3BP1", "GENE_OR_GENE_PRODUCT", 46, 51], ["cytoplasmic", "ORGANISM_SUBSTANCE", 83, 94], ["granules", "ORGANISM_SUBSTANCE", 163, 171], ["G3BP1", "PROTEIN", 46, 51], ["MNV", "SPECIES", 13, 16], ["MNV infection", "PROBLEM", 13, 26], ["G3BP1 cleavage", "PROBLEM", 46, 60], ["cytoplasmic foci", "PROBLEM", 83, 99], ["infection", "OBSERVATION", 17, 26], ["cytoplasmic", "OBSERVATION_MODIFIER", 83, 94], ["foci", "OBSERVATION", 95, 99]]], ["398 G3BP1 is one member of a group of G3BP proteins (Ras-GTPase-activating protein 399 (SH3 domain)-binding proteins), referred to as Rasputin in insects, that possess 400RNA binding activity and have multiple cellular functions including the regulation of 401RNA stability and translation in response to stress.", [["cellular", "ANATOMY", 210, 218], ["Rasputin", "CHEMICAL", 134, 142], ["G3BP1", "GENE_OR_GENE_PRODUCT", 4, 9], ["G3BP", "GENE_OR_GENE_PRODUCT", 38, 42], ["Ras-GTPase-activating protein 399 (SH3 domain)-binding proteins", "GENE_OR_GENE_PRODUCT", 53, 116], ["Rasputin", "GENE_OR_GENE_PRODUCT", 134, 142], ["400RNA", "GENE_OR_GENE_PRODUCT", 168, 174], ["cellular", "CELL", 210, 218], ["401RNA", "GENE_OR_GENE_PRODUCT", 257, 263], ["G3BP1", "PROTEIN", 4, 9], ["G3BP proteins", "PROTEIN", 38, 51], ["Ras-GTPase-activating protein 399", "PROTEIN", 53, 86], ["SH3 domain)-binding proteins", "PROTEIN", 88, 116], ["Rasputin", "PROTEIN", 134, 142], ["400RNA", "PROTEIN", 168, 174], ["401RNA", "DNA", 257, 263], ["G3BP proteins", "TEST", 38, 51], ["Ras-GTPase", "TEST", 53, 63], ["activating protein", "TEST", 64, 82], ["SH3 domain", "TEST", 88, 98], ["binding proteins", "PROBLEM", 100, 116], ["multiple cellular functions", "PROBLEM", 201, 228], ["stress", "PROBLEM", 305, 311], ["multiple", "OBSERVATION_MODIFIER", 201, 209], ["cellular functions", "OBSERVATION", 210, 228]]], ["Originally identified as a protein 402 that interacted with Ras-GTPase activating protein (RasGAP), more than two 403 decades of research have significantly expanded our knowledge of the 404 multifunctional role in cellular processes.", [["cellular", "ANATOMY", 215, 223], ["Ras-GTPase activating protein", "GENE_OR_GENE_PRODUCT", 60, 89], ["RasGAP", "GENE_OR_GENE_PRODUCT", 91, 97], ["cellular", "CELL", 215, 223], ["protein 402", "PROTEIN", 27, 38], ["Ras-GTPase activating protein", "PROTEIN", 60, 89], ["RasGAP", "PROTEIN", 91, 97], ["a protein", "TEST", 25, 34], ["RasGAP", "TEST", 91, 97], ["cellular processes", "OBSERVATION", 215, 233]]], ["It is now well accepted that G3BPs play a 405 role in cancer cell survival, cancer metastasis and invasion, processing of specific 406 miRNAs and stress granule formation (Reviewed in (Alam and Kennedy, 2019) .", [["cancer cell", "ANATOMY", 54, 65], ["cancer", "ANATOMY", 76, 82], ["stress granule", "ANATOMY", 146, 160], ["cancer", "DISEASE", 54, 60], ["cancer", "DISEASE", 76, 82], ["G3BPs", "GENE_OR_GENE_PRODUCT", 29, 34], ["cancer cell", "CELL", 54, 65], ["cancer", "CANCER", 76, 82], ["stress granule", "CELLULAR_COMPONENT", 146, 160], ["G3BPs", "PROTEIN", 29, 34], ["cancer cell survival", "PROBLEM", 54, 74], ["cancer metastasis", "PROBLEM", 76, 93], ["invasion", "PROBLEM", 98, 106], ["stress granule formation", "PROBLEM", 146, 170], ["cancer cell", "OBSERVATION", 54, 65], ["cancer", "OBSERVATION_MODIFIER", 76, 82], ["metastasis", "OBSERVATION", 83, 93], ["granule formation", "OBSERVATION", 153, 170]]], ["407RNA binding activity and have multiple cellular functions including the regulation of 401Stress granules are dynamic cytoplasmic ribonucleoprotein complexes that form 408 rapidly under stress conditions and within which cellular RNAs are stored in stalled 409 translation complexes (Protter and Parker, 2016) .", [["cellular", "ANATOMY", 42, 50], ["401Stress granules", "ANATOMY", 89, 107], ["cytoplasmic", "ANATOMY", 120, 131], ["cellular", "ANATOMY", 223, 231], ["407RNA", "GENE_OR_GENE_PRODUCT", 0, 6], ["cellular", "CELL", 42, 50], ["401Stress", "GENE_OR_GENE_PRODUCT", 89, 98], ["granules", "CELLULAR_COMPONENT", 99, 107], ["cytoplasmic", "ORGANISM_SUBSTANCE", 120, 131], ["cellular", "CELL", 223, 231], ["407RNA", "PROTEIN", 0, 6], ["cytoplasmic ribonucleoprotein complexes", "PROTEIN", 120, 159], ["cellular RNAs", "RNA", 223, 236], ["409 translation complexes", "PROTEIN", 259, 284], ["multiple cellular functions", "PROBLEM", 33, 60], ["dynamic cytoplasmic ribonucleoprotein complexes", "PROBLEM", 112, 159], ["multiple", "OBSERVATION_MODIFIER", 33, 41], ["cellular functions", "OBSERVATION", 42, 60], ["dynamic cytoplasmic", "OBSERVATION", 112, 131], ["ribonucleoprotein complexes", "OBSERVATION", 132, 159], ["cellular RNAs", "OBSERVATION", 223, 236]]], ["In the context of viral infection, 410RNA binding activity and have multiple cellular functions including the regulation of 401numerous studies have suggested that many, if not all, viruses must interact in some 411 manner with stress granules as there is growing evidence that the formation of 412 cytoplasmic stress granules is part of the antiviral defence mechanism (Reviewed in 413 (McCormick and Khaperskyy, 2017) .", [["cellular", "ANATOMY", 77, 85], ["stress granules", "ANATOMY", 228, 243], ["cytoplasmic stress granules", "ANATOMY", 299, 326], ["viral infection", "DISEASE", 18, 33], ["cellular", "CELL", 77, 85], ["stress granules", "CELLULAR_COMPONENT", 228, 243], ["cytoplasmic", "ORGANISM_SUBSTANCE", 299, 310], ["stress granules", "CELLULAR_COMPONENT", 311, 326], ["viral infection", "PROBLEM", 18, 33], ["410RNA binding activity", "PROBLEM", 35, 58], ["multiple cellular functions", "PROBLEM", 68, 95], ["stress granules", "PROBLEM", 228, 243], ["cytoplasmic stress granules", "PROBLEM", 299, 326], ["viral", "OBSERVATION_MODIFIER", 18, 23], ["infection", "OBSERVATION", 24, 33]]], ["Some viruses interact with stress granules to 414 promote viral replication (Cristea et al., 2010; Kim et al., 2016; Panas et al., 2014; 415 2012) whereas some do so to counteract the inhibitory effect of stress granules on 416 the translation of viral RNA (Panas et al., 2015; White et al., 2007) .", [["stress granules", "ANATOMY", 27, 42], ["stress granules", "ANATOMY", 205, 220], ["stress granules", "CELLULAR_COMPONENT", 27, 42], ["stress granules", "CELLULAR_COMPONENT", 205, 220], ["viral RNA", "RNA", 247, 256], ["Some viruses", "PROBLEM", 0, 12], ["stress granules", "PROBLEM", 27, 42], ["stress granules", "PROBLEM", 205, 220], ["viral RNA", "PROBLEM", 247, 256], ["viruses", "OBSERVATION", 5, 12], ["viral replication", "OBSERVATION", 58, 75], ["viral RNA", "OBSERVATION", 247, 256]]], ["417RNA binding activity and have multiple cellular functions including the regulation of 401Our data suggests that G3BP1 plays a key role in promoting the translation of 418 (Firth and Brierley, 2012; Jaafar and Kieft, 2019) and the 423 ability to target the host cell translation machinery to generate an environment where 424 viral RNA translation is favoured over cellular capped RNAs (Walsh et al., 2013) .20G3BP1 is known to associate primarily with free 40S subunits and not 80S 426 monosomes (Kedersha et al., 2016) .", [["cellular", "ANATOMY", 42, 50], ["cell", "ANATOMY", 264, 268], ["cellular", "ANATOMY", 367, 375], ["G3BP1", "CHEMICAL", 115, 120], ["417RNA", "GENE_OR_GENE_PRODUCT", 0, 6], ["cellular", "CELL", 42, 50], ["G3BP1", "GENE_OR_GENE_PRODUCT", 115, 120], ["cell", "CELL", 264, 268], ["cellular", "CELL", 367, 375], [".20G3BP1", "GENE_OR_GENE_PRODUCT", 409, 417], ["417RNA", "PROTEIN", 0, 6], ["401Our", "DNA", 89, 95], ["G3BP1", "PROTEIN", 115, 120], ["cellular capped RNAs", "RNA", 367, 387], ["40S subunits", "PROTEIN", 460, 472], ["multiple cellular functions", "PROBLEM", 33, 60], ["Jaafar", "TEST", 201, 207], ["the host cell translation machinery", "TREATMENT", 255, 290], ["viral RNA translation", "TREATMENT", 328, 349]]], ["Our data supports a hypothesis whereby the 427 association of G3BP1 with 40S ribosomal subunits provides a selective advantage 428 for norovirus VPg-dependent translation, thereby uncovering a new function in virus 429 specific translation.", [["G3BP1", "GENE_OR_GENE_PRODUCT", 62, 67], ["40S ribosomal subunits", "GENE_OR_GENE_PRODUCT", 73, 95], ["norovirus", "ORGANISM", 135, 144], ["VPg", "GENE_OR_GENE_PRODUCT", 145, 148], ["G3BP1", "PROTEIN", 62, 67], ["40S ribosomal subunits", "PROTEIN", 73, 95], ["norovirus VPg", "PROTEIN", 135, 148], ["norovirus", "SPECIES", 135, 144], ["G3BP1", "PROBLEM", 62, 67], ["40S ribosomal subunits", "TREATMENT", 73, 95], ["a selective advantage", "TREATMENT", 105, 126], ["norovirus VPg", "PROBLEM", 135, 148], ["a new function in virus", "PROBLEM", 191, 214]]], ["The mechanism by which G3BP1 contributes to this process has 430 yet to be fully explored but our data supports the hypothesis that G3BP1 directly or 43120indirectly promotes the recruitment of 40S ribosomal subunits to VPg-driven 432 translation complexes.", [["G3BP1", "CHEMICAL", 23, 28], ["G3BP1", "GENE_OR_GENE_PRODUCT", 23, 28], ["G3BP1", "GENE_OR_GENE_PRODUCT", 132, 137], ["VPg", "GENE_OR_GENE_PRODUCT", 220, 223], ["G3BP1", "PROTEIN", 23, 28], ["G3BP1", "PROTEIN", 132, 137], ["40S ribosomal subunits", "PROTEIN", 194, 216], ["VPg-driven 432 translation complexes", "PROTEIN", 220, 256], ["40S ribosomal subunits", "TREATMENT", 194, 216], ["VPg", "TEST", 220, 223]]], ["The RGG motif of G3BP1 is known to be essential for the 433 association between G3BP1 and 40S subunits as well as the ability to from stress 434 granules, whereas data would suggest that the RRM may play a regulatory role 435 (Kedersha et al., 2016) .", [["G3BP1", "GENE_OR_GENE_PRODUCT", 17, 22], ["G3BP1", "GENE_OR_GENE_PRODUCT", 80, 85], ["40S subunits", "GENE_OR_GENE_PRODUCT", 90, 102], ["granules", "ORGANISM_SUBSTANCE", 145, 153], ["RGG motif", "PROTEIN", 4, 13], ["G3BP1", "PROTEIN", 17, 22], ["G3BP1", "PROTEIN", 80, 85], ["40S subunits", "PROTEIN", 90, 102], ["RRM", "PROTEIN", 191, 194], ["The RGG motif of G3BP1", "TEST", 0, 22], ["G3BP1", "TEST", 80, 85], ["40S subunits", "TREATMENT", 90, 102], ["stress 434 granules", "PROBLEM", 134, 153]]], ["These domains were also required for the function of G3BP1 436 in the norovirus life cycle (Fig 6) confirming that the G3BP1 association with 40S is 437 important for its role in promoting norovirus VPg-dependent translation.", [["G3BP1 436", "CHEMICAL", 53, 62], ["G3BP1 436", "GENE_OR_GENE_PRODUCT", 53, 62], ["G3BP1", "GENE_OR_GENE_PRODUCT", 119, 124], ["40S", "GENE_OR_GENE_PRODUCT", 142, 145], ["norovirus", "ORGANISM", 189, 198], ["VPg", "GENE_OR_GENE_PRODUCT", 199, 202], ["G3BP1 436", "PROTEIN", 53, 62], ["G3BP1", "PROTEIN", 119, 124], ["40S", "PROTEIN", 142, 145], ["norovirus VPg", "PROTEIN", 189, 202], ["norovirus", "SPECIES", 189, 198], ["G3BP1", "TEST", 53, 58], ["norovirus", "OBSERVATION", 189, 198]]], ["Importantly, 438 RGG domains are known to have many functions (Thandapani et al., 2013) and 439 therefore in the context of G3BP1 function in the norovirus life cycle, may also 440 contribute to unknown interactions that promote norovirus translation.", [["G3BP1", "GENE_OR_GENE_PRODUCT", 124, 129], ["norovirus", "ORGANISM", 229, 238], ["438 RGG domains", "PROTEIN", 13, 28], ["G3BP1", "PROTEIN", 124, 129], ["norovirus", "OBSERVATION", 229, 238]]], ["Previous work 441 on alphaviruses have shown that G3BP1 is sequestered by binding to the nsP3 442 protein (Panas et al., 2012; 2015) .", [["alphaviruses", "ORGANISM", 21, 33], ["G3BP1", "GENE_OR_GENE_PRODUCT", 50, 55], ["nsP3 442", "GENE_OR_GENE_PRODUCT", 89, 97], ["G3BP1", "PROTEIN", 50, 55], ["nsP3 442 protein", "PROTEIN", 89, 105], ["alphaviruses", "PROBLEM", 21, 33]]], ["Furthermore, this interaction occurs via an 443 FGDF motif also found in other viral proteins including the ICP8 protein of herpes 444 simplex virus (Panas et al., 2015) .", [["herpes 444 simplex", "DISEASE", 124, 142], ["FGDF", "GENE_OR_GENE_PRODUCT", 48, 52], ["ICP8", "GENE_OR_GENE_PRODUCT", 108, 112], ["herpes 444 simplex virus", "ORGANISM", 124, 148], ["443 FGDF motif", "PROTEIN", 44, 58], ["viral proteins", "PROTEIN", 79, 93], ["ICP8 protein", "PROTEIN", 108, 120], ["herpes 444 simplex virus", "SPECIES", 124, 148], ["herpes 444 simplex virus", "SPECIES", 124, 148], ["an 443 FGDF motif", "TEST", 41, 58], ["other viral proteins", "PROBLEM", 73, 93], ["the ICP8 protein", "TEST", 104, 120], ["herpes", "PROBLEM", 124, 130]]], ["While the MNV VPg protein has a similar motif 445 FGDGF (Fig 1A) , this motif is not conserved in the GI Norwalk virus VPg protein.", [["MNV", "ORGANISM", 10, 13], ["FGDGF (Fig 1A", "GENE_OR_GENE_PRODUCT", 50, 63], ["GI Norwalk virus", "ORGANISM", 102, 118], ["MNV VPg protein", "PROTEIN", 10, 25], ["FGDGF", "PROTEIN", 50, 55], ["GI Norwalk virus VPg protein", "PROTEIN", 102, 130], ["MNV", "SPECIES", 10, 13], ["GI Norwalk virus", "SPECIES", 102, 118], ["the MNV VPg protein", "TEST", 6, 25]]], ["44620Therefore our data suggest that the interaction of VPg with G3BP1 is not direct, 447 fitting with our observation that this interaction is reduced by mutations in the eIF4G 448 binding domain (Fig 1A and Fig 9B. )", [["44620", "CHEMICAL", 0, 5], ["VPg", "GENE_OR_GENE_PRODUCT", 56, 59], ["G3BP1", "GENE_OR_GENE_PRODUCT", 65, 70], ["eIF4G 448 binding domain", "GENE_OR_GENE_PRODUCT", 172, 196], ["VPg", "PROTEIN", 56, 59], ["G3BP1", "PROTEIN", 65, 70], ["eIF4G 448 binding domain", "PROTEIN", 172, 196], ["Fig 1A and Fig 9B", "PROTEIN", 198, 215], ["44620", "SPECIES", 0, 5], ["VPg with G3BP1", "TREATMENT", 56, 70]]], ["While our data fit with a primary role for G3BP1 449 in norovirus translation, we are unable to exclude the possibility that G3BP1 plays 450 21 other roles in the viral life cycle.", [["G3BP1", "CHEMICAL", 125, 130], ["G3BP1 449", "GENE_OR_GENE_PRODUCT", 43, 52], ["norovirus", "ORGANISM", 56, 65], ["G3BP1", "GENE_OR_GENE_PRODUCT", 125, 130], ["G3BP1 449", "DNA", 43, 52], ["G3BP1", "PROTEIN", 125, 130]]], ["Recent studies have confirmed that G3BP1 is 451 enriched at sites of viral RNA synthesis (Brocard et al., 2018; Fritzlar et al., 2019) VPg-containing complexes again fits with our hypothesis that G3BP1 plays a role in 460 promoting viral VPg-dependent protein synthesis.", [["G3BP1", "CHEMICAL", 196, 201], ["G3BP1", "GENE_OR_GENE_PRODUCT", 35, 40], ["G3BP1", "GENE_OR_GENE_PRODUCT", 196, 201], ["G3BP1", "DNA", 35, 40], ["VPg", "PROTEIN", 135, 138], ["G3BP1", "PROTEIN", 196, 201], ["viral VPg", "PROTEIN", 232, 241], ["Recent studies", "TEST", 0, 14], ["G3BP1", "TEST", 35, 40], ["viral RNA synthesis", "PROBLEM", 69, 88], ["VPg", "TEST", 135, 138], ["viral VPg-dependent protein synthesis", "PROBLEM", 232, 269], ["viral RNA synthesis", "OBSERVATION", 69, 88], ["viral VPg", "OBSERVATION", 232, 241], ["protein synthesis", "OBSERVATION", 252, 269]]], ["46120We have previously found that norovirus infection leads to a translation bias whereby 462 cellular mRNAs induced in response to infection are inefficiently translated (Emmott 463 et al., 2017) .", [["cellular", "ANATOMY", 95, 103], ["46120", "CHEMICAL", 0, 5], ["norovirus infection", "DISEASE", 35, 54], ["infection", "DISEASE", 133, 142], ["norovirus", "ORGANISM", 35, 44], ["cellular", "CELL", 95, 103], ["462 cellular mRNAs", "RNA", 91, 109], ["46120", "SPECIES", 0, 5], ["norovirus infection", "PROBLEM", 35, 54], ["a translation bias", "PROBLEM", 64, 82], ["cellular mRNAs", "PROBLEM", 95, 109], ["infection", "PROBLEM", 133, 142], ["norovirus", "OBSERVATION_MODIFIER", 35, 44], ["infection", "OBSERVATION", 45, 54], ["cellular mRNAs", "OBSERVATION", 95, 109], ["infection", "OBSERVATION", 133, 142]]], ["Our data suggested that this modification of host cell translation was at 464 least partially driven by the ability of the viral NS6 protease to cleave PABP and the 465 induction of apoptosis which results in cleavage of cellular translation initiation 466 factors (Emmott et al., 2017) .", [["cell", "ANATOMY", 50, 54], ["cellular", "ANATOMY", 221, 229], ["host cell", "CELL", 45, 54], ["NS6 protease", "GENE_OR_GENE_PRODUCT", 129, 141], ["PABP", "GENE_OR_GENE_PRODUCT", 152, 156], ["cellular", "CELL", 221, 229], ["viral NS6 protease", "PROTEIN", 123, 141], ["PABP", "PROTEIN", 152, 156], ["cellular translation initiation 466 factors", "PROTEIN", 221, 264], ["Our data", "TEST", 0, 8], ["host cell translation", "PROBLEM", 45, 66], ["the viral NS6 protease", "TREATMENT", 119, 141], ["PABP", "TREATMENT", 152, 156], ["apoptosis", "PROBLEM", 182, 191], ["host cell", "OBSERVATION", 45, 54]]], ["Furthermore, we have more recently shown that the 467 ability of the protease to cleave PABP and other substrates is controlled by 468 polyprotein processing and interactions with other viral proteins (Emmott et al., 469 2019) .", [["PABP", "GENE_OR_GENE_PRODUCT", 88, 92], ["protease", "PROTEIN", 69, 77], ["PABP", "PROTEIN", 88, 92], ["viral proteins", "PROTEIN", 186, 200], ["the protease", "TREATMENT", 65, 77], ["PABP", "TREATMENT", 88, 92], ["polyprotein processing", "TREATMENT", 135, 157]]], ["Recent work would agree with our observations and confirms that the 470 translational bias is not driven by phosphorylation of eIF2\u03b1 and that activation of 471 GCN2 leads to the phosphorylation of eIF2\u03b1 (Brocard et al., 2018) .", [["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 127, 132], ["GCN2", "GENE_OR_GENE_PRODUCT", 160, 164], ["eIF2", "GENE_OR_GENE_PRODUCT", 197, 201], ["eIF2\u03b1", "PROTEIN", 127, 132], ["471 GCN2", "PROTEIN", 156, 164], ["eIF2", "PROTEIN", 197, 201]]], ["We note however 472 that others have suggested that NS3 may contribute to translational shut off (Fritzlar 473 et al., 2019) , with the caveat that this observation was made outside of the context of 474 22 infected cells and using overexpressed tagged proteins.20We suspect that 475 noroviruses use multiple mechanisms that work co-operatively to enable the control 476 of host gene expression and the subsequent translation of the cellular mRNAs.", [["cells", "ANATOMY", 216, 221], ["cellular", "ANATOMY", 433, 441], ["NS3", "GENE_OR_GENE_PRODUCT", 52, 55], ["cells", "CELL", 216, 221], ["cellular", "CELL", 433, 441], ["NS3", "PROTEIN", 52, 55], ["474 22 infected cells", "CELL_LINE", 200, 221], ["overexpressed tagged proteins", "PROTEIN", 232, 261], ["cellular mRNAs", "RNA", 433, 447], ["NS3", "TREATMENT", 52, 55], ["overexpressed tagged proteins", "PROBLEM", 232, 261], ["noroviruses", "PROBLEM", 284, 295], ["host gene expression", "TREATMENT", 374, 394], ["the cellular mRNAs", "PROBLEM", 429, 447], ["infected cells", "OBSERVATION", 207, 221], ["cellular mRNAs", "OBSERVATION", 433, 447]]], ["The 477 relative contribution of these processes in any given cell type may also differ 478 depending on the degree to which the cells can sense and respond to viral infection 479 through the induction of innate and apototic responses.", [["cell", "ANATOMY", 62, 66], ["cells", "ANATOMY", 129, 134], ["infection", "DISEASE", 166, 175], ["cell type", "CELL", 62, 71], ["cells", "CELL", 129, 134], ["these processes", "PROBLEM", 33, 48], ["viral infection", "PROBLEM", 160, 175]]], ["Quantitative proteomics was used as described in the text to identify host factors that 554 were affinity purified following transfection of GFP-tagged derivative of either the NV 555 or MNV VPg proteins.", [["GFP", "GENE_OR_GENE_PRODUCT", 141, 144], ["NV 555", "ORGANISM", 177, 183], ["MNV", "ORGANISM", 187, 190], ["GFP", "PROTEIN", 141, 144], ["NV 555 or MNV VPg proteins", "PROTEIN", 177, 203], ["MNV", "SPECIES", 187, 190], ["Quantitative proteomics", "TEST", 0, 23], ["transfection of GFP", "TREATMENT", 125, 144]]], ["Proteins specifically enriched in comparison to the GFP 556 control are shown in Panels A and B respectively and where protein binding was 55720reduced .", [["GFP", "GENE_OR_GENE_PRODUCT", 52, 55], ["B", "GENE_OR_GENE_PRODUCT", 94, 95], ["GFP 556 control", "DNA", 52, 67], ["Proteins", "TEST", 0, 8], ["the GFP", "TEST", 48, 55], ["A and B respectively and where protein binding", "TEST", 88, 134], ["enriched", "OBSERVATION_MODIFIER", 22, 30]]], ["Panel C illustrates the proteins previously found to interact with the 5' or 3' 558 termini of the MNV genome Vashist et al., 2012b) or to associate 559 with MNV VPg using tandem affinity purification (Chung et al., 2014) .", [["3' 558 termini", "CELLULAR_COMPONENT", 77, 91], ["MNV", "ORGANISM", 158, 161], ["5' or 3' 558 termini", "DNA", 71, 91], ["MNV genome", "DNA", 99, 109], ["MNV VPg", "PROTEIN", 158, 165], ["MNV", "SPECIES", 158, 161], ["Panel C", "TEST", 0, 7], ["the proteins", "TEST", 20, 32], ["tandem affinity purification", "TREATMENT", 172, 200]]], ["Data 560 visualisation was performed using Cystoscape (Shannon et al., 2003) Capped sub-genomic (cap-sg) RNA was included to demonstrate the location of the 714 VP1 and VP2 proteins.", [["cap-sg", "GENE_OR_GENE_PRODUCT", 97, 103], ["VP1", "GENE_OR_GENE_PRODUCT", 161, 164], ["VP2", "GENE_OR_GENE_PRODUCT", 169, 172], ["genomic (cap-sg) RNA", "RNA", 88, 108], ["714 VP1 and VP2 proteins", "PROTEIN", 157, 181], ["visualisation", "TEST", 9, 22], ["Cystoscape", "TEST", 43, 53]]], ["C) The translation of MNV VPg-linked RNA in extracts 715 prepared from \u0394G3BP1 cells is reduced across multiple time points.", [["extracts", "ANATOMY", 44, 52], ["\u0394G3BP1 cells", "ANATOMY", 71, 83], ["MNV", "ORGANISM", 22, 25], ["extracts", "ORGANISM_SUBSTANCE", 44, 52], ["\u0394G3BP1 cells", "CELL", 71, 83], ["MNV VPg-linked RNA", "RNA", 22, 40], ["\u0394G3BP1 cells", "CELL_LINE", 71, 83], ["MNV", "SPECIES", 22, 25], ["MNV VPg", "TREATMENT", 22, 29], ["reduced", "OBSERVATION_MODIFIER", 87, 94]]], ["In vitro 716 translations prepared in rabbit reticulocyte lysates (RRL) using in vitro transcribed 717 capped genomic RNA (cap-g) or capped sub-genomic (cap-sg), along with viral VPg-718 linked RNA, was used as a reference for the expected mass of the viral proteins.", [["reticulocyte lysates", "ANATOMY", 45, 65], ["rabbit", "ORGANISM", 38, 44], ["reticulocyte lysates", "ORGANISM_SUBSTANCE", 45, 65], ["cap-g", "GENE_OR_GENE_PRODUCT", 123, 128], ["cap-sg", "GENE_OR_GENE_PRODUCT", 153, 159], ["capped sub-genomic", "DNA", 133, 151], ["cap", "DNA", 153, 156], ["sg", "DNA", 157, 159], ["viral VPg-718 linked RNA", "DNA", 173, 197], ["viral proteins", "PROTEIN", 252, 266], ["rabbit", "SPECIES", 38, 44], ["rabbit", "SPECIES", 38, 44], ["rabbit reticulocyte lysates", "TREATMENT", 38, 65], ["cap", "TEST", 123, 126], ["viral VPg", "TEST", 173, 182], ["the expected mass", "PROBLEM", 227, 244], ["the viral proteins", "PROBLEM", 248, 266], ["mass", "OBSERVATION", 240, 244], ["viral proteins", "OBSERVATION", 252, 266]]], ["721Cells.", [["721Cells", "PROTEIN", 0, 8]]], ["The murine microglial BV-2 cell line (Blasi et al., 1990) text.", [["microglial BV-2 cell line", "ANATOMY", 11, 36], ["murine", "ORGANISM", 4, 10], ["microglial BV-2 cell line", "CELL", 11, 36], ["murine microglial BV-2 cell line", "CELL_LINE", 4, 36], ["murine", "SPECIES", 4, 10], ["The murine microglial BV", "TEST", 0, 24], ["microglial BV", "OBSERVATION", 11, 24], ["cell line", "OBSERVATION", 27, 36]]], ["Viral replication was then assessed by plaque assay or TCID50 in BV-2 cells as 769 described in the text.", [["plaque", "ANATOMY", 39, 45], ["BV-2 cells", "ANATOMY", 65, 75], ["Viral", "ORGANISM", 0, 5], ["BV-2 cells", "CELL", 65, 75], ["Viral replication", "PROBLEM", 0, 17], ["plaque assay", "TEST", 39, 51]]], ["In cases where the appearance of virus-induced cytopathic 770 effect was examined, infected monolayers were either visualized by light microscopy 771 directly or fixed with crystal violet in formalin, prior to washing and imaging.", [["monolayers", "ANATOMY", 92, 102], ["formalin", "CHEMICAL", 191, 199], ["formalin", "CHEMICAL", 191, 199], ["monolayers", "CELL", 92, 102], ["formalin", "SIMPLE_CHEMICAL", 191, 199], ["virus", "PROBLEM", 33, 38], ["infected monolayers", "PROBLEM", 83, 102], ["light microscopy", "TEST", 129, 145], ["crystal violet in formalin", "TREATMENT", 173, 199], ["imaging", "TEST", 222, 229], ["virus", "OBSERVATION", 33, 38], ["cytopathic", "OBSERVATION_MODIFIER", 47, 57]]], ["772 773 CRISPR screens.", [["772 773 CRISPR screens", "DNA", 0, 22], ["CRISPR screens", "TEST", 8, 22]]], ["The CRISPR screen was performed similarly to that described 774Materials and methods.", [["The CRISPR screen", "TEST", 0, 17]]], ["721previously with a number of modifications that included the use 775 of the Brie gRNA library to reduce off target effects and shorter 776 infection times to improve the recovery of gRNAs that may also compromise cell 777 viability.", [["cell", "ANATOMY", 215, 219], ["infection", "DISEASE", 141, 150], ["cell 777", "CELL", 215, 223], ["Brie gRNA library", "DNA", 78, 95], ["gRNAs", "PROTEIN", 184, 189], ["the Brie gRNA library", "TREATMENT", 74, 95], ["shorter 776 infection", "PROBLEM", 129, 150], ["gRNAs", "PROBLEM", 184, 189], ["gRNAs", "OBSERVATION", 184, 189]]], ["BV-2 cells stably expressing Cas9 nuclease were 778 transduced with the Brie library using previously described protocols (Doench et al., 779 2016) .", [["BV-2 cells", "ANATOMY", 0, 10], ["BV-2 cells", "CELL", 0, 10], ["Cas9", "GENE_OR_GENE_PRODUCT", 29, 33], ["BV-2 cells", "CELL_LINE", 0, 10], ["Cas9 nuclease", "PROTEIN", 29, 42], ["Brie library", "DNA", 72, 84], ["BV", "TEST", 0, 2]]], ["MNV strains CW3 and CR6 were used to infect BV-2 CRISPR library at MOI 780 5 pfu/cell and cells were isolated 24 hours post infection and preparation of gDNA 781 for sequencing as described previously .", [["cell", "ANATOMY", 81, 85], ["cells", "ANATOMY", 90, 95], ["infection", "DISEASE", 124, 133], ["MNV", "ORGANISM", 0, 3], ["CR6", "GENE_OR_GENE_PRODUCT", 20, 23], ["cell", "CELL", 81, 85], ["cells", "CELL", 90, 95], ["BV-2 CRISPR library", "DNA", 44, 63], ["gDNA 781", "DNA", 153, 161], ["MNV", "SPECIES", 0, 3], ["MNV strains", "TEST", 0, 11], ["CR6", "TEST", 20, 23], ["BV", "TEST", 44, 46], ["MOI", "TEST", 67, 70], ["pfu/cell", "TEST", 77, 85], ["cells", "TEST", 90, 95], ["infection", "PROBLEM", 124, 133], ["preparation of gDNA", "TREATMENT", 138, 157], ["sequencing", "TEST", 166, 176], ["infection", "OBSERVATION", 124, 133]]], ["The screen relies on 782 the premise that guide RNAs targeting genes that are overrepresented following 783 infection represent genes that when disrupted are protected against infection and 784 therefore likely represent factors with pro-viral activity.", [["infection", "DISEASE", 108, 117], ["infection", "DISEASE", 176, 185], ["pro-viral", "CANCER", 234, 243], ["The screen", "TEST", 0, 10], ["infection", "PROBLEM", 176, 185], ["pro-viral activity", "PROBLEM", 234, 252], ["likely represent", "UNCERTAINTY", 204, 220], ["pro-viral activity", "OBSERVATION", 234, 252]]], ["Likewise, genes for which 785 guide RNA are underrepresented suggest that infection had proceeded faster and 786 the gene is antiviral.", [["infection", "DISEASE", 74, 83], ["785 guide RNA", "RNA", 26, 39], ["infection", "PROBLEM", 74, 83], ["antiviral", "TREATMENT", 125, 134], ["infection", "OBSERVATION", 74, 83]]], ["Following sequencing, the data was analyzed by STARS 787 method as previously described Orchard et al., 2016) .", [["the data", "TEST", 22, 30]]]], "418de726b79a729527c03b6999b053720b26d988": [["IntroductionThe frequency and impact of large-scale disasters in Korea are not decreasing, and the characteristics of such disasters are becoming more complicated than ever before.", [["large-scale disasters", "TREATMENT", 40, 61], ["such disasters", "PROBLEM", 118, 132], ["large", "OBSERVATION_MODIFIER", 40, 45], ["not", "UNCERTAINTY", 75, 78], ["decreasing", "OBSERVATION_MODIFIER", 79, 89]]], ["In addition, disasters have become more heterogeneous.", [["disasters", "PROBLEM", 13, 22], ["disasters", "OBSERVATION", 13, 22], ["more", "OBSERVATION_MODIFIER", 35, 39], ["heterogeneous", "OBSERVATION_MODIFIER", 40, 53]]], ["The current structure of Korean disaster management is unable to fully address the impacts of disasters, due to political, economic, social, and cultural reasons.", [["Korean disaster management", "TREATMENT", 25, 51]]], ["To resolve this, a more collaborative, integrated, and comprehensive form of emergency management is required.IntroductionSeveral sub-areas in Korea including firefighting, civil engineering, and other businesses officially proclaim that they have produced emergency managers through their own individual programs, focusing on their specific discipline.", [["emergency management", "TREATMENT", 77, 97]]], ["Restrictively speaking, professional emergency managers concentrate on their own areas of responsibility, but they clearly need multiple disciplines apart from their own specialization.IntroductionThe premise of this study is that a unidisciplinary approach does not lead to effective disaster planning, whereas a multidisciplinary approach does (DOE, 2006) .", [["this study", "TEST", 212, 222], ["a unidisciplinary approach", "TREATMENT", 231, 257]]], ["By depending upon a single aspect or onesided viewpoint, the unidisciplinary model addresses reactive disaster management, which does not consider planning (Culwick and Patel, 2013; Hartkopf, 2003) .", [["reactive disaster management", "TREATMENT", 93, 121], ["reactive", "OBSERVATION_MODIFIER", 93, 101]]], ["On the other hand, a multidisciplinary approach strongly supports disaster planning.", [["disaster planning", "TREATMENT", 66, 83]]], ["What they all have in common is the need for more than one discipline and the interconnection of one discipline to another.IntroductionMany developed nations have strongly relied upon the multidisciplinary approach for disaster management.", [["disaster management", "TREATMENT", 219, 238]]], ["Japan has also implemented the multidisciplinary approach to deal with earthquakes and tsunamis, floods accompanying typhoons, and other complex natural disasters (Nazarov, 2011) .", [["earthquakes", "DISEASE", 71, 82], ["tsunamis", "DISEASE", 87, 95], ["floods", "DISEASE", 97, 103], ["typhoons", "DISEASE", 117, 125]]], ["The Emergency Planning College in the United Kingdom has traditionally offered multidisciplinary programs, while educating their emergency managers (EPC, 2016) .IntroductionKorean emergency managers have unique characteristics.", [["multidisciplinary programs", "TREATMENT", 79, 105]]], ["The job itself lacks professionalism and popularity in Korea.", [["popularity", "OBSERVATION_MODIFIER", 41, 51]]], ["For advanced nations, their emergency managers are regularly recruited, paid, and thus contribute significantly to efficient disaster management.", [["efficient disaster management", "TREATMENT", 115, 144]]], ["Modern disaster management in Korea started 10 years ago, which is 'new' or less experienced when compared with developed nations such as the United States, the United Kingdom, Japan, and others.", [["Modern disaster management", "TREATMENT", 0, 26]]], ["This means that Korea has much room for improvement in this field and can learn from examples and practices by developed nations such as the whole community approach in the United States, the establishment of integrated emergency management system in United Kingdom, the role of small-scale voluntary organizations in Japan, among others.", [["small-scale voluntary organizations", "TREATMENT", 279, 314], ["small", "OBSERVATION_MODIFIER", 279, 284]]], ["A specific area to consider is adopting a multidisciplinary approach for/by emergency managers to widen their exposure in the field.IntroductionThe purpose of this article is to investigate how Korea might improve the disciplinary approach of its emergency managers towards the ultimate goal of effective transnational disaster management through mitigating human loss, economic damages, and psychological impacts.", [["human loss", "DISEASE", 358, 368], ["human", "ORGANISM", 358, 363], ["human", "SPECIES", 358, 363], ["human", "SPECIES", 358, 363], ["a multidisciplinary approach", "TREATMENT", 40, 68], ["effective transnational disaster management", "TREATMENT", 295, 338], ["mitigating human loss", "PROBLEM", 347, 368], ["economic damages", "PROBLEM", 370, 386], ["psychological impacts", "PROBLEM", 392, 413]]], ["We maintain that Korea has to change its emergency managers' unidisciplinary status to multidisciplinary status, and given Korea's own experience, the international community must address the need to change related educational curricula, collaborative learning, and sustainable evaluation.Studies on Korean disaster managementThere have been two kinds of studies on Korean disaster management in the past: those within Korea, and those outside of it.", [["sustainable evaluation", "TEST", 266, 288], ["Korean disaster management", "TREATMENT", 300, 326], ["Korean disaster management", "TREATMENT", 366, 392], ["two kinds", "OBSERVATION_MODIFIER", 342, 351]]], ["Considering that the history of modern disaster management in Korea started in 2004 with the establishment of the National Emergency Management Agency (NEMA), related researchers paid attention to predicting the next head of NEMA.", [["head", "ANATOMY", 217, 221], ["head", "ORGANISM_SUBDIVISION", 217, 221], ["modern disaster management", "TREATMENT", 32, 58]]], ["With the rise of Ministry of Public Safety and Security (MPSS) at the end of 2014, they continued to study which professions would require the human resources of MPSS.", [["human", "ORGANISM", 143, 148], ["human", "SPECIES", 143, 148], ["human", "SPECIES", 143, 148], ["rise", "OBSERVATION_MODIFIER", 9, 13]]], ["In fact, the NEMA was transformed into the MPSS after experiencing the sinking of ferry Sewol in mid-2014.Studies on Korean disaster managementOutside Korea, some English language researchers have looked into how disaster management principles would be applied to the case of Korea (Park, 2015) .", [["NEMA", "DNA", 13, 17], ["Korean disaster management", "TREATMENT", 117, 143]]], ["For example, while disasters have both physical and social impacts, many Korean researchers focused only on the physical impacts in the following cases: typhoon Maemi in 2003, the sinking of ferry Sewol in 2014, the outbreak of Middle-East Respiratory Syndrome (MERS) in 2015, among others.", [["Middle-East Respiratory Syndrome", "DISEASE", 228, 260], ["MERS", "DISEASE", 262, 266], ["Respiratory Syndrome", "PROBLEM", 240, 260], ["Middle", "ANATOMY_MODIFIER", 228, 234], ["Respiratory Syndrome", "OBSERVATION", 240, 260]]], ["Conversely, researchers outside Korea often delve into the social impact including the psychological impact of disasters, the status of special needs population, and the application of equity to emergency professionals.Necessity of multidisciplinary approachMany researchers have examined the significance of a multidisciplinary aspect on disaster management in the international community (Fazey et al., 2014; Leonard et al., 2014; Quick, 1998; Rose, 2007) .", [["disaster management", "TREATMENT", 339, 358]]], ["At the same time, they have identified, promoted, and implemented multidisciplinary status for professional emergency managers, while elaborating on environmental change, holistic problem solving, dynamic change, and case studies, among many others.Necessity of multidisciplinary approachAlthough some researchers have attempted to create boundaries between their preferred subject and other specialized subjects in the field of disaster management, many researchers have shared basic knowledge or common disciplines (Macinnis and Folkes, 2010; Zhang et al., 2015) .", [["professional emergency managers", "TREATMENT", 95, 126], ["case studies", "TEST", 217, 229], ["disaster management", "TREATMENT", 429, 448]]], ["Multidisciplinary approach does not stunt but fuels the advancement of disaster management.", [["disaster management", "TREATMENT", 71, 90]]], ["Further, with a multidisciplinary approach, there is comprehensive planning as part of proactive management.Necessity of multidisciplinary approachWhen analyzing that a specific disaster may lead to multiple disasters, disaster management is not oriented for a unidisciplinary but a multidisciplinary model.", [["a multidisciplinary approach", "TREATMENT", 14, 42], ["proactive management", "TREATMENT", 87, 107], ["disaster management", "TREATMENT", 219, 238]]], ["To illustrate, when a typhoon hits a local area, it usually causes flooding.", [["a typhoon hits a local area", "PROBLEM", 20, 47], ["flooding", "PROBLEM", 67, 75], ["flooding", "OBSERVATION", 67, 75]]], ["Subsequently, flooding may cause fires due to electric leakage.", [["electric leakage", "PROBLEM", 46, 62], ["leakage", "OBSERVATION", 55, 62]]], ["Complex situations such as these scenarios will not be addressed by a linear or single approach.", [["Complex situations", "PROBLEM", 0, 18]]], ["Understanding and quick action, looking into alternatives, and applying a multidisciplinary approach have a greater chance of succeeding and in helping to mobilize as many people and organizations as possible to work together to resolve problems.", [["people", "ORGANISM", 172, 178], ["people", "SPECIES", 172, 178], ["a multidisciplinary approach", "TREATMENT", 72, 100]]], ["Given that disaster management involves a number of interrelated factors and parties, a multidisciplinary perspective is needed to identify and evaluate complicated issues (Ali and Nitivattananon, 2012) .Theoretical aspects on multidisciplinary approachUnidisciplinary disaster plans typically outline actions for emergency managers from a single discipline or common background.", [["disaster management", "TREATMENT", 11, 30], ["multidisciplinary approachUnidisciplinary disaster", "TREATMENT", 227, 277], ["emergency managers", "TREATMENT", 314, 332]]], ["In addition, they are oriented to handle only one specific aspect of disaster management.", [["disaster management", "TREATMENT", 69, 88]]], ["In contrast, multidisciplinary disaster plans cover those for emergency managers from diverse fields or different backgrounds.", [["emergency managers", "TREATMENT", 62, 80]]], ["To this point, emergency managers from different disciplines or multidisciplinary disaster plan(s) are expected to handle the multi-faceted aspects of disaster management better than unidisciplinary emergency managers.Theoretical aspects on multidisciplinary approachMany challenges come with disaster awareness, decision flexibility, adapting to volatile environments, among others, and for this reason, relying on a single discipline is not likely to adequately explain certain complicated aspects of hazards or risks in disaster management nor will it provide comprehensive solutions (Doren et al., 2012; Jensenius, 2012) .", [["disaster management", "TREATMENT", 151, 170], ["multidisciplinary approachMany challenges", "TREATMENT", 241, 282], ["disaster management", "TREATMENT", 523, 542]]], ["Conversely, a multidisciplinary approach may fully address many fragmented issues and concerns towards the goal of effective disaster management, in particular, by comprehensively combining or integrating various knowledge and information.Value of this studyAs decision-makers, professional emergency managers in developed nations may get diverse support from their multidisciplinary background (Sterlacchini et al., 2007) .", [["effective disaster management", "TREATMENT", 115, 144], ["this study", "TEST", 248, 258], ["diverse support", "TREATMENT", 339, 354]]], ["Whether as part-time or full-time, shared position or not, as they go about making sound decisions, they also utilize their knowledge on preventive measures during dangerous events.", [["preventive measures", "TREATMENT", 137, 156]]], ["As a result, professional emergency managers play a role in maximizing potential benefits despite limited resources, as long as they fully utilize a multidisciplinary approach.Value of this studyOn the other hand, professional emergency managers in Korea have not played a specific role in managing diverse disasters.", [["a multidisciplinary approach", "TREATMENT", 147, 175], ["this study", "TEST", 185, 195]]], ["Rather, they have taken part in many roles in disaster management such as planners, leaders, administrators, trainers, protectors, communicators, and problem solvers, among others.", [["disaster management", "TREATMENT", 46, 65], ["protectors", "TREATMENT", 119, 129]]], ["Accordingly, the whole community has expected them to carry out many activities such as hazard identification, efficient emergency response, systematic emergency recovery, ethical conduct, and others (FEMA, 2013-1).Value of this studyIn Korea, an increasing number of researchers have studied how efficiently the nation has to operate its disaster management.", [["ethical conduct", "TEST", 172, 187], ["its disaster management", "TREATMENT", 335, 358], ["increasing", "OBSERVATION_MODIFIER", 247, 257], ["number", "OBSERVATION_MODIFIER", 258, 264]]], ["However, when reflecting that the concept of professional emergency managers is a relatively new one to Korea, almost no rigorous study has been attempted to delve into the issue (Yoon, 2015; Yoo et al., 2015) .", [["rigorous study", "TEST", 121, 135]]], ["To the author's best knowledge, this study is the first to systematically investigate Korean professional emergency managers.Value of this studyAlthough this study is not a new attempt outside Korea, researchers from other nations can also benefit from or adopt the results of this study at a national level, in particular while studying their national disaster management systems.", [["this study", "TEST", 32, 42], ["this study", "TEST", 134, 144], ["this study", "TEST", 153, 163], ["this study", "TEST", 277, 287]]], ["In other words, this study can serve as an example to other nations in terms of learning from and avoiding similar mistakes.", [["this study", "TEST", 16, 26]]], ["Korea can also learn from the experience of advanced nations, potentially applying principles that reflect a multidisciplinary approach.", [["advanced nations", "TREATMENT", 44, 60], ["a multidisciplinary approach", "TREATMENT", 107, 135]]], ["With all the above in mind, the scope of this paper includes not only the characteristics of Korean disaster management but also many disaster management principles as observed in the international community.Challenges to having multidisciplinary emergency managersIt is not easy to have and maintain emergency managers who are multidisciplined.", [["Korean disaster management", "TREATMENT", 93, 119], ["many disaster management", "TREATMENT", 129, 153], ["multidisciplinary emergency managers", "TREATMENT", 229, 265]]], ["For this reason, it is crucial to discuss and establish appropriate techniques and strategies for better communications including exchange of best practices towards solidifying multidisciplinary approach.MethodWe used qualitative content analysis as it is able to provide meaningful insights and generalizations that may not be possible in quantitative analysis.", [["solidifying multidisciplinary approach", "TREATMENT", 165, 203], ["qualitative content analysis", "TEST", 218, 246], ["quantitative analysis", "TEST", 340, 361], ["may not be possible", "UNCERTAINTY", 317, 336]]], ["This is particularly helpful in evaluating characteristics of professional emergency managers and how they relate to multidisciplines in disaster management (Fig. 1 ).", [["disaster management", "TREATMENT", 137, 156]]], ["In addition, we used comparative perspective, while focusing on qualitative content analysis.MethodSimilarly, we used qualitative data in this paper.", [["qualitative content analysis", "TEST", 64, 92]]], ["Qualitative data are useful in studying disaster management as they may describe qualities, features, or certain characteristics relevant to disaster management including stakeholders' behavior, human relations, effective strategies, and other information (Gorodzinsky et al., 2015) .", [["human", "ORGANISM", 195, 200], ["human", "SPECIES", 195, 200], ["human", "SPECIES", 195, 200], ["Qualitative data", "TEST", 0, 16], ["disaster management", "TREATMENT", 40, 59], ["disaster management", "TREATMENT", 141, 160]]], ["Further, those qualities are helpful in analyzing the disciplinary status of professional emergency managers or in examining the interaction between emergency managers and disaster management.MethodTo elaborate, we primarily used several databases for qualitative data collection.", [["emergency managers", "TREATMENT", 149, 167], ["disaster management", "TREATMENT", 172, 191], ["qualitative data collection", "TEST", 252, 279]]], ["In the case of Korean data, we utilized Korean databases to include DBpia, KISS, and government websites.", [["Korean data", "TEST", 15, 26], ["Korean databases", "TEST", 40, 56]]], ["We typed some keywords such as emergency managers, unidisciplinary study, multidisciplinary study, and Korean disaster management, among others.", [["unidisciplinary study", "TEST", 51, 72], ["multidisciplinary study", "TEST", 74, 97], ["Korean disaster management", "TREATMENT", 103, 129]]], ["In terms of English data analysis, we evaluated data on the U.S. emergency managers that indicate many significant lessons for Korea.", [["English data analysis", "TEST", 12, 33]]], ["When thinking that Korean data did not directly analyze many things about its emergency managers, we had no choice but to qualitatively interpret them.MethodWe maintain that Korea has to transform its current emergency managers' unidisciplinary approach into a multidisciplinary approach.", [["a multidisciplinary approach", "TREATMENT", 259, 287]]], ["In a unidisciplinary setup, the decision-making process is linear whereas in a multidisciplinary approach, inputs come from multiple areas and there is an opportunity to evaluate before concretizing a decision (as reflected by the 'decision box' in the flowchart).MethodTo systematically compare two disciplinary approaches, we initiated listing important stakeholders surrounding emergency managers in Korea by relying on many qualitative techniques, such as analyzing government documents, discussions with experts, Internet searches, and others.", [["a unidisciplinary setup", "TREATMENT", 3, 26]]], ["The list included the MPSS, local governments, disaster management trainers, industries, job applicants, and others.", [["disaster management trainers", "TREATMENT", 47, 75]]], ["Finally, we chose four major stakeholder areas, namely government policies, college curricula, NGOs' emergency-manager certification, and mass media coverage.MethodThe identified stakeholders and emergency managers are expected to play a number of roles within the field of emergency and disaster management (Kim et al., 2015; Yo, 2014) .", [["mass media coverage", "TREATMENT", 138, 157], ["disaster management", "TREATMENT", 288, 307]]], ["Even though they were accustomed to dealing with maritime accidents, the maritime policemen were unable to consider important issues such as disaster victims' psychological needs, the operation of rapid and complex disaster management, interaction with other institutions, and how to use public information officer(s).", [["accidents", "DISEASE", 58, 67], ["the operation", "TREATMENT", 180, 193], ["rapid and complex disaster management", "TREATMENT", 197, 234]]], ["After rescuing only 172 out of 476 passengers, the public became angry at the poor disaster management actions of the maritime policemen, causing the President to dismantle the institution, which is the NEMA (Hong, 2016) .", [["angry", "PROBLEM", 65, 70]]], ["The procedures followed by emergency managers during the Sewol ferry incident are considered typical of the unidisciplinary approach.MethodOnly three professionals, namely firefighters, civil engineers, and maritime police make up the MPSS, which is a comprehensive disaster management agency in Korea (MPSS, 2016) .", [["The procedures", "TREATMENT", 0, 14]]], ["Since the ferry Sewol sinking in 2014, the MPSS has placed most of the emphasis on maritime accidents as well as house fires and flood accompanied by typhoon.", [["accidents", "DISEASE", 92, 101]]], ["Therefore, those who are dealing with each hazard have also turned into the emergency managers for those fields or areas.MethodEach professional under the MPSS has strongly wanted to dominate the field of disaster management in Korea.", [["disaster management", "TREATMENT", 205, 224]]], ["Further, other professionals such as humanists, natural scientists, mechanical engineers, lawyers, sociologists, and public administrators have not been allowed to work for disaster management.", [["disaster management", "TREATMENT", 173, 192]]], ["Under politics-oriented management, each of the three emergency managers has come to embrace his or her own principles based on their own disciplines or areas of expertise.Method4.1.2.", [["Method4", "PROTEIN", 172, 179], ["oriented management", "TREATMENT", 15, 34], ["Method4", "TREATMENT", 172, 179]]], ["Korean health workers in college hospitals were heavily involved in dealing with the outbreak of the MERS in 2015.", [["MERS", "DISEASE", 101, 105]]], ["Although health workers knew their responsibilities in terms of medical treatment, they knew relatively little about the phase of medical prevention as part of disaster management lifetime, how to coordinate with other stakeholders to include patients' family members, government officials, and local communities, and other emergency management principles.", [["patients", "ORGANISM", 243, 251], ["patients", "SPECIES", 243, 251], ["medical treatment", "TREATMENT", 64, 81], ["medical prevention", "TREATMENT", 130, 148], ["disaster management", "TREATMENT", 160, 179], ["emergency management principles", "TREATMENT", 324, 355]]], ["Consequently, because the unidisciplined health workers in college hospitals were not able to consider the other equally important aspects surrounding the situation, the outbreak claimed the lives of 36 patients (Ha, 2016a) .MethodMany departments in colleges have recently begun offering disaster management programs such as firefighting science, civil engineering, ocean science, medical science, nursing science, public administration, and safety engineering, among others (Ha, 2015) .", [["patients", "ORGANISM", 203, 211], ["patients", "SPECIES", 203, 211], ["disaster management programs", "TREATMENT", 289, 317], ["public administration", "TREATMENT", 416, 437]]], ["Each department has maintained that their own academic subject, which is a unidisciplinary approach, is the key major in the field of disaster management.", [["disaster management", "TREATMENT", 134, 153]]], ["Without emphasizing the role of emergency managers, they have tried to describe how each has operated its own disaster management.", [["disaster management", "TREATMENT", 110, 129]]], ["In general, many departments have not realized the status of emergency managers as a professional in the field of disaster management Having such certificates is a requirement for some public institutions' recruitment.", [["disaster management", "TREATMENT", 114, 133]]], ["Nevertheless, many emergency manager certificates have been based on the unidisciplinary approach.", [["the unidisciplinary approach", "TREATMENT", 69, 97]]], ["It means that they have been taught in only one area of study when a more comprehensive and diverse curriculum/training would be better.", [["diverse curriculum/training", "TREATMENT", 92, 119]]], ["Certificates from KFSA, KDPA, MRSA, and LSA are oriented on their own disciplines including firefighting, flood accompanied by typhoon, maritime rescue, and maritime search and rescue.", [["MRSA", "SPECIES", 30, 34], ["KFSA", "TEST", 18, 22], ["KDPA", "TEST", 24, 28], ["MRSA", "PROBLEM", 30, 34], ["MRSA", "OBSERVATION", 30, 34]]], ["Although the KBCPA has supported multidisciplined emergency managers via classroom sessions, the program towards certification still lacks the aspect of multidisciplinary training.Method4.1.4.", [["Method4", "PROTEIN", 180, 187], ["classroom sessions", "TREATMENT", 73, 91], ["multidisciplinary training", "TREATMENT", 153, 179], ["Method4", "TREATMENT", 180, 187]]], ["Mass media coverage Diverse mass media including TV, radio, Internet, mobile phones, newspapers, and others have exerted efforts to cover the occurrence of a disaster as breaking news.", [["Mass media coverage Diverse mass media", "TREATMENT", 0, 38], ["Diverse", "OBSERVATION_MODIFIER", 20, 27], ["mass", "OBSERVATION", 28, 32]]], ["In general, many mass media networks have not clearly recognized emergency managers as entities in the field of disaster management.MethodNotwithstanding, few mass media such as Arirang TV and YTN TV have just begun to talk about emergency managers.", [["many mass media networks", "PROBLEM", 12, 36], ["disaster management", "TREATMENT", 112, 131], ["MethodNotwithstanding", "TREATMENT", 132, 153], ["few mass media", "PROBLEM", 155, 169], ["Arirang TV", "TREATMENT", 178, 188], ["YTN TV", "TREATMENT", 193, 199], ["mass", "OBSERVATION", 17, 21], ["few", "OBSERVATION_MODIFIER", 155, 158], ["mass", "OBSERVATION", 159, 163]]], ["The discussion about the criticality of the profession has not also touched on the needed multidisciplinary approach.Multidisciplinary emergency managersKorea has a small number of multidisciplined emergency managers in the field of disaster management.", [["disaster management", "TREATMENT", 233, 252], ["small", "OBSERVATION_MODIFIER", 165, 170]]], ["They are those professionals who are open-minded and used to interpreting various disaster management concepts in a more critical manner (MacAskill and Guthrie, 2014).", [["various disaster management", "TREATMENT", 74, 101]]], ["Without a multidisciplinary background, those emergency managers may not be able to design and implement flexible alternatives quickly during the period of disaster response.Multidisciplinary emergency managersThere are many reasons why Korea has currently had only a few multidisciplinary emergency managers.", [["flexible alternatives", "TREATMENT", 105, 126]]], ["For example, some stakeholders including governments have politically supported unidisciplinary emergency managers, when reflecting few incumbents' aspiration towards hegemony.", [["few incumbents' aspiration towards hegemony", "PROBLEM", 132, 175], ["aspiration", "OBSERVATION", 148, 158]]], ["In addition, colleges and mass media as well as NGOs have not seriously realized the importance of having a multidisciplinary approach on Korean emergency managers.", [["mass media", "PROBLEM", 26, 36], ["Korean emergency managers", "TREATMENT", 138, 163], ["mass", "OBSERVATION", 26, 30]]], ["In short, either politics or lack of expert knowledge is the fundamental reason for the lack of emergency managers' multidisciplinary approach at present (Ha, 2011) .Multidisciplinary emergency managersThe nation has just partially enhanced its multidisciplinary approach, as far as the field has failed to embody the full extent of addressing risk-oriented management.", [["oriented management", "TREATMENT", 349, 368]]], ["In particular, when assigning resources and priorities, the nation and its emergency managers have not utilized sound principles on disaster management.Multidisciplinary emergency managersTo elaborate, thanks to the support of International Association of Emergency Managers' (IAEM's) Certified Emergency Manager program, Korea now has several multidisciplined emergency managers.", [["disaster management", "TREATMENT", 132, 151]]], ["IAEM has played many roles in training emergency managers in the international community.", [["IAEM", "CHEMICAL", 0, 4], ["IAEM", "PROTEIN", 0, 4], ["many", "OBSERVATION_MODIFIER", 16, 20]]], ["Although the number of multidisciplinary emergency managers in Korea is not quite big, those Certified Emergency Managers are trying to contribute to the goal of disaster management in the government sector, in colleges, and others.Multidisciplinary emergency managersAnother good case of multidisciplinary emergency managers is that of the Association of Slope Disaster Management (ASDM).", [["disaster management", "TREATMENT", 162, 181], ["Slope Disaster Management", "TREATMENT", 356, 381], ["good", "OBSERVATION_MODIFIER", 276, 280]]], ["As an NGO in Korea, it radically adopted multidisciplinary training and exercise program in 2013 despite lack of management funds that almost closed its business.", [["multidisciplinary training", "TREATMENT", 41, 67], ["exercise program", "TREATMENT", 72, 88], ["management funds", "TREATMENT", 113, 129]]], ["Since that time though, ASDM has provided many multidisciplinary courses to the trainees by following important lessons from Hong Kong' slope management.", [["Hong Kong' slope management", "TREATMENT", 125, 152]]], ["Although the focus of each research has been distinct depending on individual viewpoints, many researchers have indicated that the characteristics of multidisciplinary emergency managers are superior to those of unidisciplinary emergency managers (Thomson and Black, 2008) .", [["distinct", "OBSERVATION_MODIFIER", 45, 53]]], ["Thus, the multidisciplinary model may be evaluated as one of the most innovative solutions for disaster management.Multidisciplinary emergency managersCertainly, there are different effects between emergency managers' unidisciplinary approach and multidisciplinary approach, see Table 1 .", [["disaster management", "TREATMENT", 95, 114], ["multidisciplinary approach", "TREATMENT", 247, 273], ["different", "OBSERVATION_MODIFIER", 172, 181]]], ["In general though, the multidisciplinary approach has more advantages when compared to a unidisciplinary one.Multidisciplinary emergency managersIn the field of disaster management, multidisciplined emergency managers have traditionally performed better than unidisciplinary emergency managers have.", [["disaster management", "TREATMENT", 161, 180]]], ["Though it is certain that unidisciplinary emergency managers also possess positive characteristics such as their speed of decision making or homogeneity, other aspects still support positive signs for the superiority of multidisciplinary status.", [["positive signs", "PROBLEM", 182, 196]]], ["In particular, if thinking that the whole community approach is quite necessary in the 21st century, multidisciplinary approach is more suitable for the operation of disaster management than unidisciplinary approach is.Multidisciplinary emergency managersSimilarly, multidisciplinary disaster plan(s) or related planning are more effective than unidisciplinary disaster plan(s) are.", [["multidisciplinary approach", "TREATMENT", 101, 127], ["disaster management", "TREATMENT", 166, 185]]], ["Effective means that multidisciplinary emergency managers produce results, and thus, may contribute to the goal of disaster management, compared with unidisciplinary emergency managers (Martensson et al., 2016) .", [["disaster management", "TREATMENT", 115, 134]]], ["While dealing with them, multidisciplinary disaster plan(s) or related emergency managers communicate with one another and then implement a series of evaluation processes on uncoordinated problems.", [["evaluation processes", "TEST", 150, 170], ["uncoordinated problems", "PROBLEM", 174, 196]]], ["In short, multidisciplinary emergency managers are able to produce successful outcomes as initially intended during disaster management planning.RecommendationsWhen Korea fully embodies the multidisciplinary approach for emergency managers, it may have the most appropriate or ideal disaster management style.", [["disaster management planning", "TREATMENT", 116, 144], ["emergency managers", "TREATMENT", 221, 239]]], ["If thinking that the field of disaster management cannot survive without those who are running it, emergency managers are the key to the efficient operations of disaster management (Wooten and James, 2008) .", [["disaster management", "TREATMENT", 30, 49], ["disaster management", "TREATMENT", 161, 180]]], ["While emergency managers have competitive advantages, the Korean field of disaster management may develop a new style of its disaster management in particular by breaking down the unidisciplinary approach.RecommendationsNot just one or two, but all four stakeholders in Korea need to carry out their own assignments for the goal of achieving multidisciplinary approach, following Table 2.", [["competitive advantages", "TREATMENT", 30, 52], ["disaster management", "TREATMENT", 74, 93], ["its disaster management", "TREATMENT", 121, 144]]], ["Hence, the field including the four stakeholders must expand the aspect of multidisciplinary approach into its culture by getting rid of vested interests of those in politics or by being well-informed, and not ignorant.International implicationsA disaster may happen to anybody, regardless of national boundary (Ha, 2016b) .", [["multidisciplinary approach", "TREATMENT", 75, 101], ["its culture", "TEST", 107, 118]]], ["With these in mind, many nations may learn important lessons from the disciplinary approach of Korean emergency managers to include mistakes or errors made by the Korean emergency managers.International implicationsOther nations, which do not have the category of emergency managers in the field or whose emergency managers lack multidiscipline, must realize why the disciplinary approach does matter for the role of emergency managers in their areas.", [["Korean emergency managers", "TREATMENT", 95, 120]]], ["When considering that educational curricula provide concepts, principles, instructions, strategies, and tools on disaster management, such curricula as an essential element should be improved by including multiple approaches.", [["disaster management", "TREATMENT", 113, 132]]], ["While studying multidisciplinary curricula, emergency managers are likely to be equipped with skills to help them quickly create appropriate strategies to address certain aspects of disaster management.International implicationsIt is also necessary for certain nations to utilize collaborative learning among different schools, teams, specialties, communities, and other institutions (Alfred et al., 2015) .", [["disaster management", "TREATMENT", 182, 201]]], ["When a specific educational unit faces its limits on the expansion of multidisciplinary curricula, it may contact neighboring units and then collaboratively develop its curricula.", [["multidisciplinary curricula", "TREATMENT", 70, 97]]], ["Vice versa, diverse trainees may outline how different disciplines can work together towards the goal of disaster management.International implicationsTraining and exercise in disaster management are also expected to expose challenges experienced by disaster victims, and thus, facilitate or simulate related experience for trainees (Martin and Hutchon, 2008) .", [["disaster management", "TREATMENT", 105, 124], ["disaster management", "TREATMENT", 176, 195]]], ["Thus, there is a need to formalize their multidisciplinary training and exercises, and then provide robust training opportunities for professional emergency managers.International implicationsSimilarly, it is necessary for other nations in the international community to reflect on diverse knowledge and information during the planning process.", [["their multidisciplinary training", "TREATMENT", 35, 67], ["professional emergency managers", "TREATMENT", 134, 165]]], ["By integrating multiple disciplines into emergency operational plans, the competencies of professional emergency managers are expected to be enhanced.", [["professional emergency managers", "TREATMENT", 90, 121]]], ["In short, multidisciplined emergency managers will be able to efficiently adjust to the demands of multidisciplinary planning process under complicated environments or situations (Khorram-Manesh, 2015) .International implicationsOther nations may not easily produce professional emergency managers via a single program or tool.", [["multidisciplinary planning process", "TREATMENT", 99, 133]]], ["Rather, they require a series of programs for the goal of developing professional emergency managers (GFDRR, 2012) .", [["a series of programs", "TREATMENT", 21, 41]]], ["In addition, because the scope of disaster management is quite wide, those nations must be flexible in introducing changes to related programs or tools via sustainable evaluation.ConclusionAmong the many challenges and alternatives, the major finding is that Korea has to transform its emergency managers' unidisciplinary approach to multidisciplinary approach in the near future.", [["disaster management", "TREATMENT", 34, 53], ["sustainable evaluation", "TEST", 156, 178]]], ["In so doing, it is necessary for each stakeholder to carry out their own assigned roles and responsibilities under the name of risk-oriented management.", [["oriented management", "TREATMENT", 132, 151]]], ["Likewise, many nations in the international community may learn important lessons from the Korean case regarding why a nation should transition to the multidisciplinary style.ConclusionAccredited researchers have studied the exact role of emergency managers in some advanced nations.", [["emergency managers", "TREATMENT", 239, 257]]], ["However, almost no rigorous study has been attempted to examine the role of Korean emergency managers or how to change their disciplinary status under their own environment.", [["rigorous study", "TEST", 19, 33]]], ["By suggesting the importance of multidisciplinary approach, this paper may be considered a pioneer study.", [["multidisciplinary approach", "TREATMENT", 32, 58], ["a pioneer study", "TEST", 89, 104]]], ["In a broad sense, this paper may contribute to the goal of transnational emergency management by highlighting the need for multidisciplined emergency managers in the international community.ConclusionAs a future study, researchers may expand their exploration on the disciplinary approaches practiced by professional emergency managers in the international community.", [["transnational emergency management", "TREATMENT", 59, 93], ["multidisciplined emergency managers", "TREATMENT", 123, 158], ["a future study", "TEST", 203, 217]]], ["Korean researchers may further study specifically how their emergency managers will utilize and benefit from a multidisciplinary approach.", [["further study", "TEST", 23, 36], ["a multidisciplinary approach", "TREATMENT", 109, 137]]]], "PMC7308002": [], "ead428adcb5af8bb764201896fd78e3f3f94a956": [["IntroductionImmigrants are growing fast in all over the world.", [["growing", "OBSERVATION_MODIFIER", 27, 34], ["fast", "OBSERVATION_MODIFIER", 35, 39]]], ["On the contrary, the non-immigrant population is expected to have a lower growth rate of 4% to 12% over the same period.", [["a lower growth rate", "TEST", 66, 85], ["lower", "OBSERVATION_MODIFIER", 68, 73], ["growth", "OBSERVATION_MODIFIER", 74, 80]]], ["With the steady rise in immigrant population and subsequent diversity in the marketplaceparticularly in North America, across Europe and Australia-immigrant entrepreneurship rose dramatically and has had a tremendous impact on the global economy.", [["steady", "OBSERVATION_MODIFIER", 9, 15], ["rise", "OBSERVATION_MODIFIER", 16, 20], ["diversity", "OBSERVATION_MODIFIER", 60, 69], ["tremendous", "OBSERVATION_MODIFIER", 206, 216], ["impact", "OBSERVATION_MODIFIER", 217, 223], ["global", "OBSERVATION_MODIFIER", 231, 237], ["economy", "OBSERVATION", 238, 245]]], ["Immigrant entrepreneurial context is full of culturally diverse, sometimes even contradictory, expectations and norms that influence how ethnic entrepreneurs are linked to the mainstream markets.IntroductionThe topic of cultural influences on immigrants' industrial marketing such as ethnic marketing entrepreneurship, supply chain management, network capability development, buyer-seller relationships, and ethnical financial cushion is attracting increasing attention (Jamal et al., 2015; Lindgreen, and Hingley, 2010; McGrath and O'Toole, 2014) .", [["supply chain management", "TREATMENT", 319, 342]]], ["This synthesis of the literature points out the need to have a holistic and contextualized approach to study immigrant entrepreneurship.IntroductionThe purpose of this special issue is to use a holistic and contextualized approach to have a deeper understanding of the role that immigrant entrepreneurs, ethnicity, and culture independently or jointly play in industrial marketing.", [["culture", "TEST", 319, 326]]], ["Following the IMM guidelines and rigorous review processes, four articles were finally selected for this special issue.", [["the IMM guidelines", "TREATMENT", 10, 28], ["rigorous review processes", "TEST", 33, 58]]], ["They are described next based on the topics covered in these articles.Social networks, embeddedness and opportunity creationLassalle, Johanson, Nicholson, and Ratajczak-Mrozek (Migrant entrepreneurship and markets:Social networks, embeddedness and opportunity creationThe dynamic role of embeddedness in networks on the creation of opportunities) develop a framework of migrant entrepreneurship, using the principles from effectuation theory of \"bird in hand\" (using available resources) and \"crazy quilt\" (selected use of networks).", [["hand", "ANATOMY", 454, 458], ["hand", "ORGANISM_SUBDIVISION", 454, 458]]], ["Getting socially and relationally embedded tends to be quicker than getting structurally embedded into the Polish migrant networks in the UK.", [["UK", "GENE_OR_GENE_PRODUCT", 138, 140]]], ["Their study reveals the role played by multidimensional and evolving embeddedness in different networks in the process of opportunity creation.Social networking ties, resources and innovationChung, Yen, and Wang (The contingent effect of social networking ties on Asian immigrant enterprises' innovation) examine the moderating role of immigrant enterprises' social network resources (business ties, political ties, and immigrant entrepreneurs' ethnic ties) in the relationship between entrepreneurial orientation and innovation.", [["social network", "MULTI-TISSUE_STRUCTURE", 359, 373], ["Their study", "TEST", 0, 11], ["embeddedness", "OBSERVATION", 69, 81]]], ["Their findings show that immigrant entrepreneurs' business ties and ethnic ties strengthen the positive effect of entrepreneurial orientation on innovation, whereas politica l ties exert little influence on the link between entrepreneurial orientation and innovation.", [["positive effect", "OBSERVATION_MODIFIER", 95, 110], ["little", "OBSERVATION_MODIFIER", 187, 193]]], ["This article advances the understanding of the contingent effect of different social networking ties in the context of immigrant enterprises' innovation, both of which remain at the heart of immigrant entrepreneurial marketing practices.Social structure, affective states and exchange strategiesZolfagharian and Iyer (The Effects of Intergroup Boundary Permeability and Hierarchy Legitimacy on Immigrant Entrepreneurs' Affective States, Exchange Strategies, and Intentions toward Suppliers) investigate the effect of social structure on immigrant entrepreneurs' affective states and exchange strategies toward supplier firms.", [["heart", "ANATOMY", 182, 187], ["heart", "ORGAN", 182, 187], ["Zolfagharian", "TREATMENT", 295, 307], ["Intergroup Boundary Permeability", "TREATMENT", 333, 365], ["Exchange Strategies", "TREATMENT", 437, 456], ["heart", "ANATOMY", 182, 187]]], ["Their findings show that boundary permeability and hierarchy legitimacy are the two key structural determinants of immigrant entrepreneurs' affective states (hope, stress, and anger) and exchange strategies (status quo acceptance, upward mobility, opportunism, rationalism, preference for ethnic supplies, commitment to mainstream suppliers).", [["boundary permeability", "PROBLEM", 25, 46], ["exchange strategies", "TREATMENT", 187, 206], ["boundary permeability", "OBSERVATION", 25, 46], ["hierarchy legitimacy", "OBSERVATION", 51, 71]]], ["Specifically, perceptions of boundary permeability embolden immigrant entrepreneurs to look beyond status quo and engage in adaptive behaviors that can facilitate upward mobility, whereas perceptions of hierarchy legitimacy inspire immigrant entrepreneurs to adhere to relationship norms and refrain from opportunistic behaviors.Transnational entrepreneurshipur u, Dana, and Volovelsky (Spanning transnational boundaries in industrial markets: A study of Israeli entrepreneurs in China) address Israeli transnational entrepreneurs who provide B2B intermediation services in China.", [["opportunistic behaviors", "DISEASE", 305, 328], ["boundary permeability", "PROBLEM", 29, 50], ["A study", "TEST", 444, 451], ["industrial markets", "OBSERVATION", 424, 442]]], ["The study is unique in the sense that it focuses on immigrant entrepreneurs from a developed economy (Israel), who pursue professional careers and business opportunities in a transitional economy (China).", [["The study", "TEST", 0, 9]]], ["Their findings show a gradual evolution of personal and professional profile among these entrepreneurs, determined by a dynamic interdependence among various forms of capital, entrepreneurial habitus, and circumstantial factors.", [["gradual", "OBSERVATION_MODIFIER", 22, 29], ["capital", "OBSERVATION_MODIFIER", 167, 174], ["entrepreneurial habitus", "OBSERVATION", 176, 199]]], ["Building upon these findings, the authors develop a comprehensive model, showing the various components and stages that lead to the development of transnational profiles and activities to enhance business success.", [["the various components", "PROBLEM", 81, 103]]], ["Collectively and in many different ways, these articles highlight the importance of networks for resource access and opportunity recognition for immigrant entrepreneurship.", [["resource access", "TREATMENT", 97, 112]]], ["This is further supported by a significant trend towards globalization, global consumption culture, and the use of new digital technologies both by the immigrant and majority business enterprises and their stakeholders like suppliers, government agencies, and customers.", [["global consumption culture", "TEST", 72, 98], ["new digital technologies", "TREATMENT", 115, 139], ["significant", "OBSERVATION_MODIFIER", 31, 42]]], ["On top of immigration, the advancement of technologies and job outsourcing create another layer of opportunities and challenges for industrial marketing.", [["industrial marketing", "TREATMENT", 132, 152]]], ["On the other hand, the contemporary business environment demands more market intelligence to take new lenses in understanding about the impact of migration, ethnicity and culture on industrial marketing, including the issues related to global outsourcing, distribution and promotion.Conclusion and Future Research DirectionsWe hope that future researchers can continue this stream of research, with a focus on such topics as (1) effects of technology use, migration, and ethnicity on business-to-business relationship management, (2) role of ethnicity and cultural diversity in value creation in industrial markets, (3) sustainability and business-to-business marketing in ethnicity contexts, (4) effects of new media and novel technology on industrial marketing across ethnic groups, and (5) role of immigrant entrepreneurs in highly anticipated changes in the global supply chain of networks due to the impact of COVID-19 crisis.", [["culture", "TEST", 171, 178], ["new media", "TREATMENT", 708, 717], ["COVID", "TEST", 915, 920], ["migration", "OBSERVATION", 146, 155]]], ["In light of increasing uncertainties in globalization and B2B markets, research on immigrant entrepreneurs is of greater J o u r n a l P r e -p r o o f Journal Pre-proof importance.", [["increasing uncertainties", "PROBLEM", 12, 36], ["increasing", "OBSERVATION_MODIFIER", 12, 22], ["uncertainties", "OBSERVATION", 23, 36]]]]}